WO2019070013A1 - 細胞傷害性t細胞枯渇用組成物 - Google Patents
細胞傷害性t細胞枯渇用組成物 Download PDFInfo
- Publication number
- WO2019070013A1 WO2019070013A1 PCT/JP2018/037139 JP2018037139W WO2019070013A1 WO 2019070013 A1 WO2019070013 A1 WO 2019070013A1 JP 2018037139 W JP2018037139 W JP 2018037139W WO 2019070013 A1 WO2019070013 A1 WO 2019070013A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- antibody
- acid sequence
- seq
- binding fragment
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Definitions
- the present invention provides a composition for cytotoxic T cell depletion comprising an antibody, a binding fragment thereof and the like, an antibody for cytotoxic T cell depletion, use of a binding fragment thereof and the like, and administering the antibody, a binding fragment thereof and the like And methods of depleting damaging T cells including T.
- T lymphocytes are cells that play a central role in the immune response, and have various antigen specificities called 10 million to 1 billion clones in vivo to cope with various antigens. T cells are present. When an antigen intrudes into the body, only a limited number of antigen-specific clones in such a large repertoire of T cells proliferate and activate, and act on bioprotection through cytokine production and cytotoxic activity. In autoimmune diseases, it is thought that various pathological conditions are formed triggered by abnormal immune responses to some self antigens. Even in such a situation, most other clones not having antigen specificity are in a quiescent state without being proliferated and activated.
- T cells having other antigen specificities it becomes possible to specifically suppress immunity without affecting most of T cells having other antigen specificities, and it is possible to self-react. It can be a useful therapeutic or preventive method for immune diseases, rejection of transplants, allergic diseases and the like. On the other hand, in the situation where T cells that negatively control the immune system such as regulatory T cells are mainly activated, removing them can be a useful treatment or prevention for malignant tumors, chronic infections, etc. .
- LAG-3 (CD 223) is a single-pass transmembrane molecule belonging to the immunoglobulin superfamily and is a molecule known to be approximately selectively expressed in activated T cells (Non-patent Document 1). .
- Administration of a rabbit antiserum with complement dependent cytotoxicity (CDC) activity against rat LAG-3 molecules in a rat allogeneic heart transplantation model reduces LAG-3 positive cells in the graft and results in graft loss It has been reported that the time until it is rejected is slightly extended (Non-patent Document 2).
- Non-patent Document 3 anti-human LAG-3 chimeric antibody A9H12, which is cross-reactive in baboon and exhibits antibody-dependent cell-mediated cytotoxicity (ADCC) activity, suppresses the delayed hypersensitivity reaction in baboon while its dose response is unclear It has also been reported that to do (Non-patent Document 3) and that a humanized product thereof was produced (Patent Document 2).
- Non-Patent Document 1 By binding to major histocompatibility complex (MHC) class II molecules, LAG-3 is known to transmit some inhibitory signals to T cells and negatively regulate T cell functions.
- Non-Patent Document 4 Of the four extracellular immunoglobulin-like domains of LAG-3, N-terminal domains 1 and 2 are considered to be important for the binding of LAG-3 and MHC class II molecules (Non-patent Document 4) It is also reported that this LAG-3 mediated suppression of T cell function is exerted cooperatively with other T cell function mediated signals such as PD-1 molecule (non-patent) Literature 5).
- Non-patent Document 6 Non-patent Document 6
- LAG-3 antibody that removes LAG-3 positive cells by ADCC activity or the like in other words, a LAG-3 antibody that depletes LAG-3 positive cells to an autoimmune disease
- LAG-3 inherently An antibody that does not have an activity to inhibit the T cell suppressive function is considered to be more desirable because there is no risk that the immune system is abnormally activated and the autoimmune disease is aggravated.
- CD4 + (positive) CD28-(negative) T cells, CD8 + CD28-T cells, CD4 + CD57 + T cells, CD8 + CD57 + T cells are cytotoxic T cell groups that highly express perforin, granzyme B, etc. (non-patented) Document 12, non-patent document 13).
- Steroid drugs are widely used for the treatment of immune system diseases, but there is a patient population intractable for steroids in immune system diseases such as asthma and chronic obstructive pulmonary disease (COPD) (Non-patent Document 14).
- COPD chronic obstructive pulmonary disease
- cytotoxic T cells as described above have been reported as one of the main inflammatory cells involved in pathological conditions (Non-patent documents 12 and 15). While cytotoxic T cells have high cytotoxic activity, resistance to anti-inflammatory activity or apoptosis induction by steroid treatment has been reported (Non-patent Document 16).
- Triebel, F. (Triebel, F.), Rug 3: The Revival Observer Cell & Dice Responses & It's Teen in Therapeutic Vaccination (LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination.), Torrens in Immunology (Trends Immunol.), December 2003; 24 (12): 619-22.
- Haudeburg, Ty et al. (Haudelaub, T. et al.), Depletion of lag 3 positive cells in cardiak allograft, Livile there roll in rejection and tolerance (Depletion of LAG-3 positive cells in cardiac allografts reveals their role in rejection and tolerance.), Transplantation, Dec.
- the present invention (1) A composition for cytotoxic T cell depletion comprising an anti-LAG-3 antibody or a binding fragment thereof having the following properties (i) to (iii): (I) with in vitro ADCC activity; (Ii) reduce the number of LAG-3 positive cells in vivo in low fucose form; and (Iii) bind to human activated T cells, (2) Cytotoxic T cells are selected from the group consisting of perforin positive T cells, granzyme B positive T cells, CD28 negative CD4 positive T cells, CD28 negative CD8 positive T cells, CD57 positive CD4 positive T cells and CD57 positive CD8 positive T cells.
- composition according to (5), wherein the immunosuppressant is a steroid
- composition according to (5) or (6), wherein the immunosuppressant is a calcineurin inhibitor
- the antibody or binding fragment thereof comprises CDRL1 having the amino acid sequence shown in SEQ ID NO: 50 or FIG. 65, CDRL2 having the amino acid sequence shown in SEQ ID NO: 51 or FIG. 66, and the amino acid sequence shown in SEQ ID NO: 52 or FIG.
- Light chain containing CDR L3 having the amino acid sequence of SEQ ID NO: 47 or FIG.
- composition according to (4) comprising a heavy chain comprising CDRH3 having (10) The composition according to (9), wherein said antibody or binding fragment thereof is a humanized antibody or binding fragment thereof, (11) In the amino acid sequence shown in SEQ ID NO: 28 or FIG. 43, an amino acid corresponding to position 68 is Gly or Ala is substituted for the antibody or a binding fragment thereof, and an amino acid corresponding to position 103 In the heavy chain containing the amino acid sequence in which is Asn or substituted with Asp, and in the amino acid sequence shown in SEQ ID NO: 32 or FIG.
- the amino acid corresponding to position 21 is Asp or Asn
- the amino acid corresponding to position 31 is Leu or is substituted by Met
- the amino acid corresponding to position 33 is Ala or is substituted by Ile
- the corresponding amino acid is Ile or substituted with Met
- the amino acid corresponding to position 58 is Gln or substituted with Lys
- the amino acid corresponding to the position No. is Ala or is substituted by Ser
- the amino acid corresponding to the position No. 80 is Ser or substituted with Asp
- amino acid corresponding to position 87 which is substituted by Gly, is Ser or Tyr, and the amino acid corresponding to position 98 is Leu or Val, 103
- the amino acid corresponding to the position No. is Phe or is substituted with Ala
- the amino acid corresponding to the position No. 105 is Thr or substituted with Phe
- a light chain comprising an amino acid sequence which is substituted by Leu or has an amino acid corresponding to position 126 is Ile or substituted by Leu;
- the amino acid sequence of the light chain of said antibody or its binding fragment comprises amino acids 21 to 234 of the amino acid sequence selected from the group consisting of SEQ ID NOs: 32, 34, 36, 38 and 40, heavy chain
- the composition according to any one of (10) to (13), wherein said antibody or binding fragment thereof is selected from the group consisting of the following [i] to [x]: [I]
- An antibody comprising a heavy chain having an amino acid sequence consisting of amino acid numbers 20 to 470 of SEQ ID NO: 30 (FIG.
- an antibody comprising a heavy chain having an amino acid sequence consisting of amino acid numbers 20 to 470 of SEQ ID NO: 30 (FIG. 45) and a light chain having an amino acid sequence consisting of amino acid numbers 21 to 234 of SEQ ID NO: 40 (FIG. 55) Its binding fragment, (15) It comprises an antibody or binding fragment thereof having a light chain variable region and a heavy chain variable region comprising an amino acid sequence 95% or more identical to the amino acid sequence of the light chain variable region and heavy chain variable region possessed by the antibody or binding fragment thereof.
- Cytotoxic T cell-related diseases include idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), multiple sclerosis, Graves' disease, ankylosing spondylitis, squamitis, asthma, rheumatoid arthritis, polymyositis, Dermatomyositis, inclusion body myositis, acute coronary syndrome, systemic lupus erythematosus, lupus nephritis, scleroderma, Crohn's disease, ulcerative colitis, aplastic anemia, myelodysplastic syndrome, Sjogren's syndrome, Wegener's granulomatosis, psoriasis,
- the pharmaceutical composition according to any one of (27) to (29), which is type 2 diabetes, host-to-graft reaction, chronic hepatitis B, and / or sarcoidosis.
- the antibody or the binding fragment thereof has an amino acid corresponding to position 68, which is GIy or substituted with Ala, and an amino acid corresponding to position 103 is Asn
- the amino acid corresponding to position 21 is Asp or Asn
- the amino acid corresponding to the position number is Leu or is substituted by Met
- the amino acid corresponding to the position 33 is Ala or is substituted by Ile
- the amino acid corresponding to the position 41 is Ile
- the amino acid corresponding to position 58 which is substituted by Met or No.
- amino acid 58 is Gln or is substituted by Lys, corresponding to position 63.
- the amino acid is Ala or substituted with Ser
- the amino acid corresponding to position 80 is Ser or substituted with Asp
- the amino acid corresponding to position 85 is Ser or Gly
- the amino acid corresponding to position 87 is substituted or Ser is substituted with Tyr
- the amino acid corresponding to position 98 is Leu or substituted for Val
- Amino acid is Phe or is substituted by Ala
- the amino acid corresponding to position 105 is Thr or is substituted by Phe
- the amino acid corresponding to position 124 is Val or Leu (38), comprising a light chain comprising an amino acid sequence which is substituted
- the amino acid corresponding to the position 126 is Ile or Leu.
- composition (40)
- the amino acid sequence of the light chain variable region of said antibody or binding fragment thereof comprises amino acids 21 to 129 of the amino acid sequence selected from the group consisting of SEQ ID NOs: 32, 34, 36, 38 and 40
- the pharmaceutical composition according to (38) or (39), wherein the amino acid sequence of the heavy chain variable region comprises amino acids 20 to 140 of the amino acid sequence selected from the group consisting of SEQ ID NOs: 28 and 30.
- the amino acid sequence of the light chain of said antibody or its binding fragment comprises amino acids 21 to 234 of the amino acid sequence selected from the group consisting of SEQ ID NOs: 32, 34, 36, 38 and 40, heavy chain
- the pharmaceutical composition according to any one of (38) to (41), wherein said antibody or binding fragment thereof is selected from the group consisting of the following [i] to [x]: [I]
- An antibody comprising a heavy chain having an amino acid sequence consisting of amino acid numbers 20 to 470 of SEQ ID NO: 30 (FIG.
- an antibody comprising a heavy chain having an amino acid sequence consisting of amino acid numbers 20 to 470 of SEQ ID NO: 30 (FIG. 45) and a light chain having an amino acid sequence consisting of amino acid numbers 21 to 234 of SEQ ID NO: 40 (FIG. 55) Its binding fragment, (43) It comprises an antibody or binding fragment thereof having a light chain variable region and a heavy chain variable region comprising an amino acid sequence 95% or more identical to the amino acid sequence of the light chain variable region and heavy chain variable region possessed by the antibody or binding fragment thereof.
- the pharmaceutical composition according to (42), (44) A second nucleic acid molecule which hybridizes under stringent conditions with a first nucleic acid molecule having a nucleotide sequence encoding the amino acid sequence of the light chain variable region of the antibody or a binding fragment thereof or a nucleotide sequence complementary thereto
- composition provided by the present invention depletes cytotoxic T cells, it can be used for the treatment and / or prevention of cytotoxic T cell related diseases (described later).
- the vertical axis shows the average fluorescence intensity measured by flow cytometry.
- Human LAG-3 expressing 293T-lacZ cells were used as target cells and human PBMC as effector cells.
- FIG. 3A shows the inhibitory activity of rat anti-LAG-3 antibodies (rLA204, rLA212, rLA225, rLA869 and rLA1264) in the LAG-3 / MHC class II binding test.
- rat IgG2b was used, and as positive control, a rat anti-LAG-3 antibody that recognizes domain 1 of LAG-3 separately prepared was used. All antibodies were evaluated at 10 ⁇ g / mL.
- FIG. 3B shows that a known antibody, human chimerized anti-LAG-3 antibody IMP 731 shows inhibitory activity in a LAG-3 / MHC class II binding test.
- the commercially available mouse anti-human LAG-3 antibody 17B4 also showed inhibitory activity.
- FIG. 5A shows a flow cytometry analysis of human LAG-3 binding epitopes of rat anti-LAG-3 antibodies (rLA204, rLA212 and rLA225).
- FIG. 5B is a diagram showing human LAG-3 binding epitope of human chimerized anti-LAG-3 antibody IMP 731 which is a prior art antibody, verified by flow cytometry.
- the vertical axis shows the average fluorescence intensity measured by flow cytometry. Antiserum used antisera obtained from the immunized rat of Example 1) -1 at a 500-fold dilution. All other antibodies were evaluated at 10 ⁇ g / mL.
- 6D7 is a rat anti-LAG-3 antibody that recognizes domain 1 of LAG-3 prepared in Example 2) -6.
- the vertical axis shows the average fluorescence intensity measured by flow cytometry.
- the vertical axis shows the average fluorescence intensity measured by flow cytometry.
- Human LAG-3 expressing 293T-lacZ cells were used as target cells and human PBMC as effector cells.
- IL-2 production to the culture supernatant was determined upon stimulation of human PBMC with SEB for 4 days in the presence of each antibody. All antibodies were evaluated at 10 ⁇ g / mL.
- FIG. 8 shows that expression of human LAG-3 in human LAG-3 / human Fc ⁇ RIIIA double transgenic mice is consistent with expression of mouse LAG-3.
- the vertical axis represents human LAG-3 positive rate in peripheral blood T cells 2 days after administration of antibody and Con A to human LAG-3 / human Fc ⁇ RIIIA double transgenic mice.
- the antibody was administered intraperitoneally immediately before Con A administration at a dose of 30 mg / kg.
- the clinical score of EAE in mice in which EAE was induced in human LAG-3 / human Fc ⁇ RIIIA double transgenic mice and administered with humanized anti-LAG-3 antibody hLA212_H4 / L2 or control antibody is shown over time.
- Nucleotide sequence encoding amino acid sequence of heavy chain variable region of rLA204 antibody (SEQ ID NO: 1) Amino acid sequence of the heavy chain variable region of rLA 204 antibody (SEQ ID NO: 2) Nucleotide sequence encoding amino acid sequence of light chain variable region of rLA204 antibody (SEQ ID NO: 3) Amino acid sequence of light chain variable region of rLA204 antibody (SEQ ID NO: 4) Nucleotide sequence encoding amino acid sequence of heavy chain variable region of rLA212 antibody (SEQ ID NO: 5) Amino acid sequence of heavy chain variable region of rLA212 antibody (SEQ ID NO: 6) Nucleotide sequence encoding amino acid sequence of light chain variable region of rLA212 antibody (SEQ ID NO: 7) Amino acid sequence of light chain variable region of rLA212 antibody (SEQ ID NO: 8) Nucleotide sequence encoding amino acid sequence of
- LAG-3 and CD28 in cells stimulated with Dynabeads Human T-Activator CD3 / CD28 in human PBMC was examined by flow cytometry (multiple staining).
- the result of having gated to the CD3 positive CD8 positive T cell for the analysis is shown.
- the four divisions of the graph were set using a sample (left figure) containing no staining antibody against human LAG-3 and human CD28.
- the expression of LAG-3 and CD57 in cells stimulated with Dynabeads Human T-Activator CD3 / CD28 in human PBMC was examined by flow cytometry (multiple staining).
- FIG. 6 shows that LAG-3 antibody selectively depletes perforin positive CD8 T cells.
- Human PBMCs were stimulated with Dynabeads Human T-Activator CD3 / CD28 for 4 days in the presence of humanized anti-LAG-3 antibody hLA212_H4 / L2, tacrolimus (Tac), dexamethasone (Dex), and the obtained cells were flow-stained. It analyzed by the metric method (multiple staining).
- FIG. 105A shows the total number of T cells
- FIG. 105B shows the number of perforin positive CD8 T cells.
- FIG. 6 shows that LAG-3 antibody depletes CD28 negative T cells.
- FIG. 106A shows the number of CD28 negative CD4 T cells
- FIG. 106B shows the number of CD28 negative CD8 T cells.
- FIG. 6 shows that LAG-3 antibody depletes CD57 positive T cells.
- Human PBMC in the presence of humanized anti-LAG-3 antibody hLA212_H4 / L2 (final concentration 10, 1, 0.1 ⁇ g / mL), control antibody (final concentration 10 ⁇ g / mL), tacrolimus (Tac), dexamethasone (Dex)
- the cells were stimulated with Dynabeads Human T-Activator CD3 / CD28 for 4 days, and the obtained cells were analyzed by flow cytometry (multiple staining).
- the results using PBMCs from two donors are shown (PBMC1 and PBMC2).
- FIG. 107A shows the number of CD57 positive CD4 T cells
- FIG. 107B shows the number of CD57 positive CD8 T cells.
- gene means a nucleic acid molecule comprising a nucleotide sequence encoding an amino acid of a protein or a complementary strand thereof, eg, a nucleotide sequence encoding an amino acid of a protein or a nucleotide complementary to that sequence
- Polynucleotides having a sequence, oligonucleotides, DNA, mRNA, cDNA, cRNA and the like are included in the meaning of "gene”.
- Such a gene is a single-stranded, double-stranded or triple-stranded nucleotide, and an association of DNA and RNA chains, and ribonucleotides (RNA) and deoxyribonucleotides (DNA) are mixed on one nucleotide chain. Also, double-stranded or triple-stranded or more nucleotides containing such nucleotide chains are included in the meaning of "gene”.
- Examples of the “LAG-3 gene” of the present invention include DNAs, mRNAs, cDNAs, cRNAs and the like containing a nucleotide sequence encoding the amino acid sequence of LAG-3 protein.
- nucleotide is synonymous, and, for example, DNA, RNA, probe, oligonucleotide, polynucleotide, primer and the like are included in their meanings.
- a nucleotide is a single-stranded, double-stranded or three or more-stranded nucleotide, and an association of a DNA strand and an RNA strand, and ribonucleotides (RNA) and deoxyribonucleotides (DNA) on a single nucleotide strand. Contaminated ones and assemblies of double-stranded or three or more strands containing such nucleotide chains are also included in the meaning of "nucleotide".
- polypeptide In the present invention, “polypeptide”, “peptide” and “protein” are synonymous.
- antigen may be used in the meaning of "immunogen”.
- cells also include various cells derived from animal individuals, subcultured cells, primary cultured cells, cell lines, recombinant cells, microorganisms and the like.
- an antibody that binds to LAG-3 and an antibody that recognizes LAG-3 may both be referred to as "anti-LAG-3 antibody” or abbreviated as "LAG-3 antibody”.
- Anti-LAG-3 antibodies include monoclonal antibodies, chimerized antibodies, humanized antibodies, human antibodies, chimeric antibodies and the like.
- the "binding fragment of antibody” in the present invention means an antibody fragment that fulfills at least a part of the function exerted by the original antibody.
- the “binding fragment of antibody” include, but are not limited to, Fab, F (ab ′) 2, scFv, Fab ′, single-chain immunoglobulin and the like, for example.
- the binding fragment of such an antibody is a recombinant protein produced in a suitable host cell using a recombinant gene, in addition to those obtained by treating the full-length molecule of the antibody protein with an enzyme such as papain or pepsin. May be
- the "site" to which an antibody binds that is, the "site” that an antibody recognizes means a partial peptide or partial conformation on an antigen to which the antibody binds or recognizes. In the present invention, such a site is also referred to as an epitope, a binding site of an antibody.
- a site on LAG-3 protein which the anti-LAG-3 antibody binds or recognizes a partial peptide or partial conformation on LAG-3 protein can be exemplified.
- CDRs complementarity determining regions
- the complementarity-determining region also called hypervariable region, is a site within the variable regions of the antibody heavy and light chains, where the variability of the primary structure is particularly high, and the heavy and light chains are The primary structure of the polypeptide chain is usually separated into three places.
- the complementarity determining region of the heavy chain is denoted as CDRH1, CDRH2, CDRH3 from the amino terminal side of the heavy chain amino acid sequence
- the complementarity determining region of the light chain is light chain amino acid.
- the amino terminal side of the sequence is referred to as CDRL1, CDRL2 and CDRL3.
- FR frameworks
- portions other than CDRL1 to CDRL3 in the light chain variable region amino acid sequence are also FR, from the amino terminus to the front of CDRL1, from CDRL1 to the front of CDRL2, from CDRL2 to the front of CDRL3, and The next to the carboxyl terminus of CDRL3 are referred to as FRL1 to FRL4, respectively. That is, in (variable amino acid sequence) of heavy chain and light chain variable regions, the amino terminal in the order of FRH1-CDRH1-FRH2-CDRH2-FRH3-CDRH3-FRH4 and FRL1-CDRL1-FRL2-CDRL2-FRL3-CDRL3-FRL4 They line up continuously from the side to the carboxyl terminus.
- the "antibody variant” has an amino acid sequence formed by substitution, deletion, addition and / or insertion (hereinafter collectively referred to as "mutation") of amino acids in the amino acid sequence possessed by the original antibody. And a polypeptide that binds to the LAG-3 protein.
- the number of mutated amino acids in such antibody variants is 1, 1, 2, 2, 3, 4, 3, 4, 5, 6, 7, 8, 7, 8, 9, 10. 1 to 7, 1 to 7, 1 to 8, 1 It is 9 to 1, 1 to 10, 1 to 12, 1 to 15, 1 to 20, 1 to 25, 1 to 30, 1 to 40 or 1 to 50.
- Such antibody variants are also encompassed in the "antibody” of the present invention.
- Examples of the activity / properties exhibited by LAG-3 antibody in the present invention include biological activity, physicochemical properties, etc. Specifically, various biological activities, binding activities to antigens and epitopes, production and storage The stability at the time, the thermal stability, etc. can be raised.
- hybridize under stringent conditions refers to hybridization in a solution containing 5 ⁇ SSC at 65 ° C., and then in an aqueous solution containing 2 ⁇ SSC-0.1% SDS 20 minutes at 65 ° C., 20 minutes at 65 ° C. in an aqueous solution containing 0.5 ⁇ SSC-0.1% SDS, and 65 ° C. in an aqueous solution containing 0.2 ⁇ SSC-0.1% SDS The hybridization is performed under the conditions for washing for 20 minutes, respectively, or conditions equivalent thereto.
- SSC is an aqueous solution of 150 mM NaCl-15 mM sodium citrate, and n ⁇ SSC means n-fold concentration of SSC.
- cytotoxicity refers to causing a pathological change in cells in any way, and is not limited to direct trauma, such as DNA breakage, base dimer formation, chromosome breakage, It means damage to the structure and function of all cells, including damage to the cell division apparatus and reduction in various enzyme activities.
- cytotoxic activity means causing the above-mentioned cytotoxicity.
- antibody-dependent cellular cytotoxicity refers to "antibody dependent cellular cytotoxicity (ADCC) activity", and means an activity of NK cells or the like to injure a target cell via an antibody.
- ADCC antibody dependent cellular cytotoxicity
- the "host-to-graft reaction” refers to the state of the recipient's immune enhancement observed after organ transplantation and injury of the transplanted organ by this.
- graft-versus-host disease refers to a condition developed by immune attack on a recipient by transplanted cells after hematopoietic cell transplantation.
- depletion decreases or increases the number of cells contained in a specific cell group. Not in the state.
- deplete decreases or increases the number of cells contained in a particular cell group, such as by cytotoxic activity It means that.
- cytotoxic T cells refers to T cells having cytotoxicity to cells contained in a specific cell group, for example, CD4 + (positive) CD28-(negative) T cells, CD8 + CD28 -T cell subsets such as T cells, CD4 + CD57 + T cells, CD8 + CD57 + T cells, perforin + T cells, granzyme B + T cells, etc. can be mentioned.
- Cytotoxic T cells are one of the major inflammatory cells involved in immune system diseases and autoimmune diseases such as asthma and severe asthma (hereinafter collectively referred to as "asthma") and chronic obstructive pulmonary disease (COPD). It has been reported (Non-patent document 12, Non-patent document 15) and has high cytotoxic effect, while resistance to anti-inflammatory action or apoptosis induction by steroid treatment has been reported (Non-patent document 16)
- LAG-3 protein (hereinafter, also simply referred to as "LAG-3") is a transmembrane receptor protein, and it is extracellular with a ligand binding site consisting of immunoglobulin-like domains (IgD1 to 4). It consists of a region, a type I single transmembrane region, and an intracellular region. LAG-3 is synonymous with CD223.
- LAG-3 is of vertebrate origin, preferably of mammalian origin, and more preferably of human origin.
- the LAG-3 protein has the following properties. (I) bind to major histocompatibility complex (MHC) class II molecules on antigen presenting cells. (Ii) By binding to MHC class II molecules, they transmit inhibitory signals to T cells expressing the molecules and negatively regulate the function of the T cells.
- MHC major histocompatibility complex
- the LAG-3 protein comprises the amino acid sequence described in any one of the following (a) to (d) (hereinafter referred to as "LAG-3 amino acid sequence") or Consisting of an amino acid sequence comprising a -3 amino acid sequence or consisting of a LAG-3 amino acid sequence: (A) the amino acid sequence shown in SEQ ID NO: 86 (FIG. 101); (B) 80% or more, 82% or more, 84% or more, 86% or more, 88% or more, 90% or more, 92% or more, 94% or more, 96% or more of the amino acid sequence shown in SEQ ID NO: 86 (FIG.
- LAG-3 protein expresses LAG-3 in vertebrates, preferably mammals, more preferably rodents and humans such as mice and rats, even more preferably humans, rats and mice These cells can be obtained from the cells, tissues or cancer tissues, cells derived from such tissues, cultures of such cells, etc. LAG-3 is expressed in activated T cells and the like at inflammatory sites in vivo, and is scarcely expressed or at very low expression levels in cells of normal tissues.
- the LAG-3 protein may be either natural (non-recombinant) or recombinant.
- fusions with other peptides and proteins such as carriers and tags are also included in the meaning of LAG-3 protein.
- chemical modifications including polymer addition such as PEG and / or biological modifications including glycosylation are also included in the meaning of LAG-3 protein.
- LAG-3 protein fragments are also included in the meaning of LAG-3 protein.
- those having the properties described in the above (i) and / or (ii) are called LAG-3 protein binding fragments.
- the LAG-3 gene comprises the nucleotide sequence described in any one of the following (a) to (c) (hereinafter referred to as "LAG-3 gene sequence"): Or consists of a nucleotide sequence comprising LAG-3 gene sequence, or consists of LAG-3 gene sequence:
- A A nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO: 86 (FIG. 101);
- B Hybridizes under stringent conditions with a polynucleotide (nucleic acid molecule) consisting of a nucleotide sequence complementary to the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 86 (FIG.
- polypeptide having the amino acid sequence encoded by the nucleotide sequence described in (b) or (c) may have other activities possessed by LAG-3 in addition to the MHC class II molecule binding activity.
- LAG-3 gene may be determined using either the transcript of LAG-3 gene or LAG-3 protein as an indicator, the former by RT-PCR method, Northern blot hybridization method, etc. The latter can be measured by an immunoassay such as flow cytometry, western blotting, immunohistological staining and the like.
- LAG-3 protein is purified and isolated from animal tissue (including body fluid), cells derived from the tissue or cell culture, gene recombination, in vitro translation, chemical synthesis, etc. It can be prepared by (2-3-1) Purification and Isolation of Non-Recombinant LAG-3
- Non-recombinant LAG-3 protein can be purified and isolated from cells expressing LAG-3.
- cells expressing LAG-3 those described in (iv) of (2-1) can be exemplified, but the origin of non-recombinant LAG-3 protein is not limited thereto. .
- LAG-3 protein can also be prepared as a recombinant form. That is, a gene encoding the amino acid sequence of LAG-3 protein or LAG-3 protein fragment can be introduced into a host cell, and LAG-3 protein can be recovered from the culture of such cells.
- a fusion protein with a secretion signal an intracellular localization signal, a tag for affinity purification, and a partner peptide, as well as a molecule having the same amino terminal (N terminal) and / or carboxy terminal (C terminal) as the natural type. It can also be expressed.
- LAG-3 protein For purification and isolation of LAG-3 protein from such recombinant cell culture, the purification and isolation of the non-recombinant LAG-3 protein described in (2-3-1), the fractions described in isolation, chromatography, etc. It can carry out by combining the operation of.
- the LAG-3 protein-containing solution can be subjected to buffer exchange and / or concentration with a concentration device such as gel filtration or Centriprep.
- LAG-3 protein can also be prepared by in vitro translation.
- Such translation method is not particularly limited as long as it is a method utilizing a cell-free translation system including an enzyme, a substrate, and an energy substance necessary for transcription and translation, but, for example, Roche Diagnostics Co., Ltd. There is a way to use the Rapid Translation System (RTS).
- RTS Rapid Translation System
- Chemical Synthesis LAG-3 protein can also be prepared by chemical synthesis. Examples of chemical synthesis methods include peptide solid phase synthesis methods such as Fmoc synthesis method and Boc synthesis method.
- LAG-3 antibody may be either a monoclonal antibody or a polyclonal antibody.
- monoclonal antibodies include non-human animal-derived antibodies (non-human animal antibodies), human-derived antibodies (human antibodies), chimerized antibodies (also referred to as "chimeric antibodies”), humanized antibodies and the like.
- non-human animal antibodies include antibodies derived from vertebrates such as mammals and birds.
- mammalian-derived antibodies include murine antibodies, rat antibodies such as rodent-derived antibodies, and the like.
- avian-derived antibodies include chicken antibodies.
- anti-human LAG-3 rat monoclonal antibodies include, but are not limited to, rLA204, rLA212, rLA225, 4LA869, rLA1264 and the like.
- chimerized antibodies include, but are not limited to, antibodies formed by binding a variable region derived from a non-human animal antibody and a human antibody (human immunoglobulin) constant region.
- chimeric antibodies in which the variable region derived from the non-human animal antibody and the human antibody constant region are combined include heavy and light chain variable regions derived from the above-described rat monoclonal antibodies rLA204, rLA212, rLA225, 4LA869 or rLA1264; Examples thereof include those having human heavy chain and light chain constant regions (referred to as “cLA204”, “cLA212”, “cLA225”, “cLA869” or “cLA1264”, respectively) and the like.
- a humanized antibody one obtained by grafting a CDR in a variable region of a non-human animal antibody to a human antibody (a variable region of a human immunoglobulin), a part of the FR sequence of the non-human animal antibody is also grafted to a human antibody And those obtained by substituting one or more amino acids derived from any of those non-human animal antibodies with human or other amino acids, but are not limited thereto.
- CDRs in the variable region of the non-human animal antibody it is possible to exemplify CDRH1 to CDRH3 in the heavy chain variable region derived from rLA204, rLA212, rLA225, rLA869 or rLA1264 described above and CDRL1 to CDRL3 in the light chain variable region.
- L2 etc. can be raised.
- the human antibody is not particularly limited as long as it is an antibody that recognizes LAG-3 protein, but a human antibody that binds to the same site as the antibody having a CDR of LAG-3 antibody, the aforementioned non-human animal antibody Examples include human antibodies that bind to the same site on LAG-3 with any one of chimeric antibodies and humanized antibodies, and antibodies that compete with such antibodies for binding to LAG-3. .
- the antibody in the present invention may be an antibody composed of portions derived from a plurality of different antibodies as long as it has an activity of binding to LAG-3, for example, a heavy chain and a plurality of different antibodies. And / or replacement of the light chain, replacement of the entire length of heavy chain and / or light chain, replacement of only the variable region or only constant region, replacement of all or part of CDRs, etc. Can.
- the heavy and light chain variable regions of the chimeric antibody may be derived from different LAG-3 antibodies.
- the CDRH1 to CDRH3 and the CDRL1 to CDRL3 in the variable regions of the heavy and light chains of the humanized antibody may be derived from two or more LAG-3 antibodies.
- CDRH1 to CDRH3 and CDRL1 to CDRL3 in the variable regions of the heavy and light chains of a human antibody may be a combination of CDRs possessed by two or more LAG-3 antibodies.
- An antibody or a binding fragment thereof composed of parts derived from such multiple different antibodies is preferably (3-2) and (3-3) described below, preferably in addition to (3-4) ), More preferably in addition to (3-5), and even more preferably (3-2) to (3-8) all have the properties, functions, activities and the like described in each.
- the isotype of the monoclonal antibody is not particularly limited, and examples thereof include IgG such as IgG1, IgG2, IgG3 and IgG4, IgA such as IgM, IgA1 and IgA2, IgD, IgE and the like, preferably IgG And IgM.
- the isotype and subclass of the monoclonal antibody may be determined, for example, by the Ouchterlony method, Enzyme-linked immuno-sorbent assay: hereinafter referred to as "ELISA” method, Radio immunoassay (hereinafter referred to as "RIA”) method or the like.
- ELISA Enzyme-linked immuno-sorbent assay
- RIA Radio immunoassay
- LAG-3 antibody recognizes LAG-3 protein.
- LAG-3 antibody binds to LAG-3 protein.
- Such antibodies are also referred to as "anti-LAG-3 antibodies”.
- suitable antibodies for use in the present invention specifically recognize LAG-3 protein.
- the preferred antibody used in the present invention specifically binds to the LAG-3 protein (hereinafter collectively referred to as “LAG-3 binding activity of the antibody.” Furthermore, the more preferred used in the present invention The antibody specifically binds to the extracellular domain of LAG-3 protein, and the more preferred antibody specifically binds to an immunoglobulin like domain (hereinafter referred to as "Ig like domain”) possessed by LAG-3 protein, Even more preferred antibodies specifically bind to such Ig-like domain 3.
- Ig like domain immunoglobulin like domain
- telomere binding means binding that is not nonspecific adsorption.
- KD dissociation constant
- the KD value for the LAG-3 protein of the suitable antibody used in the present invention is 1 ⁇ 10 ⁇ 5 or less, 5 ⁇ 10 ⁇ 6 or less, 2 ⁇ 10 ⁇ 6 or less or 1 ⁇ 10 ⁇ 6 or less, more preferably 5 ⁇ 10 -7 or less, 2 ⁇ 10 -7 or less or 1 ⁇ 10 -7 or less, more preferably 5 ⁇ 10 -8 or less, 2 ⁇ 10 -8 or less or 1 ⁇ 10 -8 or less, still more Preferably, it is 5 ⁇ 10 ⁇ 9 or less, 2 ⁇ 10 ⁇ 9 or less or 1 ⁇ 10 ⁇ 9 or less, optimally 5 ⁇ 10 ⁇ 10 or less, 2 ⁇ 10 ⁇ 10 or less or 1 ⁇ 10 ⁇ 10 or less.
- Binding between an antigen and an antibody in the present invention can be measured or determined by ELISA method, RIA method, Surface Plasmon Resonance (hereinafter referred to as "SPR") analysis method or the like.
- SPR Surface Plasmon Resonance
- BIAcoreTM manufactured by GE Healthcare
- ProteOnTM manufactured by BioRad
- SPR-NaviTM manufactured by BioNavis
- SpreetaTM manufactured by Texas Instruments
- SPRi-Plex IITM manufactured by Horiba
- Autolab SPRTM manufactured by Metrohm
- the binding between the antigen expressed on the cell surface and the antibody can be measured by flow-sertometry, Cell ELISA, etc.
- the anti-LAG-3 antibody used in the present invention has antibody-dependent cellular cytotoxicity (ADCC) activity, preferably ADCC activity in vitro. And more preferably has ADCC activity on T cells expressing LAG-3.
- the anti-LAG-3 antibody used in the present invention may have complement-dependent cytotoxicity (CDC) activity and / or antibody-dependent cell-mediated phagocytic activity (ADCP) activity in addition to the ADCC activity.
- ADCC activity may be simply referred to as "ADCC activity”.
- ADCC activity can be measured by known methods.
- cells expressing the target antigen (target cells) and effector cells that kill the target cells are used. Effector cells recognize the Fc region of an antibody bound to a target cell via Fc ⁇ receptor. The signal transmitted from the Fc ⁇ receptor causes the effector cell to kill the target cell.
- human NK cells are used as effector cells.
- Human NK cells can be prepared from human peripheral blood mononuclear cells (PMBC) by known methods. Alternatively, PBMC can be used as effector cells as they are.
- LAG-3 antibody reduces the number of LAG-3 positive cells in one embodiment, preferably in vivo (in vivo).
- the number of LAG-3 positive cells is reduced in vivo, and more preferably the number of LAG-3 positive cells is reduced in vivo in a low fucose form.
- LAG-3 positive cells include cells in which LAG-3 is forcibly expressed, cells in which LAG-3 expression is induced by stimulation, etc. However, cells that express LAG-3 are limited thereto I will not.
- the number of LAG-3 positive cells can be counted by standard methods, for example, flow cytometry.
- the “low fucose form” means that (i) the amount of fucose (fucose residue) in the N-glycosidic bond complex type sugar chain bound to a certain antibody or a binding fragment thereof is the original (parent) An amount less than the amount of fucose (fucose residue) in the N-glycosidic bond complex-type sugar chain bound to the antibody or binding fragment thereof, (ii) N-glycoside bound to an antibody or binding fragment thereof A form in which the amount of fucose (fucose residue) in the conjugated complex-type sugar chain is smaller than the amount of fucose (fucose residue) in the N-glycosidic-linked complex-type carbohydrate which is naturally bound to the antibody or its binding fragment Or (iii) a sugar chain containing fucose (fucose residue) or fucose (fucose residue) in the N-glycosidic bond complex-type
- fucose residue in the N-glycosidic-linked complex-type sugar chain linked to a certain modified antibody or binding fragment thereof is small compared to that before such modification, such a modified antibody or It is understood that the binding fragment is in "low fucose form".
- Modified form hLA212_H4 / L2 of the humanized antibody described later is also an embodiment of the antibody in the low fucose form.
- the antibody or binding fragment in the low fucose form has a high affinity for Fc ⁇ receptor IIIA and a strong ADCC activity, as compared to those not in the low fucose form.
- the LAG-3 antibody has an encephalomyelitis inhibitory activity in one embodiment, and preferably in vivo In vivo, it has experimental autoimmune encephalomyelitis inhibitory activity, and more preferably it has experimental autoimmune encephalomyelitis inhibitory activity in vivo in a low fucose form.
- experimental autoimmune encephalomyelitis is caused by injection of a peptide derived from MOG (Myelin Oligodendrocyte Glycoprotein), which is one of central myelin constituent proteins, into mice together with Freund's Adjuvant into mice. Means flame.
- MOG Myelin Oligodendrocyte Glycoprotein
- the experimental autoimmune encephalomyelitis inhibitory activity can be measured by daily observation of a clinical score reflecting the degree of paralysis.
- the clinical score can be set, for example, as follows: Score 0: no symptoms, score 1: tail weakness, score 2: gait abnormality, loss of righting reflex, score 3: hindlimb paralysis, score 4: forelimb Partial paralysis, score 5: death or euthanasia.
- the LAG-3 antibody binds to human activated T cells, preferably to LAG-3 positive activated human T cells Join.
- the binding of the antibody to activated human activated T cells can be measured or detected, for example, by flow cytometry.
- human LAG-3 and human MHC Class II Molecules Bind in the Presence of Antibody
- human LAG-3 and human MHC class II molecules bind in the presence of antibody
- LAG-3 antibody does not inhibit the binding of human LAG-3 and human MHC class II molecules.
- the binding of the fusion protein of the extracellular region of LAG-3 molecule and the Fc portion of IgG to Raji cells that endogenously express MHC class II molecules over and above is evaluated by measuring or detecting, for example, by flow cytometry. can do.
- Human LAG-3 exerts human T cell suppressive function in the presence of antibody
- human LAG-3 exerts human T cell suppressive function in the presence of LAG-3 antibody in the present invention Play.
- T cell suppressive function means reduction or suppression of the amount of cytokine produced upon stimulation of T cells.
- T cell suppression function by human LAG-3 can be measured, for example, by quantifying a cytokine produced upon stimulation of human T cells to induce LAG-3 expression.
- stimulation of human T cells is not particularly limited. It is possible to use Staphylococcal Enterotoxin B, stimulation by cells derived from another donor with different MHC, and the like.
- cytokines include cytokines produced from activated T cells, preferably various interleukins and interferons, and more preferably interleukin 2 (IL-2) and interferon ⁇ .
- the present invention provides an anti-LAG-3 monoclonal antibody and a binding fragment thereof.
- monoclonal antibodies include rat antibodies, mouse antibodies, rabbit antibodies, chicken antibodies, monoclonal antibodies derived from non-human animals such as fish antibodies, chimeric antibodies, humanized antibodies, human antibodies, their binding fragments, modified products thereof, etc. included.
- examples of rat monoclonal antibodies include rLA204, rLA212, rLA225, rLA869, rLA1264 and the like.
- RLA204 is an anti-human LAG-3 rat monoclonal antibody obtained by the method described in Example 1.
- the nucleotide sequence of the heavy chain variable region of rLA204 is set forth in SEQ ID NO: 1 (FIG. 16) and the amino acid sequence is set forth in SEQ ID NO: 2 (FIG. 17).
- the nucleotide sequence of the light chain variable region of rLA204 is set forth in SEQ ID NO: 3 (FIG. 18) and the amino acid sequence is set forth in SEQ ID NO: 4 (FIG. 19).
- the amino acid sequence of CDRH1 of rLA204 is SEQ ID NO: 41 (FIG. 56), the amino acid sequence of CDRH2 is SEQ ID NO: 42 (FIG.
- the amino acid sequence of CDRH3 is SEQ ID NO: 43 (FIG. 58)
- the amino acid sequence of CDRL1 is the sequence The amino acid sequence of CDR L2 is described in SEQ ID NO: 45 (FIG. 60), and the amino acid sequence of CDR L3 in SEQ ID NO: 46 (FIG. 61), respectively.
- RLA212 is an anti-human LAG-3 rat monoclonal antibody obtained by the method described in Example 1.
- the nucleotide sequence of the heavy chain variable region of rLA212 is set forth in SEQ ID NO: 5 (FIG. 20) and the amino acid sequence is set forth in SEQ ID NO: 6 (FIG. 21).
- the nucleotide sequence of the light chain variable region of rLA212 is set forth in SEQ ID NO: 7 (FIG. 22) and the amino acid sequence is set forth in SEQ ID NO: 8 (FIG. 23).
- the amino acid sequence of CDRH1 of rLA212 is SEQ ID NO: 47 (FIG. 62), the amino acid sequence of CDRH2 is SEQ ID NO: 48 (FIG.
- the amino acid sequence of CDRH3 is SEQ ID NO: 49 (FIG. 64)
- the amino acid sequence of CDR L1 is the sequence The amino acid sequence of CDR L2 is described in SEQ ID NO: 51 (FIG. 66), and the amino acid sequence of CDR L3 in SEQ ID NO: 52 (FIG. 67), respectively.
- RLA 225 is an anti-human LAG-3 rat monoclonal antibody obtained by the method described in Example 1.
- the nucleotide sequence of the heavy chain variable region of rLA225 is set forth in SEQ ID NO: 9 (FIG. 24) and the amino acid sequence is set forth in SEQ ID NO: 10 (FIG. 25).
- the nucleotide sequence of the light chain variable region of rLA225 is set forth in SEQ ID NO: 11 (FIG. 26) and the amino acid sequence is set forth in SEQ ID NO: 12 (FIG. 27).
- the amino acid sequence of CDRH1 of rLA225 is SEQ ID NO: 53 (FIG. 68), the amino acid sequence of CDRH2 is SEQ ID NO: 54 (FIG.
- the amino acid sequence of CDRH3 is SEQ ID NO: 55 (FIG. 70)
- the amino acid sequence of CDR L1 is the sequence
- the amino acid sequence of CDRL2 is set forth in SEQ ID NO: 57 (FIG. 72)
- the amino acid sequence of CDRL3 is set forth in SEQ ID NO: 58 (FIG. 73) at 56 (FIG. 71).
- RLA869 is an anti-human LAG-3 rat monoclonal antibody obtained by the method described in Example 1.
- the nucleotide sequence of the heavy chain variable region of rLA869 is set forth in SEQ ID NO: 13 (FIG. 28) and the amino acid sequence is set forth in SEQ ID NO: 14 (FIG. 29).
- the nucleotide sequence of the light chain variable region of rLA869 is set forth in SEQ ID NO: 15 (FIG. 30) and the amino acid sequence is set forth in SEQ ID NO: 16 (FIG. 31).
- the amino acid sequence of CDRH1 of rLA869 is SEQ ID NO: 59 (FIG. 74), the amino acid sequence of CDRH2 is SEQ ID NO: 60 (FIG.
- the amino acid sequence of CDRH3 is SEQ ID NO: 61 (FIG. 76)
- the amino acid sequence of CDR L1 is the sequence
- the amino acid sequence of CDRL2 is set forth in SEQ ID NO: 63 (FIG. 78) and the amino acid sequence of CDRL3 is set forth in SEQ ID NO: 64 (FIG. 79) at number 62 (FIG. 77).
- RLA1264 is an anti-human LAG-3 rat monoclonal antibody obtained by the method described in Example 1.
- the nucleotide sequence of the heavy chain variable region of rLA1264 is set forth in SEQ ID NO: 17 (FIG. 32) and the amino acid sequence is set forth in SEQ ID NO: 18 (FIG. 33).
- the nucleotide sequence of the light chain variable region of rLA1264 is set forth in SEQ ID NO: 19 (FIG. 34) and the amino acid sequence is set forth in SEQ ID NO: 20 (FIG. 35).
- the amino acid sequence of CDRH1 of rLA1264 is SEQ ID NO: 65 (FIG. 80), the amino acid sequence of CDRH2 is SEQ ID NO: 66 (FIG.
- the amino acid sequence of CDRH3 is SEQ ID NO: 67 (FIG. 82)
- the amino acid sequence of CDR L1 is the sequence
- the amino acid sequence of CDRL2 is set forth in SEQ ID NO: 69 (FIG. 84) and the amino acid sequence of CDRL3 is set forth in SEQ ID NO: 70 (FIG. 85) at number 68 (FIG. 83).
- anti-human LAG-3 monoclonal antibodies examples include anti-human LAG-3 mouse antibody A9H12 (see WO2008 / 132601) and the like.
- antibody variants preferably have reduced sensitivity to degradation or oxidation of proteins, improved biological activity, improved antigen binding ability, or impart of physicochemical properties or functional properties, etc. .
- antibody variants include antibodies having an amino acid sequence in which one or more, preferably one to several amino acids in the amino acid sequence possessed by the antibody are conservatively substituted. Conservative amino acid substitutions are those that occur within a group of amino acids that are related to amino acid side chains.
- amino acid substitution in such antibody variants is preferably performed within the range that does not reduce the antigen binding activity of the original (parent) antibody.
- Aspartic acid contained in the protein is easily converted to isoaspartic acid by isomerization when the amino acid linked to the C-terminal side has a small side chain, while deamidating to aspartic acid in the case of asparagine It is susceptible to conversion and may be further converted to isoaspartic acid by isomerization. If such isomerization or deamidation proceeds, protein stability may be affected. Therefore, in order to avoid such isomerization and deamidation, aspartate and asparagine in the protein or amino acids adjacent thereto can be substituted with other amino acids. It is preferable that the antibody variant in which such amino acid substitution has been made retains the antigen binding activity possessed by the original antibody.
- Antibody variants having an amino acid sequence in which conservative amino acid substitution has been made in the amino acid sequence possessed by rLA204, rLA212, rLA225, rLA869, rLA1264 or A9H12 of the present invention, and rLA204, rLA212, rLA225, rLA869, LA2264 or A9H12 are derived from A mouse antibody, a rat antibody, a chimerized antibody, a humanized antibody, a human antibody and the like comprising the CDR having an amino acid sequence having a conservative amino acid mutation in any amino acid sequence of CDRH1 to CDRH3 and CDRL1 to CDRL3 are also disclosed in the present invention. Is included.
- a variant of an antibody comprising CDRH1 to CDRH3 and CDRL1 to CDRL3 having an amino acid sequence in which one or two, and optimally one amino acid is substituted by another amino acid, and human LAG-3 Those that bind to are included in the variants of the antibody of the present invention.
- antibodies having CDRH1 to CDRH3 and CDRL1 to CDRL3 derived from a plurality of antibodies are also included in antibody variants.
- antibody variants derived from an antibody with only CDRH3, and CDRH1 and CDRH2 and CDRL1 to CDRL3 derived from another antibody.
- antibody variants are also encompassed in the term "antibody".
- the constant region of the antibody in the present invention is not particularly limited, but as LAG-3 antibody for cytotoxic T cell depletion, human antibody is preferably used.
- heavy chain constant regions of human antibodies include C ⁇ 1, C ⁇ 2, C ⁇ 3, C ⁇ 4, C ⁇ , C ⁇ , C ⁇ 1, C ⁇ 2, C ⁇ and the like.
- light chain constant regions of human antibodies include CC, C ⁇ , and the like.
- the anti-LAG-3 chimerized antibody or binding fragment thereof used in the present invention comprises (3-2) and (3-3), preferably in addition thereto (3-4) More preferably, in addition to (3-5), and even more preferably (3-2) to (3-8), all have the properties, functions, activities and the like described in the foregoing.
- the heavy chain nucleotide and amino acid sequences and light chain nucleotide and amino acid sequences of cLA 212 exemplified as rat-human chimerized antibodies of the present invention are shown in SEQ ID NOs: 23, 24, 25 and 26 (FIGS. 38, 39, 40 and 41). Respectively.
- Nucleotide numbers 1 to 57 in the nucleotide sequence of the heavy chain and amino acids 1 to 19 in the amino acid sequence of the heavy chain are signal sequences, and are usually included in the nucleotide and amino acid sequences of most mature heavy chains, respectively. Absent.
- nucleotide numbers 1 to 60 in the nucleotide sequence of the light chain and amino acids 1 to 20 in the amino acid sequence of the light chain are signal sequences, and usually the nucleotide and amino acid sequences of most mature light chains Not included.
- rat-human chimeric antibodies cLA204, cLA225, cLA869 and cLA1264 have been described elsewhere.
- IMP 731 chimeric type A9H12: see WO2008 / 132601 which is a mouse-human chimera of anti-human LAG-3 mouse antibody A9H12 can be exemplified.
- the antibody used in the present invention may be a binding fragment of anti-LAG-3 antibody.
- the binding fragment of an antibody means a fragment which retains at least a part of the function of the antibody.
- Such antibody functions generally include an antigen binding activity, an activity that regulates the activity of an antigen, an antibody-dependent cellular cytotoxicity (ADCC) activity, and the like.
- Binding fragments of suitable anti-LAG-3 antibodies for use in the present invention are (3-2) and (3-3), preferably in addition thereto (3-4), more preferably in addition thereto (3-5), and even more preferably all of (3-2) to (3-8) have the properties, functions, activities, etc. described in (5).
- the binding fragment of the antibody is not particularly limited as long as it is a fragment of the antibody that retains at least a part of the activity of the antibody, and examples thereof include Fab, F (ab ') 2, Fv, heavy chain and light Single chain Fv (scFv), diabody (diabodies), linear antibody, and multispecific antibody formed from antibody fragment, F (ab ') 2 formed by linking chain Fv with appropriate linker under reducing conditions
- Fab 'and the like which are monovalent fragments of the variable region of the treated antibody, it is not limited thereto.
- a molecule containing a portion other than a fragment of an antibody, such as a scFv having a linker portion is also included in the meaning of a binding fragment of an antibody.
- a molecule in which one to several or more amino acids and / or carboxy terminal amino acids of the antibody protein are deleted and which retains at least a part of the function of the antibody is also a binding fragment of the antibody Included in the meaning.
- the lysine residue at the carboxyl terminus of the heavy chain of an antibody produced in mammalian cultured cells is deleted (Journal of Chromatography A, 705: 129-134 (1995)), It is known that glycine at the carboxyl terminus of the chain and two amino acid residues of lysine are deleted and that a proline residue newly located at the carboxyl terminus is amidated (Analytical Biochemistry, 360: 75-83 (2007) ).
- deletions and modifications of these heavy chain sequences do not affect the antigen binding ability and effector functions (such as complement activation and antibody-dependent cellular cytotoxicity) of the antibody. Modifications of such antibody binding fragments are also encompassed in the antibody or its binding fragments, or modifications thereof (described later).
- the antibody or binding fragment thereof may be a multispecific antibody having specificity for at least two different antigens.
- a multispecific antibody is not limited to a bispecific antibody that binds to two different antigens, and an antibody having specificity for three or more different antigens is also a subject of the present invention. Within the meaning of "antibody” is included.
- the multispecific antibodies of the invention may be full length antibodies or binding fragments thereof (e.g. F (ab ') 2 bispecific antibodies).
- Bispecific antibodies can also be made by linking the heavy and light chains (HL pair) of the two antibodies. Alternatively, they can be obtained by fusing two or more types of hybridomas producing monoclonal antibodies to produce bispecific antibody-producing fusion cells (Millstein et al., Nature (1983) 305, p. 537). -539). Multispecific antibodies can also be prepared by similar methods.
- the LAG-3 antibody in the present invention is a single chain antibody (hereinafter referred to as "scFv").
- the scFv is obtained by linking the heavy chain V region and the light chain V region of an antibody with a polypeptide linker (Pluckthun, The Pharmacology of Monoclonal Antibodies, 113, edited by Rosenburg and Moore, Springer Verlag, New York, p. 269-315 (1994), Nature Biotechnology (2005), 23, p. 1126-1136).
- a BiscFv produced by linking two scFvs with a polypeptide linker can be used as a bispecific antibody.
- MultiscFv can also be used as a multispecific antibody from three or more scFv.
- single chain immunoglobulin full chain immunoglobulin in which the full-length sequences of antibody heavy and light chains are linked using an appropriate linker is included (Lee, HS, et al., Molecular Immunology (1999) 36, p. 61-71; Shirrmann, T. et. Al., MAbs (2010), 2, (1) p. 1-4).
- Such single-chain immunoglobulins can retain their structure and activity similar to that of an antibody that is originally tetramer by dimerizing.
- the antibody may be an antibody having a single heavy chain variable region and no light chain sequence.
- Such an antibody is called a single domain antibody (sdAb) or a nanobody, and it has been reported that the antigen binding ability is maintained (Muyldemans S. et. Al. , Protein Eng. (1994) 7 (9), 1129-35, Hamers-Casterman C. et. Al., Nature (1993) 363 (6428) 446-8). These antibodies are also included in the meaning of functional fragments of antibodies.
- the present invention provides a humanized antibody or a binding fragment thereof.
- Preferred humanized anti-LAG-3 antibodies or binding fragments thereof for use in the present invention are (3-2) and (3-3), preferably in addition thereto (3-4), more preferably In addition to them, (3-5), and even more preferably (3-2) to (3-8) all have the properties, functions, activities and the like described in the above.
- Suitable humanized antibodies for use in the present invention include the CDRH1 to CDRH3 and light chains of the heavy chain of rLA204, rLA212, rLA225, rLA869, rLA1264, A9H12 or H5L7, as described in AF below. And humanized antibodies having CDRL1 to CDRL3 of
- the humanized anti-LAG-3 antibody or binding fragment thereof of the present invention includes, for example, CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 41 (FIG. 56), CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 42 (FIG. 57) And a heavy chain having a variable region containing CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 43 (FIG. 58), and CDR L1 consisting of the amino acid sequence shown in SEQ ID NO: 44 (FIG.
- B A humanized antibody having CDRH1 to CDRH3 of the heavy chain of the rLA212 antibody and CDRL1 to CDRL3 of the light chain
- CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 47
- amino acid sequence shown in SEQ ID NO: 48 (FIG. 63)
- a heavy chain having a variable region containing CDRH3 consisting of the amino acid sequence shown in CDRH2 and SEQ ID NO: 49 (FIG. 64)
- CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 50 (FIG.
- a light chain having a variable region comprising CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 52 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 52 (FIG. 67), and a humanized antibody or binding fragment thereof that recognizes LAG-3 protein Or variants thereof.
- CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 53 (FIG. 68), amino acid sequence shown in SEQ ID NO: 54 (FIG. 69)
- CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 56 (FIG.
- a humanized antibody having CDRH1 to CDRH3 of the heavy chain of the D. rLA869 antibody and CDRL1 to CDRL3 of the light chain Furthermore, as another humanized anti-LAG-3 antibody or a binding fragment thereof, for example, CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 59 (FIG. 74), amino acid sequence shown in SEQ ID NO: 60 (FIG. 75)
- CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 59 (FIG. 74), amino acid sequence shown in SEQ ID NO: 60 (FIG. 75)
- a heavy chain having a variable region containing CDRH3 consisting of the amino acid sequence shown in CDRH2 and SEQ ID NO: 61 (FIG. 76), and CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 62 (FIG.
- CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 65 (FIG. 80), amino acid sequence shown in SEQ ID NO: 66 (FIG. 81)
- a light chain having a variable region comprising CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 70 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 70 (FIG. 85), and a humanized antibody or binding fragment thereof that recognizes LAG-3 protein Or variants thereof.
- a humanized antibody or a binding fragment thereof that recognizes LAG-3 protein or a variant thereof can be mentioned, which comprises CDRH1 to CDRH3 and CDRL1 to CDRL3 contained in A9H12 antibody or H5L7 antibody.
- Preferred humanized antibodies for use in the present invention include those described above A to F, and examples of more suitable humanized antibodies include hLA212_H2 / L1 to hLA212_H2 / L5, hLA212_H3 / L1 to hLA212_H3 / L5 And hLA212_H4 / L2 (see [i] to [x] below) and humanized versions of IMP 731 H5L7, H1L7, J7L7, H4L7, J11L7, H2L7, J13L7, H7L7, J0L7, H0L7 and H5L7BW (Patent Document 2) And the like, but not limited thereto, for example, any of hLA212_H2 / L1 to hLA212_H2 / L5, hLA212_H3 / L1 to hLA212_H3 / L5, hLA212_H4 / L2, H5L7 and H5L7BW
- [I] [1 of 1] hLA212_H3 / L2 is the humanized antibody obtained in Example 6.
- the nucleotide sequence of the heavy chain of the antibody is nucleotide number 58 to 1410 (including the variable region 58 to 420) of SEQ ID NO: 29 (FIG. 44), and the amino acid sequence is amino acid number 20 to 470 of SEQ ID NO: 30 (FIG. 45)
- the variable region is 20 to 140
- the nucleotide sequence of the light chain is nucleotide number 61 to 702 of SEQ ID NO: 33 (FIG. 48) (the variable region is 61 to 387)
- the amino acid sequence is SEQ ID NO: 34 (FIG. 49).
- the antibody is a composition suitable for cytotoxic T cell depletion according to the present invention, a method for treating or preventing cytotoxic T cell related diseases, physical properties suitable for use for treatment or prophylaxis (data not shown), (3 -2), and the LAG-3 binding activity described in (3-3) and the in vitro ADCC activity and the properties described in (3-8), that is, human LAG-3 suppresses human T cells in the presence of the antibody It can be evaluated, for example, by the method described in the examples that the function is exhibited (see examples) and the activities, properties and the like described in (3-4) to (3-7).
- hLA212_H4 / L2 is a glycosylated modified humanized antibody obtained in Example 8 and is one of hLA212_H3 / L2 in a low fucose form.
- the nucleotide sequence of the heavy chain of the antibody is nucleotide number 58 to 1410 (including the variable region 58 to 420) of SEQ ID NO: 29 (FIG. 44), and the amino acid sequence is amino acid number 20 to 470 of SEQ ID NO: 30 (FIG. 45)
- the variable region is 20 to 140
- the nucleotide sequence of the light chain is nucleotide number 61 to 702 of SEQ ID NO: 33 (FIG.
- the antibody is a composition suitable for cytotoxic T cell depletion according to the present invention, a method for treating or preventing cytotoxic T cell related diseases, physical properties suitable for use for treatment or prophylaxis (data not shown), (3 LAG-3 binding activity described in (2) to (3-6), in vitro ADCC activity, LAG3-positive cell number reducing activity, experimental autoimmune encephalomyelitis inhibitory activity and human activated T cell binding activity And having the properties described in (3-7), that is, in the presence of the antibody, human LAG-3 and human MHC class II molecules bind (see Examples), and the properties described in (3-8), that is, the presence of the antibody
- the ability of human LAG-3 to exert a human T cell suppressive function can be evaluated, for example, by the method described in the Examples.
- [Ii] hLA212_H2 / L1 is the humanized antibody obtained in Example 6.
- the nucleotide sequence of the heavy chain of the antibody is nucleotide number 58 to 1410 (including the variable region 58 to 420) of SEQ ID NO: 27 (FIG. 42), and the amino acid sequence is amino acid number 20 to 470 (SEQ ID NO: 28) (FIG. 43).
- the variable region is 20 to 140
- the nucleotide sequence of the light chain is nucleotide number 61 to 702 of SEQ ID NO: 31 (FIG. 46) (the variable region is 61 to 387)
- the amino acid sequence is SEQ ID NO 32 (FIG. 47).
- Amino acid numbers 21 to 234 (of which variable regions are 21 to 129), respectively.
- the antibody has physical properties (data not shown), LAG-3 binding activity described in (3-2) and (3-3) and in vitro ADCC activity suitable for the composition of the present invention, treatment or prevention etc. It can be evaluated, for example, by the method described in Examples, that the activity, properties and the like described in (see Examples) and (3-4) to (3-8).
- [Iii] hLA212_H3 / L3 is the humanized antibody obtained in Example 6.
- the nucleotide sequence of the heavy chain of the antibody is nucleotide number 58 to 1410 (including the variable region 58 to 420) of SEQ ID NO: 29 (FIG. 44), and the amino acid sequence is amino acid number 20 to 470 of SEQ ID NO: 30 (FIG. 45)
- the variable region is 20 to 140
- the nucleotide sequence of the light chain is nucleotide number 61 to 702 of SEQ ID NO: 35 (FIG. 50) (the variable region is 61 to 387), and the amino acid sequence is SEQ ID NO: 36 (FIG. 51).
- Amino acid numbers 21 to 234 (of which variable regions are 21 to 129), respectively.
- the antibody has physical properties (data not shown), LAG-3 binding activity described in (3-2) and (3-3) and in vitro ADCC activity suitable for the composition of the present invention, treatment or prevention etc. It can be evaluated, for example, by the method described in Examples, that the activity, properties and the like described in (see Examples) and (3-4) to (3-8).
- [Iv] hLA212_H2 / L2 is the humanized antibody obtained in Example 6.
- the nucleotide sequence of the heavy chain of the antibody is nucleotide number 58 to 1410 (including the variable region 58 to 420) of SEQ ID NO: 27 (FIG. 42), and the amino acid sequence is amino acid number 20 to 470 (SEQ ID NO: 28) (FIG. 43).
- the variable region is 20 to 140
- the nucleotide sequence of the light chain is nucleotide number 61 to 702 of SEQ ID NO: 33 (FIG. 48) (the variable region is 61 to 387)
- the amino acid sequence is SEQ ID NO: 34 (FIG. 49).
- Amino acid numbers 21 to 234 (of which variable regions are 21 to 129), respectively.
- the antibody has physical properties (data not shown), LAG-3 binding activity described in (3-2) and (3-3) and in vitro ADCC activity suitable for the composition of the present invention, treatment or prevention etc. It can be evaluated, for example, by the method described in Examples, that the activity, properties and the like described in (see Examples) and (3-4) to (3-8).
- [V] hLA212_H2 / L3 is the humanized antibody obtained in Example 6.
- the nucleotide sequence of the heavy chain of the antibody is nucleotide number 58 to 1410 (including the variable region 58 to 420) of SEQ ID NO: 27 (FIG. 42), and the amino acid sequence is amino acid number 20 to 470 (SEQ ID NO: 28) (FIG. 43).
- the variable region is 20 to 140
- the nucleotide sequence of the light chain is nucleotide number 61 to 702 of SEQ ID NO: 35 (FIG. 50) (the variable region is 61 to 387)
- the amino acid sequence is SEQ ID NO: 36 (FIG. 51).
- Amino acid numbers 21 to 234 (of which variable regions are 21 to 129), respectively.
- the antibody has physical properties (data not shown), LAG-3 binding activity described in (3-2) and (3-3) and in vitro ADCC activity suitable for the composition of the present invention, treatment or prevention etc. It can be evaluated, for example, by the method described in Examples, that the activity, properties and the like described in (see Examples) and (3-4) to (3-8).
- [Vi] hLA212_H2 / L4 is the humanized antibody obtained in Example 6.
- the nucleotide sequence of the heavy chain of the antibody is nucleotide number 58 to 1410 (including the variable region 58 to 420) of SEQ ID NO: 27 (FIG. 42), and the amino acid sequence is amino acid number 20 to 470 (SEQ ID NO: 28) (FIG. 43).
- the variable region is 20 to 140
- the nucleotide sequence of the light chain is nucleotide number 61 to 702 of SEQ ID NO: 37 (FIG. 52) (the variable region is 61 to 387)
- the amino acid sequence is SEQ ID NO: 38 (FIG. 53).
- Amino acid numbers 21 to 234 (of which variable regions are 21 to 129), respectively.
- the antibody has physical properties (data not shown), LAG-3 binding activity described in (3-2) and (3-3) and in vitro ADCC activity suitable for the composition of the present invention, treatment or prevention etc. It can be evaluated, for example, by the method described in Examples, that the activity, properties and the like described in (see Examples) and (3-4) to (3-8).
- [Vii] hLA212_H2 / L5 is the humanized antibody obtained in Example 6.
- the nucleotide sequence of the heavy chain of the antibody is nucleotide number 58 to 1410 (including the variable region 58 to 420) of SEQ ID NO: 27 (FIG. 42), and the amino acid sequence is amino acid number 20 to 470 (SEQ ID NO: 28) (FIG. 43).
- the variable region is 20 to 140
- the nucleotide sequence of the light chain is nucleotide number 61 to 702 of SEQ ID NO: 39 (FIG. 54) (the variable region is 61 to 387)
- the amino acid sequence is SEQ ID NO: 40 (FIG. 55).
- Amino acid numbers 21 to 234 (of which variable regions are 21 to 129), respectively.
- the antibody has physical properties (data not shown), LAG-3 binding activity described in (3-2) and (3-3) and in vitro ADCC activity suitable for the composition of the present invention, treatment or prevention etc. It can be evaluated, for example, by the method described in Examples, that the activity, properties and the like described in (see Examples) and (3-4) to (3-8).
- [Viii] hLA212_H3 / L1 is the humanized antibody obtained in Example 6.
- the nucleotide sequence of the heavy chain of the antibody is nucleotide number 58 to 1410 (including the variable region 58 to 420) of SEQ ID NO: 29 (FIG. 44), and the amino acid sequence is amino acid number 20 to 470 of SEQ ID NO: 30 (FIG. 45) Among them, the variable region is 20 to 140), the nucleotide sequence of the light chain is nucleotide number 61 to 702 of SEQ ID NO: 31 (FIG. 46) (the variable region is 61 to 387), and the amino acid sequence is SEQ ID NO 32 (FIG. 47).
- Amino acid numbers 21 to 234 (of which variable regions are 21 to 129), respectively.
- the antibody has physical properties (data not shown), LAG-3 binding activity described in (3-2) and (3-3) and in vitro ADCC activity suitable for the composition of the present invention, treatment or prevention etc. It can be evaluated, for example, by the method described in Examples, that the activity, properties and the like described in (see Examples) and (3-4) to (3-8).
- [Ix] hLA212_H3 / L4 is the humanized antibody obtained in Example 6.
- the nucleotide sequence of the heavy chain of the antibody is nucleotide number 58 to 1410 (including the variable region 58 to 420) of SEQ ID NO: 29 (FIG. 44), and the amino acid sequence is amino acid number 20 to 470 of SEQ ID NO: 30 (FIG. 45) Among them, the variable region is 20 to 140), the nucleotide sequence of the light chain is nucleotide number 61 to 702 of SEQ ID NO: 37 (FIG. 52) (the variable region is 61 to 387), and the amino acid sequence is SEQ ID NO: 38 (FIG. 53).
- Amino acid numbers 21 to 234 (of which variable regions are 21 to 129), respectively.
- the antibody has physical properties (data not shown), LAG-3 binding activity described in (3-2) and (3-3) and in vitro ADCC activity suitable for the composition of the present invention, treatment or prevention etc. It can be evaluated, for example, by the method described in Examples, that the activity, properties and the like described in (see Examples) and (3-4) to (3-8).
- [X] hLA212_H3 / L5 is the humanized antibody obtained in Example 6.
- the nucleotide sequence of the heavy chain of the antibody is nucleotide number 58 to 1410 (including the variable region 58 to 420) of SEQ ID NO: 29 (FIG. 44), and the amino acid sequence is amino acid number 20 to 470 of SEQ ID NO: 30 (FIG. 45)
- the variable region is 20 to 140
- the nucleotide sequence of the light chain is nucleotide number 61 to 702 of SEQ ID NO: 39 (FIG. 54) (the variable region is 61 to 387)
- the amino acid sequence is SEQ ID NO: 40 (FIG. 55).
- Amino acid numbers 21 to 234 (of which variable regions are 21 to 129), respectively.
- the antibody has physical properties (data not shown), LAG3-binding activity described in (3-2) and (3-3) and in vitro ADCC activity (the data are not shown) suitable for the composition of the present invention, etc. It can be evaluated, for example, by the method described in Examples, that the activity, properties and the like described in Examples) and (3-4) to (3-8).
- the activities described in (3-4) and (3-5) can be preferably evaluated in a low fucose form.
- "physical properties" refers to the stability of an antibody used in the present invention and a binding fragment thereof etc., and can be evaluated using a known index. Thermal stability, storage stability, etc. can be raised as the stability as a product, and Tm values derived from thermograms, changes in antigen binding activity under storage conditions or accelerated deterioration conditions, or aging over time as their indices Change can be raised.
- the antibodies used in the present invention have safety suitable for treatment or prevention of cytotoxic T cell depletion, cytotoxic T cell related diseases (as defined elsewhere), etc. Is desirable.
- hLA212_H3 / L2, hLA212_H2 / L1, hLA212_H3 / L3, hLA212_H3 / L6, hLA212_H4 / L2 are more preferred.
- H5L7 and H5L7BW are more preferred.
- HLA212_H2 / L1 to H2 / L5, hLA212_H3 / L1 to H3 / L5, hLA212_H4 / L2, H5L7 and H5L7BW, etc. which are included in the range of more preferable humanized anti-LAG-3 antibodies used in the present invention
- amino acid sequences FRL1 to FRL4 a heavy chain consisting of an amino acid sequence in which one to several, preferably one or two amino acids are substituted with another amino acid, and a light chain amino acid sequence FRH1 to FRH4 And a light chain consisting of an amino acid sequence in which one or more amino acids, preferably 1 to 14 amino acids in any number, are substituted with other amino acids.
- the first amino acid of FRL1 ie, the first amino acid of the mature variable region (sequence The amino acid corresponding to the position 32 of FIG. 32 or FIG. 47 is Asp or Asn, the 11th amino acid of FRL1, ie, the 11th amino acid of the mature variable region (SEQ ID NO: 32 or 31 of FIG.
- Amino acid corresponding to the position is Leu or Met
- amino acid 13 of FRL1 ie, amino acid 13 corresponding to the position 33 of SEQ ID NO: 32 or FIG. 47
- amino acid 21 of FRL1 ie, amino acid 21 of the mature variable region
- the amino acid corresponding to the position 32 of FIG. 32 or FIG. 47 is Ile or Met
- the amino acid 4 of FRL2 ie, the amino acid 38 of the mature variable region (SEQ ID NO 32 or 58 of FIG. 47).
- Amino acid corresponding to the position is Gln or Lys
- amino acid 9 of FRL2 ie, amino acid 43 of the mature variable region (amino acid corresponding to position 63 of SEQ ID NO: 32 or FIG. 47) is Ala or Ser
- Amino acid number 4 of FRL3 ie, amino acid number 60 of the mature variable region (amino acid corresponding to position 80 in SEQ ID NO: 32 or FIG. 47) is Ser or Asp
- Amino acid number 65 of the mature variable region is Ser or Gly. No. 11 of FRL3, ie, amino acid No.
- 67 of the mature variable region is Ser or Tyr, and amino acid No. 22 of FRL3, ie mature
- the 78th amino acid of the variable region (the amino acid corresponding to the position 98 of SEQ ID NO: 32 or FIG. 47) is Leu or Val, and the 27th amino acid of FRL3, ie, the 83rd amino acid of the mature variable region (SEQ ID NO:
- the amino acid corresponding to the position 32 of FIG. 32 or FIG. 47 is Phe or Ala, the 29th amino acid of FRL3, ie, the 85th amino acid of the mature variable region (the position 105 of SEQ ID NO: 32 or FIG.
- Amino acid (Thr) or Phe corresponding to (SEQ ID
- the amino acid (the amino acid corresponding to the position 124 of SEQ ID NO: 32 or FIG. 47) is Val or Leu, the 9th amino acid of FRL4, ie, the 106th amino acid of the mature variable region (SEQ ID NO: 32 or FIG.
- the amino acid corresponding to the position 126) is Ile or Leu.
- amino acid No. 49 of FRH2, ie, amino acid 49 of the mature variable region amino acid No. 49 of FRH2, ie, amino acid 49 of the mature variable region (sequence
- the amino acid corresponding to position 68 of FIG. 28 or FIG. 43 is Gly or Ala
- the 25th amino acid of FRH3, ie, the 84th amino acid of the mature variable region SEQ ID NO: 28 or 103 of FIG. 43
- the amino acid (corresponding to the position) is Asn or Asp.
- RLA204, rLA225, rLA826, rLA1264, cLA204, cLA212, cLA225, cLA869, rLA1264 and A9H12 of the present invention and humanized hLA212_H2 / L1 to hLA212_H2 / L5, hLA212_H3 / L1 to hLA212_H3 / L5, L5
- the amino acid sequence of the full or variable region of the heavy chain and / or light chain of any one of H5L7BW and H5L7BW, respectively, 80% or more, 82% or more, 84% or more, 86% or more, 88% or more, 90% or more % Or more, 92% or more, 94% or more, 96% or more, 98% or more or 99% or more of the heavy chain and / or light chain containing the same amino acid sequence, and which binds to LAG-3 or the binding thereof Fragments are also present invention It is included.
- Such sequence identity is preferably at least 94%, more preferably at least 96%, even more preferably at least 98%, optimally at least 99%.
- their antibodies or binding fragments thereof are preferably (3-2) and (3-3), preferably in addition to (3-4), more preferably in addition to (3-5), Even more preferably, all of (3-2) to (3-8) have the properties, functions, activities and the like described in the above.
- the identity or homology between the two amino acid sequences can be determined from Blast algorithm version 2.2.2 (Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25: 3389-3402).
- Blast algorithm can also be used, for example, by accessing http://blast.ncbi.nlm.nih.gov/ on the Internet.
- the present invention rLA 204, rLA 212, rLA 825, rLA 1264, cLA 204, cLA 212, cLA 225, cLA 869, cLA 1264 and A9H12, and hLA212_H2 / L1 to hLA212_H2 / L5, hLA212_H3 / L1 to hLA212_H3 / L7, HLhLh, HLhLh, HLhLhLhHh 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30 in the amino acid sequence of the full length or variable region of the heavy chain and / or light chain of any one of 1 to 25 1 to 20 1 to 15 1 to 10 1 to 8 1 to 6 1 to 5 1 to 4 1 to 3 1 or 2
- single amino acid substitutions, deletions, And / or insert comprises a heavy chain and / or light chain comprising an amino acid sequence comprising, and antibodies or binding fragments thereof that bind to L
- Such amino acid mutations are preferably substitutions, and the number of amino acids to be mutated is preferably 1 to 5, more preferably 1 to 4, still more preferably 1 to 3, still more preferably Is one or two, optimally one.
- their antibodies or binding fragments thereof are preferably (3-2) and (3-3), preferably in addition to (3-4), more preferably in addition to (3-5) And even more preferably all of the properties, functions, activities and the like described in (3-2) to (3-8).
- the present invention provides a human antibody or a binding fragment thereof.
- the human antibody or binding fragment thereof is not particularly limited as long as it is a human-derived antibody or binding fragment thereof which binds to LAG-3, but (3-2) and (3-3), preferably In addition to (3-4, more preferably in addition to (3-5), still more preferably (3-2) to (3-8), all of the properties, functions, activities, etc. described in Each has.
- antibody that binds to the same site as the antibody used in the present invention can also be used in the present invention.
- an antibody that binds to the same site as an antibody refers to another antibody that binds to a site on an antigen molecule that the antibody recognizes. If the second antibody binds to the partial peptide or partial conformation on the antigen molecule to which the first antibody binds, it can be determined that the first antibody and the second antibody bind to the same site.
- the second antibody competes for the binding of the first antibody to the antigen, ie confirming that the second antibody interferes with the binding of the first antibody to the antigen, the peptide sequence of the specific binding site or Even if the three-dimensional structure has not been determined, it can be determined that the first antibody and the second antibody bind to the same site. Furthermore, when the first antibody and the second antibody bind to the same site, and the first antibody has an effect such as ADCC activity, the probability that the second antibody has similar activity is extremely high. Therefore, if the second anti-LAG-3 antibody binds to the binding site of the first anti-LAG-3 antibody, it is determined that the first antibody and the second antibody bind to the same site on the LAG-3 protein be able to.
- the second anti-LAG-3 antibody competes with the binding of the first anti-LAG-3 antibody to the LAG-3 protein, then the first antibody and the second antibody form LAG-3 protein It can be determined that the antibody binds to the same site of
- antibodies that bind to a site on LAG-3 protein that a monoclonal antibody recognizes are also included in antibodies that can be used in the present invention.
- Such antibodies and their binding fragments are preferably (3-2) and (3-3), preferably in addition to (3-4), more preferably in addition to (3-5), More preferably, all (3-2) to (3-8) have the properties, functions, activities and the like described in the above.
- the binding site of an antibody can be determined by methods well known to those skilled in the art, such as immunoassays. For example, after preparing a series of peptides in which the amino acid sequence of the antigen is appropriately truncated from the C-terminus or N-terminus, the reactivity of the antibody against them is examined, and after rough recognition sites are determined, shorter peptides are synthesized Binding sites can be determined by examining the reactivities of antibodies to those peptides. Antigen fragment peptides can be prepared using techniques such as gene recombination and peptide synthesis.
- the binding site of such antibody is determined by using X-ray structural analysis to identify amino acid residues on the antigen adjacent to the antibody. be able to. For example, by combining and crystallizing an antibody or a fragment thereof and an antigen or a fragment thereof and analyzing the structure, amino acid residues on the antigen having an interaction distance with the antibody can be identified.
- the interaction distance is 8 ⁇ or less, preferably 6 ⁇ or less, and more preferably 4 ⁇ or less.
- Amino acid residues having an interaction distance with such an antibody may constitute one or more antigen binding sites (epitopes) of the antibody. When two or more such amino acid residues are present, each amino acid may not be adjacent to each other on the primary sequence.
- the epitope of the LAG-3 antibody in the present invention is present in human LAG-3 or its amino acid sequence.
- An antibody, a binding fragment thereof or a modified form thereof, which binds to such an epitope, competes with the antibody used in the present invention for binding to such an epitope, or has an interaction distance with such an amino acid residue is also disclosed. It is encompassed in an antibody which can be used in the present invention, a binding fragment thereof or a modified product thereof.
- the present invention provides a composition comprising a modified form of an antibody or a binding fragment thereof.
- the modified form of the antibody or its binding fragment means that the antibody or its binding fragment is chemically or biologically modified.
- Chemical modifications include attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and the like.
- Biologically modified forms include post-translational modifications (eg, glycosylation to N- or O-link, N- or C-terminal processing, deamidation, aspartic acid isomerization, methionine oxidation) And those obtained by adding a methionine residue at the N-terminus by expression using a prokaryotic host cell.
- modified antibodies or binding fragment thereof is useful for improving the stability and retention in blood of the original antibody or binding fragment thereof, reducing antigenicity, detecting or isolating such an antibody or antigen, etc. .
- Examples of the chemical moiety contained in the chemical modification can include water-soluble polymers such as polyethylene glycol, ethylene glycol / propylene glycol copolymer, carboxymethyl cellulose, dextran, polyvinyl alcohol and the like.
- Bioly modified products include those modified by enzyme treatment or cell treatment, fusions to which other peptides such as tags have been added by genetic recombination, and endogenous or foreign sugar chain modifying enzymes Cells prepared using as a host cells expressing.
- Antibody-dependent cytotoxic activity can be enhanced by modulating the glycosylation (glycosylation, defucosification, etc.) bound to the antibody or its binding fragment.
- glycosylation glycosylation, defucosification, etc.
- modified forms of antibodies also include antibodies in which the sugar chain modification has been adjusted.
- Such modifications may be made at any position in the antibody or binding fragment thereof, or at a desired position, and the same or two or more different modifications may be made at one or more positions.
- modified antibody fragment also includes “fragment of modified antibody” in its meaning.
- a modified form of an antibody and a modified form of its binding fragment may be simply referred to as "antibody” or "binding fragment of antibody”.
- antibody or "binding fragment of antibody”.
- hLA212_H4 / L2 is the humanized antibody with modified sugar chain modification obtained in Example 8.
- humanized antibodies are also encompassed in the antibodies that can be used in the present invention.
- the antibody, binding fragment thereof and modified form thereof which can be used in the present invention are preferably compositions for cytotoxic T cell depletion of the present invention, treatment or prevention of cytotoxic T cell related diseases. And physical properties, pharmacokinetics, retention in blood, safety, etc. suitable for use for treatment or prevention.
- a LAG-3 antibody that can be used for cytotoxic T cell depletion is preferably an ADCC activity, a CDC activity and / or an ADCP for LAG-3 expressing cells. It is an antibody that exhibits cytotoxic activity such as activity, more preferably a LAG-3 antibody with enhanced ADCC activity, CDC activity and / or ADCP activity.
- LAG-3 antibodies in which the ADCC activity has been enhanced by hypofucosification, afucosylation, etc., ie, LAG-3 antibodies in a hypofucose form include hLA212_H4 / L2, H5L7BW, etc.
- LAG-3 antibody against cytotoxic T cells can be evaluated based on assays known in the art, and described in Examples 13 and 14 as in vitro assays, in vivo As the assay of the above, those described in Example 11-1) can be exemplified, but are not limited thereto.
- An antigen for producing an anti-LAG-3 antibody can be prepared according to the method for preparing natural or recombinant LAG-3 protein described in the other part of the present invention, etc. It can be acquired. Antigens that can be prepared as such include LAG-3 protein or a LAG-3 protein fragment comprising at least 6 consecutive partial amino acid sequences thereof, or to which any amino acid sequence or carrier is added. Derivatives and the like (hereinafter collectively referred to as "LAG-3 antigen": the same as "LAG-3 protein”) can be mentioned.
- a recombinant LAG-3 antigen is prepared by introducing a gene containing a nucleotide sequence encoding an amino acid sequence possessed by LAG-3 antigen into a host cell and recovering the antigen from a culture of the cell. Can. Such recombinant antigens may be fusion proteins with other proteins such as immunoglobulin Fc regions.
- the recombinant LAG-3 antigen also includes the LAG-3 antigen obtained in a cell-free system by a gene containing a nucleotide sequence encoding the amino acid sequence of the LAG-3 antigen by an in vitro translation system. .
- Non-recombinant LAG-3 antigen can be purified and isolated from cells expressing LAG-3.
- an anti-LAG-3 monoclonal antibody that exerts the T cell function suppressive function of LAG-3 even in the presence or does not suppress or inhibit the T cell functional suppressive function of LAG-3
- LAG-3 mutants in which immunoglobulin-like domains 1 and 2 have been deleted can be used.
- a culture step of a hybridoma As necessary, (g) a culture step of a hybridoma, a breeding step of an animal to which a hybridoma is transplanted, and the like, and (h) a measurement step / judging step of biological activity of a monoclonal antibody are added.
- the method for producing a monoclonal antibody is described in detail below along the above steps, but the method for producing the antibody is not limited thereto, and for example, antibody-producing cells other than splenocytes can also be used.
- step (B) Step of Preparing Antibody-Producing Cells
- the antigen obtained in step (a) is mixed with Freund's complete or incomplete adjuvant or an adjuvant such as potassium alum to immunize experimental animals as an immunogen.
- animals used in known hybridoma production methods can be used without problems. Specifically, for example, mice, rats, goats, sheep, cattle, horses and the like can be used. However, it is preferable to use a mouse or a rat as an animal to be immunized from the viewpoint of the availability of myeloma cells to be fused with the antibody-producing cells that have been extracted.
- mice and rats to be actually used are not particularly limited, and in the case of mice, for example, A, AKR, BALB / c, BALB / c An NCrj, BDP, BA, CE, C3H, 57BL, C57BL, C57L , DBA, FL, HTH, HT1, LP, NZB, NZW, RF, RIII, SJL, SWR, WB, 129 etc., in the case of a rat, for example, Wistar, Low, Lewis, Spraque, Daweley, ACI, BN, Fischer, etc. can be used.
- mice and rats can be obtained, for example, from Nippon Crea, Japan Charles River, etc. from laboratory animal breeding dealers.
- the BALB / c strain in mice and the Wistar and Low strains in rats are particularly preferable as the animals to be immunized, in consideration of fusion compatibility with the later-described myeloma cells.
- mice in which the biological mechanism for removing autoantibodies has been reduced that is, autoimmune disease mice, in consideration of the homology between human and mouse antigens.
- the age of these mice or rats at the time of immunization is preferably 5 to 12 weeks, and more preferably 6 to 8 weeks.
- antibody titer measurement methods include immunoassays such as RIA method and ELISA method, but are not limited to these methods.
- Antibody-producing cells derived from spleen cells or lymphocytes isolated from immunized animals are described, for example, by Kohler et al. , Nature (1975) 256, p. 495 ,; Kohler et al. , Eur. J. Immnol. (1977) 6, p. 511 ,; Milstein et al. , Nature (1977), 266, p. 550 ,; Walsh, Nature, (1977) 266, p. It can be prepared according to known methods such as 495,).
- spleen cells In the case of spleen cells, a general method may be employed in which the spleen is minced and the cells are filtered through a stainless mesh and suspended in Eagle's minimal essential medium (MEM) or the like to separate antibody-producing cells.
- MEM Eagle's minimal essential medium
- (C) Step of preparing myeloma There is no particular limitation on the myeloma cell used for cell fusion, and it can be appropriately selected from known cell lines, but the convenience in selecting hybridomas from fused cells is taken into consideration. Then, the HGPRT (Hipoxanthine-guanine phosphoribosyl transferase) -deficient strain whose selection procedure has been established, that is, X63-Ag8 (X63), NS1-ANS / 1 (NS1), P3X63-Ag8.
- HGPRT Hipoxanthine-guanine phosphoribosyl transferase
- These cell lines can be prepared by using an appropriate culture medium, for example, 8-azaguanine culture medium [RPMI-1640 culture medium supplemented with glutamine, 2-mercaptoethanol, gentamycin, and fetal bovine serum (hereinafter referred to as “FBS”) Added culture medium], Iscove's Modified Dulbecco's Medium (hereinafter referred to as "IMDM”), or subcultured in Dulbecco's Modified Eagle Medium (hereinafter referred to as "DMEM”)
- IMDM Iscove's Modified Dulbecco's Medium
- DMEM Dulbecco's Modified Eagle Medium
- (E) Step of Selecting Hybridoma Group Producing Target Antibody The method of selecting hybridomas obtained by cell fusion is not particularly limited, but usually the HAT (hypoxanthine aminopterin thymidine) selection method (Kohler et al. , Nature (1975) 256, p. 495; Milstein et al., Nature (1977) 266, p. 550) are used. This method is effective in obtaining hybridomas using myeloma cells of HGPRT-deficient strains that can not survive in aminopterin. That is, by culturing unfused cells and hybridomas in HAT medium, only those hybridomas resistant to aminopterin can be selectively left to grow.
- HAT hyperxanthine aminopterin thymidine
- Step of obtaining single cell clone Step of obtaining single cell clone (cloning)
- a cloning method of a hybridoma for example, known methods such as methyl cellulose method, soft agarose method, limiting dilution method and the like can be used (for example, Barbara, B. M. and Stanley, M. S .: Selected Methods in Cellular Immunology, W. H. Freeman and Company, San Francisco (1980)), preferably the limiting dilution method.
- the monoclonal antibodies produced by such hybridomas can be recovered from cultures of the hybridomas. Alternatively, it can be recovered as a recombinant antibody from a culture of cells into which the monoclonal antibody gene has been introduced. In addition, hybridomas can be injected into the peritoneal cavity of mice of the same strain (eg, BALB / cAnNCrj described above) or Nu / Nu mice, and the hybridomas can be recovered from the ascites by growing the hybridomas. (H) Measurement Step / Determination Step of Biological Activity of Monoclonal Antibody Various biological tests can be selected and applied according to the purpose.
- LAG-3 antibodies By using cells expressing a natural LAG-3 protein, cells expressing a recombinant LAG-3 protein or a fragment thereof as an immunogen, it is possible to LAG-3 antibodies can be prepared.
- Cells expressing LAG-3 are 1 ⁇ 10 5 to 1 ⁇ 10 9 cells, preferably 1 ⁇ 10 6 to 1 ⁇ 10 8 cells, more preferably 0.5 to 2 ⁇ 10 7 cells, even more preferably Although 1 ⁇ 10 7 cells are used for one immunization, the number of cells to be immunized can be changed according to the expression level of LAG-3 protein.
- Such an immunogen is generally administered intraperitoneally, but can also be administered intradermally.
- the method described in (4-1-2) can be applied as a method for producing a hybridoma.
- the antibody used in the present invention includes a nucleotide (heavy chain nucleotide) including a nucleotide sequence encoding the heavy chain amino acid sequence and a nucleotide sequence encoding the light chain amino acid sequence Introducing a nucleotide (light chain nucleotide) or a vector into which such heavy chain nucleotide is inserted and a vector into which the light chain nucleotide is inserted into a host cell, culturing the cell and recovering the antibody from the culture It can be prepared by Heavy chain nucleotides and light chain nucleotides may be inserted into one vector.
- prokaryotic cells or eukaryotic cells can be used as host cells.
- eukaryotic cells animal cells, plant cells, and eukaryotic microorganisms can be used.
- mammalian-derived cells ie, monkey-derived COS cells (Gluzman, Y. Cell (1981) 23, p. 175-182, ATCC CRL-1650), mouse fibroblast NIH 3 T 3 (ATCC No. CRL-1658), mouse NS0 cell line (ECACC), Chinese hamster ovary cells (CHO cells, ATCC CCL-61), its dihydrofolate reductase deficient line (CHOdhfr-: Urlaub, G. and Chasin, L. A. Proc. Natl. Acad. Sci. U. S. A. (1980) 77, p. 4126-4220), CHOK1 SV (Lonza Biologics), cells from birds such as chickens, cells from insects, etc. can be mentioned. .
- mammalian-derived cells ie, monkey-derived COS cells (Gluzman, Y. Cell (1981) 23, p. 175-182, ATCC CRL-1650), mouse fibroblast NIH 3 T 3 (ATCC No
- cells modified to control sugar chain modification of proteins such as antibodies can also be used as hosts.
- an antibody using CHO cells modified to reduce or eliminate fucose binding to N-acetylglucosamine at the reducing end of the carbohydrate among N-glycosidic bond complex-type sugar chains binding to the Fc region of the antibody It is possible to prepare a reduced or defucosated antibody (also referred to as a modified antibody) by expressing E. coli (WO 00/61739, WO 02/31140, etc.).
- yeast etc. can be mentioned, for example.
- prokaryotic cells examples include Escherichia coli, Bacillus subtilis and the like.
- an antibody As a signal peptide for secreting an antibody (a monoclonal antibody derived from various animals, a rat antibody, a mouse antibody, a chimerized antibody, a humanized antibody, a human antibody etc.), an antibody of the same type, same type and same type as the said antibody Secretory signal of the antibody as well as the secretory signal of the antibody itself, but of secretory signals of other types or subtypes of antibodies, or secretory signals of proteins from other eukaryotic species or prokaryotes If there is, you can select and use any one.
- an antibody a monoclonal antibody derived from various animals, a rat antibody, a mouse antibody, a chimerized antibody, a humanized antibody, a human antibody etc.
- an antibody of the same type, same type and same type as the said antibody Secretory signal of the antibody as well as the secretory signal of the antibody itself, but of secretory signals of other types or subtypes of antibodies, or secretory signals of proteins from
- the antibodies that can be used in the present invention can further include human antibodies.
- the anti-LAG-3 human antibody means an anti-LAG-3 antibody consisting of the amino acid sequence of a human-derived antibody.
- the anti-LAG-3 human antibody is a method using a human antibody-producing mouse having a human genomic DNA fragment containing heavy and light chain genes of human antibody (Tomizuka, K. et al., Nature Genetics (1997) 16, p Kuroiwa, Y. et. Al., Nuc. Acids Res. (1998) 26, p. 3447-3448; Yoshida, H. et. Al., Animal Cell Technology: Basic and Applied Aspects vol. 10, p.
- human antibody-producing animals are disrupted by the loci of endogenous immunoglobulin heavy and light chains of non-human mammals, and instead, they are replaced by humans via a yeast artificial chromosome (YAC) vector or the like. It may be a recombinant animal into which immunoglobulin heavy chain and light chain loci have been introduced, or a recombinant animal produced by crossing the animals.
- YAC yeast artificial chromosome
- eukaryotic cells are transformed with a cDNA encoding each of heavy and light chains of such human antibody, preferably a vector containing the cDNA, by genetic recombination technology to produce a recombinant human monoclonal antibody.
- This antibody can also be obtained from the culture supernatant by culturing transformed cells.
- eukaryotic cells preferably CHO cells
- mammalian cells such as lymphocytes and myelomas
- a method for obtaining a phage display-derived human antibody selected from a human antibody library (Wormstone, IM et al., Investigative Ophthalmology & Visual Science. (2002) 43 (7), p. 2301-2308; Mé, S. et. Al., Briefings in Functional Genomics and Proteomics (2002), 1 (2), p. 189-203; Siriwardena, D. et. Al., Opthalmology (2002) 109 (3), p. 427-431, etc.) are also known.
- a phage display method (Nature Biotechnology (2005), 23, (9), p. 1105) in which the variable region of human antibody is expressed on the phage surface as a single chain antibody (scFv) and phages that bind to the antigen are selected. -1116) can be used.
- the DNA sequence encoding the variable region of human antibody binding to the antigen can be determined.
- a human antibody can be obtained by preparing an expression vector having the sequence and introducing it into an appropriate host for expression (WO 92/01047, WO 92 / 20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, WO 95/15388, Annu. Rev. Immunol (1994) 12, p. 433-455, Nature Biotechnology (2005) 23 (9), p. 1105-1116).
- any single-chain peptide consisting of 12 to 19 residues is used as a polypeptide linker for linking variable regions.
- the DNA encoding the scFv is a DNA encoding the heavy chain or heavy chain variable region of the antibody, and a DNA encoding the light chain or light chain variable region, all or desired amino acid sequence of those sequences
- the DNA fragment to be encoded is used as a template and amplified by PCR using a primer pair that defines both ends, and then DNA encoding the polypeptide linker moiety is further ligated to heavy chain and light chain respectively. It is obtained by combining and amplifying the primer pair prescribed in.
- an expression vector containing the DNA and a host cell transformed with the expression vector can be prepared according to a conventional method, and by culturing the host cell, The scFv can be recovered from such cultures according to methods.
- Binding fragments of other antibodies can also be obtained by obtaining a gene encoding the binding fragment according to the method described above, introducing it into cells, and recovering the binding fragment from the culture of the cells.
- the antibodies may be multimerized to increase their affinity for the antigen.
- the antibody to be multimerized may be a single antibody or multiple antibodies that recognize multiple epitopes of the same antigen. Examples of methods for multimerizing antibodies include binding of an IgG CH3 domain to two scFvs, binding to streptavidin, introduction of a helix-turn-helix motif, and the like.
- the antibody may be a mixture of multiple types of anti-LAG-3 antibodies differing in amino acid sequence, ie, a polyclonal antibody.
- the polyclonal antibody can include, for example, a mixture of multiple types of antibodies in which part or all of the CDRs are different.
- Such polyclonal antibodies can be cocultured from cells producing different antibodies and recovered from the culture (WO 2004/061104). It is also possible to mix separately prepared antibodies.
- an antiserum which is one embodiment of a polyclonal antibody can be prepared by immunizing an animal with a desired antigen and recovering the serum from the animal according to a conventional method.
- antibodies conjugated to various molecules such as polyethylene glycol (PEG) can also be used.
- PEG polyethylene glycol
- the antibody may further be one in which these antibodies and other agents form a conjugate (immunoconjugate).
- conjugate examples include those in which the antibody is linked to a radioactive substance or a compound having pharmacological activity (Nature Biotechnology (2005) 23, p. 1137-1146).
- antibodies as exemplified or described in (3-11), (3-14), (4-6), etc., binding fragments thereof, and modified products thereof are defined as “molecules containing antibody or binding fragment thereof” Also called.
- the obtained antibody can be purified to homogeneity.
- separation and purification methods used for ordinary proteins may be used.
- antibodies can be separated and purified by appropriately selecting and combining chromatography columns, filters, ultrafiltration, salting out, dialysis, polyacrylamide gel electrophoresis for preparation, isoelectric focusing electrophoresis, etc. (Strategies for Protein Purification and Charcterization: A Laboratoy Course Manual, Daniel R. Marshak et al. Eds., Cold Spring Harbor Laboratory Press (1996); Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory (198) )) It is not intended to be limited thereto.
- Chromatography includes affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, adsorption chromatography and the like.
- chromatographies can be performed using liquid phase chromatographies, such as HPLC and FPLC.
- Examples of columns used for affinity chromatography include protein A column, protein G column, antigen column and the like.
- Examples of the protein A column include Hyper D (manufactured by Pall Corporation, POROS (manufactured by Applied Systems)), Sepharose F. F. (manufactured by GE Healthcare), and the like.
- a nucleotide encoding an antibody, a recombinant vector, a recombinant cell A nucleotide encoding an antibody or a binding fragment thereof or a modified form thereof (referred to as “antibody gene”), a recombinant vector into which the gene is inserted, Cells into which a gene or vector has been introduced (referred to as “antibody-transgenic cells”), cells producing other antibodies or binding fragments or modified products thereof (referred to as “antibody-producing cells”) are also for preparing the composition of the present invention used.
- the antibody gene comprises a nucleotide sequence according to any one of the following (a) to (e) (hereinafter referred to as "antibody gene sequence") or a nucleotide sequence comprising an antibody gene sequence: Consists of or consisting of antibody gene sequences: (A) Rat antibodies rLA204, rLA212, rLA225, rLA869, and rLA1264 and mouse antibody A9H12, which is a chimeric antibody cLA204, cLA212, cLA225, cLA869, in which the constant regions of their heavy and light chains are replaced with those of human antibodies.
- the heavy chain amino acid sequence of any one of cLA1264 and chimeric A9H12 (IMP 731) and their humanized hLA212_H2 / L1 to hLA212_H2 / L5, LA212_H3 / L1 to hLA212_H3 / L5, H5L7 and H5L7BW is encoded.
- a chimeric A9H12 (IMP 731), and a heavy chain comprising a CDRH1 to CDRH3 of one of the humanized antibodies hLA212_H2 / L1 to hLA212_H2 / L5, LA212_H3 / L1 to hLA212_H3 / L5, H5L7 and H5L7BW
- C Rat antibodies rLA204, rLA212, rLA225, rLA869 and rLA1264 and mouse antibody A9H12, a chimeric antibody cLA204, cLA212, cLA225, cLA869, which have constant regions of their heavy and light chains replaced with human antibodies.
- cLA1264 and chimeric A9H12 (IMP 731), and amino acids of heavy chain variable region of any one of hLA212_H2 / L1 to hLA212_H2 / L5, LA212_H3 / L1 to hLA212_H3 / L5, H5L7 and H5L7BW, which are humanized versions thereof
- antibody gene is not limited to those described in (a) to (e) above.
- the antibody or its binding fragment or a modified form thereof comprises the steps of culturing an antibody gene-transduced cell as described in (4-3), and recovering the antibody or its binding fragment or its modified form from the culture And a process for producing the antibody or its binding fragment or a modified form thereof.
- compositions for cytotoxic T cell depletion comprising an anti-LAG-3 antibody or a binding fragment thereof or a modification thereof.
- the composition of the present invention is preferably used in immunosuppressant-resistant cytotoxic T cell related diseases in medical treatment for diseases involving cytotoxic T cells (hereinafter referred to as "cytotoxic T cell related diseases").
- cytotoxic T cell related diseases include chronic obstructive pulmonary disease (COPD: non-patent document 16), multiple sclerosis (non-patent document 15), Graves' disease (Sun, Z. et al., J. Clin. Immunol., 2008). 28 (5): 464-472), ankylosing spondylitis (Schirmer, M. et al., Arthritis.
- Non-patent Document 15 systemic lupus erythematosus (Zabinska et al. 2016, J Immunol Res. 1058165), lupus nephritis (Zabinska et al. 2016, J Immunol Res. 1058165), Scleroderma (Li et al. 2017, J Invest Dermatol. 137 (5): 1042-1050), Crohn's disease (Dai et al.
- composition of the present invention is preferably selected from immunosuppressant-resistant COPD, immunosuppressant-resistant Graves's disease, immunosuppressant-resistant ankylosing spondylitis, immunosuppressant-resistant squamitis , Immunosuppressant-resistant asthma, immunosuppressant-resistant rheumatoid arthritis, immunosuppressant-resistant polymyositis and dermatomyositis, immunosuppressant-resistant inclusion body myositis, immunosuppressant-resistant acute coronary syndrome , Immunosuppressive resistant systemic lupus erythematosus, immunosuppressive resistant lupus nephritis, immunosuppressive resistant scleroderma, immunosuppressive resistant Crohn's disease, immunosuppressive resistant ulcerative colitis, Immunosuppressant resistant aplastic anemia, immunosuppressant resistant myelodysplastic syndrome, immunosuppressive resistant Sjogren's syndrome
- cytotoxic T cells and cytotoxic T cell related diseases for example, the following reports have been made: In idiopathic pulmonary fibrosis, a correlation has been reported between the number of CD4 + CD28-T cells and poor prognosis. (Gilani et. Al., PLoS One 2010, 5 (1): e8959); In ankylosing spondylitis, there is a correlation between disease severity and the number of CD8 + CD28- T cells in the blood (Schirmer, M.
- CD8 + CD28-T cells have been suggested to be involved in exacerbation (Zabinska et al. 2016). J Immunol Res. 1058165); for scleroderma, CD8 + CD2 -T cells have been suggested to be involved in early stage disease (Li et al. 2017, J Invest Dermatol. 137 (5): 1042-1050); CD28-T cells are involved in polymyositis and dermatomyositis It is involved in the pathology (Fasth, AE. Et al., J.
- CD28-T cells are the pathology Involved (Pandya et al. 2010, Arthritis Rheum. 62 (11): 3457-66); Crohn's disease and ulcerative colitis have a poor prognosis when the percentage of CD8 + CD28- T cells is increased (Dai et al. 2017, Clin Res Hepatol Gast 41 (6): 693-702); in aplastic anemia and myelodysplastic syndromes, the number of CD8 + CD28-T cells in patients is increasing (Kook et al. 2001, Exp Hematol.
- CD4 + CD28-T cell count is a prognostic predictor (Peeters et al. 2017, Front Immunol. 8: 1160); for Sjogren's syndrome, CD8 + CD28-T cell count and There is a correlation in severity (Smolenska et al. 2012, Cell Immunol. 278 (1-2): 143-51); for Vegener's granulomatosis, CD28-T cells are involved in the pathology (Lamprechht. Et al. 2001, Thorax. 56 (10): 751-7); for psoriasis, CD4 + CD28-T cells are involved in the pathology (Lima et al.
- CD8 + CD28-T cells The number of CD8 + CD28-T cells is increasing in asthma (Hamzaoui, A. et al., Mediators. Inflamm., 2005; 3; 160- P. 166); for chronic hepatitis B, CD4 + CD28-T cells are involved in the pathology (Wang et al. 2009, Immunol Invest. 2009; 38 (5): 434-46); in sarcoidosis, CD4 + CD28- The number of T cells is increasing (Roberts et al. 2005, Sarcoidosis Vasc Diffuse Lung Dis. 22 (1): 13-9).
- the term "immunosuppressive agent” means a drug that acts in a suppressive manner on the immune system, which is used for the treatment of autoimmune diseases, etc., and it is an antifolate, calcineurin inhibitor, corticosteroids (Also referred to as “steroids”), antithymocyte globulin agents, nucleic acid anti-metabolites, nucleic acid synthesis inhibitors, biological agents targeting cell surface antigens, biological agents targeting cytokine or cytokine receptors, and the like.
- steroids corticosteroids
- the term "immunosuppressive drug resistance” refers to a state in which the disease is not sufficiently controlled even by the treatment with the above-mentioned immunosuppressant, and ineffective or effective in the treatment with the above-mentioned immunosuppressant. Insufficient cases, cases of recurrence of the disease, cases where side effects make treatment with the drug difficult, and the like.
- a disease for the treatment or prevention of a disease, such disease, preferably prevention of onset of such disease in an individual expressing LAG-3 protein, suppression or inhibition of progression of the disease, or suffering from such disease It includes, but is not limited to, alleviation of one or more symptoms exhibited by an individual, suppression or amelioration of progression or progression, or treatment or prevention of a secondary disease.
- the present invention provides a pharmaceutical composition comprising an anti-LAG-3 antibody or a binding fragment thereof or a modified form thereof.
- the pharmaceutical composition of the present invention can be suitably applied to the treatment and / or treatment of cytotoxic T cell related diseases, more preferably perforin positive, granzyme B positive, CD28 negative CD4 positive, CD28 negative CD8 Positive, CD57 positive, CD4 positive, and / or CD57 positive, CD8 positive, more preferably, perforin positive, granzyme B positive, CD28 negative CD4, CD28 negative, CD8 positive, CD57 positive, CD4 positive, and / or, It is characterized in that CD57 positive CD8 positive is determined for a biological sample comprising cytotoxic T cells or a cell membrane fraction thereof, and even more preferably, said biological sample is a cytotoxic T cell Derived from or derived from an individual suffering from or for whom it is desirable to avoid the disease And wherein the door.
- Such biological sample is preferably a sample containing cytotoxic T cells derived from or collected
- the cytotoxic T cell related disease which can be treated or prevented by the pharmaceutical composition of the present invention is preferably chronic obstructive pulmonary disease (COPD), multiple sclerosis, Graves' disease, ankylosing spondylitis, squamitis , Asthma, rheumatoid arthritis, polymyositis and dermatomyositis, inclusion body myositis, acute coronary syndrome, systemic lupus erythematosus, lupus nephritis, scleroderma, Crohn's disease, ulcerative colitis, aplastic anemia, myelodysplastic syndrome, Sjogren's syndrome, Wegener's granulomatosis, psoriasis, type 2 diabetes, host-to-graft reaction, chronic hepatitis B, and / or sarcoidosis.
- COPD chronic obstructive pulmonary disease
- multiple sclerosis Graves' disease
- cytotoxic T cell related diseases which can be treated or prevented by the pharmaceutical composition of the present invention are preferably LAG-3 positive, more preferably suffering from cytotoxic T cell related diseases. It is a disease determined to be LAG-3 positive for biological samples from individuals who are or are desired to avoid disease. Such biological sample is preferably a sample containing cytotoxic T cells derived from or collected from a lesion site, more preferably a cytotoxicity invading the lesion site. It is a sample containing sexual T cells.
- compositions or pharmaceutical compositions of the invention may be administered to an individual in a method of treatment or prevention of cytotoxic T cell related diseases. That is, the present invention is suffering from or suffering from a cytotoxic T cell related disease of perforin positive, granzyme B positive, CD28 negative CD4 positive, CD28 negative CD8 positive, CD57 positive CD4 positive, and / or CD57 positive CD8 positive. Also provided is a method of treating or preventing a cytotoxic T cell related disease comprising administering to the individual it is desirable to avoid A. or a composition or pharmaceutical composition of the invention.
- the scope of “desirable to avoid morbidity” also includes prophylactic or prophylactic treatment to be administered, which is intended for prophylactic or prophylactic treatment, or scheduled for prophylactic or prophylactic treatment.
- the scope of “prevention” includes the prevention of onset, recurrence or symptom aggravation, etc.
- the composition of the present invention for the purpose of maintaining the condition or preventing recurrence for individuals whose symptoms have been ameliorated or ameliorated by treatment etc.
- the administration of a substance or a pharmaceutical composition can be exemplified.
- delaying the aggravation or progression of a disease, a pathological condition or a symptom is also included in the scope of “treatment or prevention”.
- composition or pharmaceutical composition of the present invention a therapeutically or prophylactically effective amount of an anti-LAG-3 antibody or a binding fragment of the antibody and a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative And / or adjuvants can be included.
- terapéuticaally or prophylactically effective amount means an amount that exerts a therapeutic or prophylactic effect for a particular disease, dosage form and administration route, and is synonymous with “pharmacologically effective amount”.
- composition or pharmaceutical composition of the present invention pH, osmotic pressure, viscosity, transparency, color, isotonicity, sterility, stability, solubility, sustained release, absorption of the composition or the antibody contained therein
- substance for preparation a substance for changing, maintaining, or holding the properties, permeability, dosage form, strength, properties, shape, etc.
- the substance for preparation is not particularly limited as long as it is a pharmacologically acceptable substance.
- non-toxic or low toxicity is a property which the substance for formulation suitably comprises.
- Examples of the substance for preparation include, but are not limited to, the following: amino acids such as glycine, alanine, glutamine, asparagine, histidine, arginine or lysine, antibacterial agents, ascorbic acid Antioxidants such as sodium sulfate or sodium bisulfite, buffers such as phosphoric acid, citric acid, borate buffer, sodium hydrogencarbonate, tris-hydrochloric acid (Tris-Hcl) solution, fillers such as mannitol or glycine, ethylene diamine Chelating agents such as tetraacetic acid (EDTA), caffeine, polyvinyl pyrrolidine, complexing agents such as ⁇ -cyclodextrin and hydroxypropyl- ⁇ -cyclodextrin, extenders such as glucose, mannose or dextrin, monosaccharides, disaccharides Glucose, mannose and dextrin And other carbohydrates, coloring agents, flavoring agents, diluents, emul
- Preservatives such as methyl paraben, propyl paraben, chlorexidine, sorbic acid or hydrogen peroxide, solvents such as glycerin, propylene glycol or polyethylene glycol, sugar alcohols such as mannitol or sorbitol, suspending agents, PEG, sorbitan ester, polysorbate 20 And polysorbate 80, etc.
- surfactants such as lecithin or cholesterol
- stabilization enhancers such as sucrose or sorbitol, sodium chloride Potassium, potassium chloride, mannitol and elasticity enhancers such as sorbitol, transport agent, diluent, excipient, and / or pharmaceutically adjuvants.
- the addition amount of the substance for these preparations is 0.001 to 1000 times, preferably 0.01 to 100 times, more preferably, the weight of the anti-LAG-3 antibody or its binding fragment or its modified form. It is 0.1 to 10 times.
- An immunoliposome containing an anti-LAG-3 antibody or its binding fragment or a modified form thereof in a liposome, a composition or a drug containing an antibody modified form (such as US Pat. No. 6,214,388) formed by binding of the antibody and the liposome A composition is also included in the composition or the pharmaceutical composition of the present invention.
- excipients and carriers are not particularly limited as long as they are usually liquid or solid, and water for injection, saline, artificial cerebrospinal fluid, or any other substance used for preparation for oral administration or parenteral administration.
- physiological saline include neutral ones and those containing serum albumin.
- Tris buffer prepared so that the final pH of the composition or the pharmaceutical composition is 7.0 to 8.5, an acetate buffer similarly prepared so as to be 4.0 to 5.5, The citrate buffer similarly prepared to be 5.0-8.0, the histidine buffer similarly prepared to be 5.0-8.0, etc. can be illustrated.
- composition or pharmaceutical composition of the present invention is a solid, liquid, suspension or the like. Lyophilized formulations can be mentioned. For shaping a freeze-dried preparation, excipients such as sucrose can be used.
- the route of administration of the composition or pharmaceutical composition of the present invention may be any of enteral administration, topical administration and parenteral administration, for example, intravenous administration, intraarterial administration, intramuscular administration, intradermal administration, subcutaneous administration Intraperitoneal administration, percutaneous administration, intraosseous administration, intraarticular administration and the like.
- composition of such composition or pharmaceutical composition can be determined depending on the method of administration, the LAG-3 protein binding affinity of the antibody, and the like.
- the dosage of the anti-LAG-3 antibody is not limited as long as it is a pharmacologically effective amount, and the species of the individual, type of disease, symptom, sex, age, chronic disease, LAG-3 protein binding affinity of the antibody Or it may be determined appropriately depending on the biological activity and other factors, but usually 0.01 to 1000 mg / kg, preferably 0.1 to 100 mg / kg, once every 1 to 180 days, or It can be administered twice or three or more times a day.
- the form of the composition or the pharmaceutical composition includes an injection (lyophilized preparation, including drops), suppositories, nasal absorption preparations, transdermal absorption preparations, sublingual preparations, capsules, tablets, ointments, granules Agents, aerosols, pills, powders, suspensions, emulsions, eye drops, bioimplantable preparations and the like can be exemplified.
- injection lyophilized preparation, including drops
- suppositories nasal absorption preparations, transdermal absorption preparations, sublingual preparations, capsules, tablets, ointments, granules Agents, aerosols, pills, powders, suspensions, emulsions, eye drops, bioimplantable preparations and the like can be exemplified.
- composition or pharmaceutical composition containing the anti-LAG-3 antibody or its binding fragment or a modified form thereof as an active ingredient can be administered simultaneously with or separately from other medicines.
- the drug may be administered, or the composition or pharmaceutical composition and the other drug may be administered simultaneously.
- compositions or pharmaceutical composition of the present invention include, for example, antifolates, calcineurin inhibitors, corticosteroids, antithymocyte globulin agents, nucleic acid antimetabolites, nucleic acid synthesis Inhibitors, biologics that target cell surface antigens, or biologics that target cytokines or cytokine receptors, etc. can be mentioned, which are for the treatment or prevention of rejection of autoimmune diseases and / or transplants. Preferred.
- Methotrexate an antifolate, Cyclosporin, Tacrolimus, calcineurin inhibitor, Methylprednisolone, adrenocortical steroid, Methylprednisolone, Prednisolone, a nucleic acid synthesis inhibitor, Cyclophosphamide, Azathioprine, an antithymocyte globulin agent Zetbulin, Lymphoglobuline, Thymoglobulin, Mycophenolate mofetil, a nucleic acid antimetabolite, Alemtuzumab, Rituximab, Abatacept, Denosumab, a biological product targeting a cytokine or cytokine receptor, etc.
- compositions or pharmaceutical composition of the present invention may be used in combination with high-dose intravenous immunoglobulin (IV Ig) therapy, plasma exchange therapy and the like to treat or prevent rejection of autoimmune diseases and / or transplants. it can.
- IV Ig intravenous immunoglobulin
- these other medicaments and therapies can also be combined with the compositions of the invention in the treatment or prevention of autoimmune diseases and diseases other than rejection of transplants.
- anticancer agents such as various molecular targeting agents, chemotherapeutic agents, radiation therapy, anti-PD-1
- cancer immunotherapeutic agents such as antibodies, anti-PD-L1 antibodies, and anti-CTLA-4 antibodies.
- compositions of the invention that are used or used in combination with other therapies as a "combination with other medication” or “combination with other medication” aspect.
- the present invention relates to a method of depleting cytotoxic T cells, use of LAG-3 antibody for depleting cytotoxic T cells or for preparing a composition or pharmaceutical composition for cytotoxic T cell depletion, cells
- LAG-3 antibody for the treatment or prevention of damaging T cell related diseases
- LAG-3 antibody for the treatment or prevention of cytotoxic T cell related diseases
- treatment or prevention of cytotoxic T cell related diseases Also provided is a LAG-3 antibody for use in A kit for cytotoxic T cell depletion comprising LAG-3 antibody, and a kit for treating or preventing cytotoxic T cell related diseases are also included in the present invention.
- Example 1 Preparation of rat anti-human LAG-3 antibody 1) -1 Immunization 1st and 2nd from the N terminus (No. 23-262) of 4 extracellular immunoglobulin-like domains of human LAG-3 (SEQ ID NO: 86: FIG. 101)
- pcDNA3.1-hLAG-3_D3D4 was intramuscularly injected to the same site. Subsequently, in vivo electroporation was performed at the same site using ECM 830 (BTX) using a 2-needle electrode. After repeating the same in vivo electroporation a total of three or five times every two weeks, rat lymph nodes were collected and used for hybridoma production.
- OPD solution 0.05 M trisodium citrate, 0.1 M dibasic hydrogen phosphate, 12 water pH 4.5
- 25 ⁇ L / well of o-phenylenediamine dihydrochloride manufactured by Wako Pure Chemical Industries, Ltd.
- H 2 O 2 were respectively added so as to be 0.4 mg / mL and 0.6% (v / v).
- the color reaction was carried out with occasional stirring, and after stopping color reaction by adding 25 ⁇ L / well of 1 M HCl, absorbance at 490 nm was measured with a plate reader (ENVISION: PerkinElmer).
- LAG-3 expression vector introduced Hybridomas producing culture supernatants exhibiting higher absorbance in HEK 293 cells were selected as positive for anti-LAG-3 antibody production.
- the FACS buffer contains LIVE / DEAD Fixable Dead Cell Stain Kit-near-IR fluorescent reactive dye (manufactured by Invitrogen) 200
- a secondary antibody such as Anti-Rat IgG PE conjugate (manufactured by Jackson ImmunoResearch Laboratories) diluted by a factor of two was added and suspended, and allowed to stand at 4 ° C. for 30 minutes.
- the cells were resuspended in PBS containing 1 to 2% paraformaldehyde, and detection was carried out using a flow cytometer (Canto II: manufactured by BD or FC500: manufactured by Beckman Coulter).
- 293T-lacZ human LAG-3 full-length expression plasmid into 293T cells
- 293T-lacZ stably expressing this ⁇ -lactosidase using Lipofectamine 2000 (manufactured by Invitrogen), and culturing it for 1 day
- the cells are washed twice with phenol red-free RPMI 1640 containing 5% FBS (hereinafter abbreviated as “media for ADCC”), the number of viable cells is measured by trypan blue dye exclusion test, and 1 ⁇ 10 5 cells / media for ADCC.
- the cells resuspended to ml were used as target cells.
- PBMCs were isolated from human peripheral blood by Ficoll centrifugation and suspended to a viable cell density of 1.2 ⁇ 10 6 cells / mL in ADCC medium. , Used as effector cells.
- Cell lysis rate (%) (A-B) / (C-B) x 100
- B: Average value of spontaneous release (non antibody added wells) counts (n 3).
- 50 ⁇ l and 75 ⁇ l of medium for ADCC were added at the time of antibody addition and effector cell addition, respectively.
- 175 ⁇ l of ⁇ -Glo assay system solution was added to the wells containing cells and mixed, and 100 ⁇ l of the mixture was added to the black plate to carry out the measurement.
- Non-patent Document 8 20 ⁇ L / well of LAG-3-Fc (manufactured by R & D Systems) diluted to 25 nM with RPMI 1640 containing 10% FBS is added to a 96-well U-bottom microplate, and 20 ⁇ L / well of hybridoma culture supernatant is added thereto and stirred. And left at 4 ° C. for 20 minutes. Thereto was added 10 ⁇ L / well (2.5 ⁇ 10 5 cells / well) of Raji cells which endogenously highly express MHC class II molecules, stirred, and left still at 4 ° C. for 30 minutes.
- LAG-3-Fc manufactured by R & D Systems
- Inhibition rate (%) 100-(A-B) / (C-B) x 100
- A Average fluorescence intensity of sample wells
- B Average fluorescence intensity of background.
- C Average fluorescence intensity of maximal binding. At the time of antibody addition, 20 ⁇ L of culture medium was added.
- the rat anti-human LAG-3 monoclonal antibody was purified from hybridoma culture supernatant. That is, first, hybridoma culture supernatant was applied to a Protein G column (manufactured by GE Healthcare) equilibrated with PBS. After washing the column with PBS, it was eluted with 0.1 M aqueous glycine / hydrochloric acid (pH 2.7), and fractions containing the antibody were collected.
- the collected fractions are adjusted to pH 7.0-7.5 by adding 1 M Tris-HCl (pH 9.0), and then buffer with PBS with Centrifugal UF Filter Device VIVASPIN 20 (fractional molecular weight UF 30 K, Sartorius). While performing substitution, concentration of the antibody was performed, and the antibody concentration was adjusted to 2 mg / mL or more. Finally, it was filtered through Minisart-Plus filter (manufactured by Sartorius) to obtain a purified sample.
- Example 2 In vitro evaluation of rat anti-human LAG-3 antibodies (rLA204, rLA212, rLA225, rLA869 and rLA1264) 2)-1 Obtained rat anti-LAG-3 antibodies (rLA204, rLA212, rLA225, rLA869 and rLA1264) human activated T cells Binding to Human Activated T Cells The ability of purified rat anti-human LAG-3 antibodies rLA204, rLA212, rLA225, rLA869 and rLA1264 to human activated T cells was examined by the method described in Example 1) -7. As shown in FIG. 1, all of these rat anti-human LAG-3 antibodies bound to PHA blast prepared as in vitro activated human T cells in a concentration dependent manner.
- rat anti-LAG-3 antibodies (rLA204, rLA212, rLA225, rLA869 and rLA1264)
- Purified rat anti-human LAG-3 antibodies rLA204, rLA212, rLA225, rLA869 and rLA1264 have ADCC activities as follows: It examined by the method. Add 50 ⁇ L / well of target cells of Example 1) -5-1 (hereinafter referred to as 293T-lacZ / hLAG-3 cells) to a 96-well U-bottom microplate containing 50 ⁇ L / well of antibody solution and Let stand for 30 minutes.
- Cell lysis rate (%) (A-B) / (C-B) x 100
- B: Average value of spontaneous release (non antibody added wells) counts (n 3).
- 50 ⁇ l and 75 ⁇ l of medium for ADCC were added at the time of antibody addition and effector cell addition, respectively.
- 175 ⁇ l of ⁇ -Glo assay system solution was added to the wells containing cells and mixed, and 100 ⁇ l of the mixture was added to the black plate to carry out the measurement.
- Example 1 Purified anti-LAG-3 antibodies (rLA204, rLA212, rLA225, rLA869 and rLA1264) are reported as LAG-3 and its ligand according to the LAG-3 / MHC class II binding test described in -6. We examined whether it had the activity to inhibit the binding of certain MHC class II molecules. As a result, as shown in FIG. 3A, all the antibodies of these five clones showed almost no inhibitory activity in the LAG-3 / MHC class II binding test, and are considered to be necessary for exerting the T cell inhibitory function of LAG-3. It has been found that it does not affect binding to MHC class II molecules. On the other hand, as shown in FIG. 3B, the human chimeric anti-LAG-3 antibody IMP 731 (patent document 1), which is a prior art antibody, has strong concentration-dependent inhibitory activity in LAG-3 / MHC class II binding test. Indicated.
- Human LAG-3 expression plasmid pcDNA3.1 / hLAG-3 was introduced into 293T cells using Lipofectamine 2000 (manufactured by Life Technologies) and seeded in BioCoat Poly-D-Lysine coated 96-well microplate (manufactured by BD) And cultured overnight.
- Raji cells are labeled in the medium (RPMI 1640 with 10% FBS) with BCECF-AM (made by Dojindo, 10 ⁇ M) for 1 hour at 37 ° C. and washed, 1.6 ⁇ 10 6 cells / cell. It suspended in the culture medium so that it might become mL.
- the medium of overnight cultured cells (293T-hLAG-3 cells) was removed, 50 ⁇ l / well of medium and 25 ⁇ l / well of antibody solution were added, and preincubated at 37 ° C. for 30 minutes. Thereafter, BCECF-AM labeled Raji cells were added at 25 ⁇ L / well, centrifuged at 900 rpm for 30 seconds, and then incubated at 37 ° C. for 1 hour.
- Inhibition rate (%) 100-(A-B) / (C-B) x 100
- A Fluorescence intensity of sample well
- B Fluorescence intensity of background. Media was added at the time of Raji cells and antibody addition. Other than that, the same operation as the sample well was performed.
- C Fluorescence intensity of maximum binding. Media was added at the time of antibody addition.
- Rat anti-LAG-3 antibody rLA204, rLA212, rLA225, rLA869 and rLA1264 is the extracellular domain of LAG-3 Since the antibody is produced by using as a immunogen a variant in which the first and second N-terminal (hereinafter referred to as domain 1 and 2 respectively) of the four immunoglobulin-like domains present in B are deleted, the remaining N A cell in which only domains 3 and 4 or domain 4 were expressed, in order to clarify which domain from the third to the fourth (hereinafter referred to as domains 3 and 4 respectively) these antibodies bind Flow of Binding of Obtained Rat Anti-LAG-3 Antibody to It was examined by cytometry.
- Lipofectamine 2000 (all were cloned into pcDNA3.1) an expression plasmid of domain 3 or less (263-525) or domain 4 or less (353-525) of human LAG-3 to which a FLAG tag sequence (DYKDDDDK) was added at the N terminus
- the cells were introduced into HEK293T cells using Life Technologies), cultured for 1 day, collected, and collected.
- the binding properties of the antibodies were examined by flow cytometry according to the method described in Example 1) -4. As a result, as shown in FIG.
- FIG. 5B The result of examining the binding domain of human chimerized anti-human LAG-3 antibody IMP 731 which is a prior art antibody in a similar manner is shown in FIG. 5B.
- a FLAG tag sequence DYKDDDDK
- Example 1 After 3 weeks, 200 ⁇ g / mouse of antigen protein alone was administered to the ridge, and 2 weeks after that, lymph nodes were collected, and hybridomas were produced by the method of Example 1) -2. Examples 1) -3 and 1) -4 and the like were screened, and the epitope of the obtained monoclonal antibody was analyzed by the method of Example 2) -5, and 58% of the evaluated clones were LAG-3. Of the four immunoglobulin-like domains present in the extracellular region, it was revealed that 26% of the four immunoglobulin-like domains were bound to domain 2 and that monoclonal antibodies against the portion near the N-terminus were preferentially obtained.
- N-terminal domains 1 and 2 out of four extracellular immunoglobulin-like domains of LAG-3 are important for the binding of LAG-3 to MHC class II molecules
- Example 1 It is shown that it is necessary to make monoclonal antibodies by devising an immunization method such as 1) -1.
- Example 3 Determination of the nucleotide sequence of the cDNA encoding the variable region of rat anti-human LAG-3 antibody (rLA204, rLA212, rLA225, rLA869 and rLA1264) 3) -1 Determination of the nucleotide sequence of the cDNA encoding the variable region of rLA204 3)- 1-1.
- Preparation of total RNA from rLA204-producing hybridoma In order to amplify cDNA containing the variable region of rLA204, total RNA was prepared from rLA204-producing hybridoma using TRIzol Reagent (Ambion).
- the cDNA containing the heavy chain variable region of rLA204 was amplified by 5'-RACE PCR using the combination of this primer and the cDNA synthesized in Example 3) -1-2 (5'-RACE-Ready cDNA) as a template .
- PCR was carried out with a touchdown PCR program according to the manual of SMARTer RACE cDNA Amplification Kit (Clontech) using KOD-Plus- (TOYOBO) as Polymerase.
- the cDNA containing the variable region of the heavy chain amplified by 5'-RACE PCR is purified using MinElute PCR Purification Kit (QIAGEN) and then cloned and cloned using Zero Blunt TOPO PCR Cloning Kit (Invitrogen) Sequence analysis of the nucleotide sequence of the cDNA containing the chain variable region was performed.
- oligonucleotide having the sequence of 5′-CTCAGAGTTCCAGGTCACACTGTGACTGGC-3 ′ (RG2AR3; SEQ ID NO: 71) designed from the sequence of the constant region of rat heavy chain in the database as a sequence primer, and NUP (Nested Universal Primer A: SMARTer RACE cDNA Amplification (Supplied with Kit) was used.
- nucleotide sequence of the cDNA encoding the variable region of the heavy chain of rLA204 determined is shown in SEQ ID NO: 1 and the amino acid sequence is shown in SEQ ID NO: 2.
- the cDNA containing the light chain variable region of rLA204 was amplified by 5'-RACE PCR using the combination of this primer and the cDNA synthesized in Example 3) -1-2 (5'-RACE-Ready cDNA) as a template .
- PCR was carried out with a touchdown PCR program according to the manual of SMARTer RACE cDNA Amplification Kit (Clontech) using KOD-Plus- (TOYOBO) as Polymerase.
- the cDNA containing the variable region of the light chain amplified by 5'-RACE PCR is purified using MinElute PCR Purification Kit (QIAGEN) and then cloned and cloned using Zero Blunt TOPO PCR Cloning Kit (Invitrogen) Sequence analysis of the nucleotide sequence of the cDNA containing the chain variable region was performed.
- oligonucleotide having the sequence of 5′-TCAGTAACACTGTCCAGGACACCATCTC-3 ′ (RKR5; SEQ ID NO: 72) designed from the sequence of the constant region of rat light chain in the database as a sequence primer, and NUP (Nested Universal Primer A: SMARTer RACE cDNA Amplification (Supplied with Kit) was used.
- nucleotide sequence of the cDNA encoding the variable region of the light chain of rLA204 determined is shown in SEQ ID NO: 3 and the amino acid sequence is shown in SEQ ID NO: 4.
- the nucleotide sequence of the cDNA encoding the variable region of the heavy chain of rLA212 determined is shown in SEQ ID NO: 5, and the amino acid sequence is shown in SEQ ID NO: 6.
- the nucleotide sequence of the cDNA encoding the variable region of the light chain is shown in SEQ ID NO: 7 and the amino acid sequence is shown in SEQ ID NO: 8.
- the nucleotide sequence of the cDNA encoding the variable region of the heavy chain of rLA225 determined is shown in SEQ ID NO: 9 and the amino acid sequence is shown in SEQ ID NO: 10.
- the nucleotide sequence of the cDNA encoding the variable region of the light chain is shown in SEQ ID NO: 11 and the amino acid sequence is shown in SEQ ID NO: 12.
- nucleotide sequence of the cDNA encoding the variable region of the heavy chain of rLA869 determined is shown in SEQ ID NO: 13 and the amino acid sequence is shown in SEQ ID NO: 14.
- the nucleotide sequence of the cDNA encoding the variable region of the light chain is shown in SEQ ID NO: 15 and the amino acid sequence is shown in SEQ ID NO: 16.
- the nucleotide sequence of the cDNA encoding the variable region of the heavy chain of rLA1264 determined is shown in SEQ ID NO: 17 and the amino acid sequence is shown in SEQ ID NO: 18.
- the nucleotide sequence of the cDNA encoding the variable region of the light chain is shown in SEQ ID NO: 19 and the amino acid sequence is shown in SEQ ID NO: 20.
- Example 4 Preparation of Human Chimerized Anti-Human LAG-3 Antibody (cLA212) 4) -1 Construction of Chimeric and Humanized Antibody Light Chain Expression Vector pCMA-LK A fragment of about 5.4 kb obtained by digestion, and a DNA fragment containing a human light chain secretion signal shown in SEQ ID NO: 21 and a DNA sequence encoding a human ⁇ chain constant region are in In-Fusion Advantage PCR cloning kit (Clontech) ) To create pcDNA3.3 / LK.
- PCR is performed with the following primer set, and the resulting approximately 3.8 kb fragment is phosphorylated and then self-ligated to determine the signal sequence, cloning site, and human light chain downstream of the CMV promoter.
- a chimeric and humanized antibody light chain expression vector pCMA-LK having a constant region was constructed.
- Primer set 5'-TATACCGTCGACCTCTAGCTAGAGCTTGGC-3 '(3.3-F1; SEQ ID NO: 73) 5'-GCTATGGCAGGGCCTGCCCCCCCGA CGTTG-3 '(3.3-R1; SEQ ID NO: 74)
- cLA212 Heavy Chain Expression Vector The cDNA containing the variable region of the heavy chain of rLA212 obtained in Example 3) -2 was used as a template and KOD-Plus- (TOYOBO) and the following primer set were used for the heavy chain In-Fusion HD PCR cloning kit (Clontech) at the site where the DNA fragment containing the cDNA encoding the variable region of the chain was amplified and the chimeric and humanized IgG1 type heavy chain expression vector pCMA-G1 was digested with restriction enzyme BlpI The cLA212 heavy chain expression vector was constructed by using and inserting. The resulting expression vector was designated "pCMA-G1 / cLA212".
- the nucleotide sequence of cLA212 heavy chain is shown in SEQ ID NO: 23 and the amino acid sequence is shown in SEQ ID NO: 24.
- Primer set 5 'for cLA212 heavy chain 5'-CCAGATGGGTGCTGAGCGAGGTGCAGCTGGTGAGTCTGGGGGAGG-3 '(212H-F; SEQ ID NO: 75) 5'-CTTGGTGGAGGCTGAGCTGACTGTGACCATGACTCCTTGGCCCAG-3 '(212H-R; SEQ ID NO: 76)
- cLA212 light chain expression vector The cDNA containing the light chain variable region of rLA212 obtained in Example 3) -2 was used as a template and KOD-Plus- (TOYOBO) and the following primer set for light In-Fusion HD PCR cloning kit (Clontech) at the site where the DAN fragment containing the cDNA encoding the chain variable region was amplified and the chimeric and humanized light chain expression general-purpose vector pCMA-LK was digested with restriction enzyme BsiWI The light chain expression vector of cLA212 was constructed by inserting it. The obtained expression vector was named "pCMA-LK / cLA212".
- cLA212 light chain primer set 5'-ATCTCC GGCGCGTACGGCAACATTGTGATGACCCAGTCTCCCAAATCC-3 '(212L-F; SEQ ID NO: 77) 5'-GGAGGGGGCGGCCACAGCCCGTTTCAGTTCCAGCTCGGTCCCAGC-3 '(212L-R; SEQ ID NO: 78)
- H chain expression vector (0.24 mg) and L chain expression prepared by dissolving 1.8 mg of Polyethyleneimine (Polyscience # 24765) in 20 ml of Opti-Pro SFM medium (Invitrogen) and using NucleoBond Xtra (TaKaRa)
- the vector (0.36 mg) was added to 20 ml of Opti-Pro SFM medium (Invitrogen).
- 20 ml of the expression vector / Opti-Pro SFM mixed solution was added to 20 ml of the polyethyleneimine / Opti-Pro SFM mixed solution, the mixture was gently stirred, allowed to stand for 5 minutes, and then added to FreeStyle 293F cells.
- the human chimeric antibody of rLA212 obtained by the combination of pCMA-G1 / cLA212 and pCMA-LK / cLA212 was named “cLA212”.
- the antibody was purified from the culture supernatant obtained in Example 4) -5 by rProtein A affinity chromatography (at 4-6 ° C.). The buffer displacement step after rProtein A affinity chromatography purification was performed at 4-6 ° C. First, the culture supernatant was applied to a column filled with MabSelectSuRe (manufactured by GE Healthcare) equilibrated with PBS. After all of the culture solution entered the column, the column was washed with a column volume of twice or more of PBS. Then, it was eluted with 2 M arginine hydrochloride solution (pH 4.0), and the fractions containing the antibody were collected.
- MabSelectSuRe manufactured by GE Healthcare
- the fraction was subjected to solution substitution to HBSor (25 mM histidine / 5% sorbitol, pH 6.0) by dialysis (Thermo Scientific, Slide-A-Lyzer Dialysis Cassette). Finally, the solution was concentrated with Centrifugal UF Filter Device VIVASPIN 20 (fractional molecular weight UF10K, Sartorius, 4 ° C.) to adjust the IgG concentration to 2 mg / ml or more, and used as a purified sample. Finally, the resultant was filtered with Minisart-Plus filter (Sartorius) to obtain a purified sample.
- HBSor 25 mM histidine / 5% sorbitol, pH 6.0
- VIVASPIN 20 fractional molecular weight UF10K, Sartorius, 4 ° C.
- Example 5 Design of Humanized Version (hLA212) of Rat Anti-Human LAG-3 Antibody (rLA212) 5-1 Humanized Design of Rat Anti-Human LAG-3 Antibody rLA212 5) -1-1 Molecular Modeling of the Variable Region of rLA212 rLA212 Molecular modeling of variable regions was performed by a method known as homology modeling (Methods in Enzymology, 203, 121-153, (1991)). Primary sequence of the variable region of human immunoglobulin registered in Protein Data Bank (Nuc. Acid Res. 35, D301-D303 (2007)) (three-dimensional structure derived from X-ray crystal structure is available) ) was compared to the variable region of rLA212 determined in Example 3) -2.
- 2GHW and 2ARJ were selected as having the highest sequence identity to the heavy chain and light chain variable regions of rLA212.
- the three-dimensional structure of the framework region was created by combining the 2GHW and 2ARJ coordinates corresponding to the heavy and light chains of rLA212 to obtain a "framework model”. Then, representative conformations for each CDR were incorporated into the framework model. Finally, in order to obtain a possible molecular model of the variable region of rLA212 in terms of energy, energy calculations were performed to remove the disadvantageous interatomic contacts. The above procedure was performed using a commercially available protein three-dimensional structure analysis program Discovery Studio (manufactured by Accelrys).
- the sequences of the framework regions of rLA212 are described by KABAT et al.
- the framework regions of human subgroup consensus sequence and Germline sequence defined in (Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service National Institutes of Health, Bethesda, MD. (1991)) were compared.
- the consensus sequence of human gamma chain subgroup 3 for heavy chain and the consensus sequence of human kappa chain subgroup 1 for light chain have high sequence identity in their framework regions, Selected as an acceptor.
- the amino acid residues of the framework region for the acceptor were aligned with the amino acid residues for rLA212 to identify positions where different amino acids were used.
- the amino acid sequence of humanized hLA212_H2 type heavy chain is set forth in SEQ ID NO: 28 in the Sequence Listing.
- a sequence consisting of the 1st to 19th amino acid residues of the amino acid sequence of SEQ ID NO: 28, a sequence consisting of the 20th to 140th amino acid residues, and a sequence consisting of the 141st to 470th amino acid residues are respectively signal sequence and heavy chain
- the variable region corresponds to the heavy chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 28 is set forth in SEQ ID NO: 27 of the Sequence Listing.
- a sequence consisting of nucleotides 1 to 57, a sequence consisting of nucleotides 58 to 420, a sequence consisting of nucleotides 421 to 1410 of the nucleotide sequence of SEQ ID NO: 27 is respectively a signal sequence, a heavy chain variable region sequence, a heavy chain It encodes a regular region array.
- the nucleotide sequence of SEQ ID NO: 27 and the amino acid sequence of SEQ ID NO: 28 are also described in FIGS. 42 and 43, respectively.
- hLA212_H3 Type Heavy Chain In the heavy chain of chimeric cLA 212 shown in SEQ ID NO: 24, arginine at amino acid No. 16 of the variable region portion is glycine, and lysine at amino acid No.
- hLA212_H3 type heavy chain (sometimes referred to as "hLA212_H3").
- the amino acid sequence of the humanized hLA212_H3 type heavy chain is described in SEQ ID NO: 30 of the sequence listing.
- a sequence consisting of the 1st to 19th amino acid residues of the amino acid sequence of SEQ ID NO: 30, a sequence consisting of the 20th to 140th amino acid residues, and a sequence consisting of the 141st to 470th amino acid residues are respectively signal sequence and heavy chain
- the variable region corresponds to the heavy chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 30 is set forth in SEQ ID NO: 29 of the Sequence Listing.
- sequence consisting of nucleotides 1 to 57, the sequence consisting of nucleotides 58 to 420, the sequence consisting of nucleotides 421 to 1410 of the nucleotide sequence of SEQ ID NO: 29 are respectively signal sequence, heavy chain variable region sequence, heavy chain determination It encodes a regular region array.
- the nucleotide sequence of SEQ ID NO: 29 and the amino acid sequence of SEQ ID NO: 30 are also described in FIGS. 44 and 45, respectively.
- Phenylalanine at amino acid number 85 threonine
- alanine at amino acid number 100 glutamine
- glutamic acid at amino acid number 103 lysine
- leucine at amino acid number 104 valine
- leucine at amino acid number 106 isoleucine
- humanized hLA212 light chain designed by replacing alanine at amino acid No. 109 with threonine was named “humanized hLA212_L1 type light chain” (sometimes referred to as “hLA212_L1”).
- the amino acid sequence of the humanized hLA212_L1 type light chain is set forth in SEQ ID NO: 32 in the Sequence Listing.
- a sequence consisting of the 1st to 20th amino acid residues of the amino acid sequence of SEQ ID NO: 32, a sequence consisting of the 21st to 129th amino acid residues, and a sequence consisting of the 130th to 234th amino acid residues are respectively signal sequence and light chain
- the variable region corresponds to the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 32 is set forth in SEQ ID NO: 31 of the Sequence Listing.
- a sequence consisting of nucleotides 1 to 60, a sequence consisting of nucleotides 61 to 387, and a sequence consisting of nucleotides 388 to 702 of the nucleotide sequence of SEQ ID NO: 31 are respectively a signal sequence, a light chain variable region sequence and a light chain It encodes a regular region array.
- the nucleotide sequence of SEQ ID NO: 31 and the amino acid sequence of SEQ ID NO: 32 are also described in FIGS. 46 and 47, respectively.
- hLA212_L2 Type Light Chain In the light chain of the chimeric cLA 212 shown in SEQ ID NO: 26, asparagine as amino acid No. 1 of amino acid No. 1 of the variable region part, valine as amino acid No. 3 as glutamine Lysine of amino acid No. 9 to serine, methionine of amino acid No. 11 to leucine, isoleucine of amino acid No. 13 to alanine, methionine of amino acid No. 21 to isoleucine, asparagine of amino acid No.
- threonine Lysine at amino acid number 38 is glutamine, aspartic acid at amino acid number 60 is serine, threonine at amino acid number 63 is serine, glycine at amino acid number 65 is serine, asparagine at amino acid number 76 is serine , Amino acid number 78 In leucine, alanine at amino acid number 80 is proline, alanine at amino acid number 83 is phenylalanine, phenylalanine at amino acid number 85 is threonine, alanine at amino acid number 100 is glutamine, glutamic acid at amino acid number 103 A humanized hLA212 light chain designed by replacing lysine with leucine at amino acid number 104 with valine, leucine with amino acid number 106 with isoleucine, and alanine with amino acid number 109 with threonine is referred to as “humanized hLA212_L2 It was named as “type light chain” (sometimes called "hLA212_L2
- the amino acid sequence of the humanized hLA212_L2 type light chain is set forth in SEQ ID NO: 34 of the Sequence Listing.
- a sequence consisting of the 1st to 20th amino acid residues of the amino acid sequence of SEQ ID NO: 34, a sequence consisting of the 21st to 129th amino acid residues, a sequence consisting of the 130th to 234th amino acid residues are respectively signal sequence and light chain
- the variable region corresponds to the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 34 is set forth in SEQ ID NO: 33 of the Sequence Listing.
- a sequence consisting of nucleotides 1 to 60, a sequence consisting of nucleotides 61 to 387, and a sequence consisting of nucleotides 388 to 702 of the nucleotide sequence of SEQ ID NO: 33 are respectively signal sequence, light chain variable region sequence, light chain It encodes a regular region array.
- the nucleotide sequence of SEQ ID NO: 33 and the amino acid sequence of SEQ ID NO: 34 are also described in FIGS. 48 and 49, respectively.
- the valine at the third amino acid number of the variable region part is glutamine and the lysine at the amino acid number nine is serine
- the 11th methionine is leucine
- the isoleucine of 13th amino acid is alanine
- the methionine of 21st amino acid is isoleucine
- the asparagine of 22nd amino acid is threonine
- the threonine of 63rd amino acid is serine
- the 76th asparagine is serine
- the valine at amino acid number 78 is leucine
- the alanine at amino acid number 80 is proline
- the alanine at amino acid number 83 is phenylalanine
- the alanine at amino acid number 100 is glutamine
- Number 103 eyes A humanized hLA212 light chain designed by replacing a minic acid with lysine, a leucine
- the amino acid sequence of the humanized hLA212_L3 type light chain is described in SEQ ID NO: 36 of the sequence listing.
- a sequence consisting of the 1st to 20th amino acid residues of the amino acid sequence of SEQ ID NO: 36, a sequence consisting of the 21st to 129th amino acid residues and a sequence consisting of the 130th to 234th amino acid residues are respectively signal sequence and light chain
- the variable region corresponds to the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 36 is set forth in SEQ ID NO: 35 of the Sequence Listing.
- a sequence consisting of nucleotides 1 to 60, a sequence consisting of nucleotides 61 to 387, and a sequence consisting of nucleotides 388 to 702 of the nucleotide sequence of SEQ ID NO: 35 are respectively a signal sequence, a light chain variable region sequence and a light chain It encodes a regular region array.
- the nucleotide sequence of SEQ ID NO: 35 and the amino acid sequence of SEQ ID NO: 36 are also described in FIGS. 50 and 51, respectively.
- the amino acid sequence of the humanized hLA212_L4 type light chain is set forth in SEQ ID NO: 38 in the Sequence Listing.
- a sequence consisting of the 1st to 20th amino acid residues of the amino acid sequence of SEQ ID NO: 38, a sequence consisting of the 21st to 129th amino acid residues, and a sequence consisting of the 130th to 234th amino acid residues are respectively signal sequence and light chain
- the variable region corresponds to the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 38 is set forth in SEQ ID NO: 37 of the Sequence Listing.
- a sequence consisting of nucleotides 1 to 60, a sequence consisting of nucleotides 61 to 387, and a sequence consisting of nucleotides 388 to 702 of the nucleotide sequence of SEQ ID NO: 37 are respectively a signal sequence, a light chain variable region sequence and a light chain It encodes a regular region array.
- the nucleotide sequence of SEQ ID NO: 37 and the amino acid sequence of SEQ ID NO: 38 are also described in FIGS. 52 and 53, respectively.
- humanized hLA212 light chain designed by replacing glutamic acid at position 103 with lysine and alanine at amino acid 109 with threonine may be referred to as "humanized hLA212_L5 type light chain" (sometimes referred to as "hLA212_L5") I named it.
- the amino acid sequence of humanized hLA212_L5 type light chain is described in SEQ ID NO: 40 of the Sequence Listing.
- a sequence consisting of the 1st to 20th amino acid residues of the amino acid sequence of SEQ ID NO: 40, a sequence consisting of the 21st to 129th amino acid residues, and a sequence consisting of the 130th to 234th amino acid residues are respectively signal sequence and light chain
- the variable region corresponds to the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 40 is set forth in SEQ ID NO: 39 of the Sequence Listing.
- a sequence consisting of nucleotides 1 to 60, a sequence consisting of nucleotides 61 to 387, and a sequence consisting of nucleotides 388 to 702 of the nucleotide sequence of SEQ ID NO: 39 are respectively a signal sequence, a light chain variable region sequence and a light chain It encodes a regular region array.
- the nucleotide sequence of SEQ ID NO: 39 and the amino acid sequence of SEQ ID NO: 40 are also described in FIGS. 54 and b55, respectively.
- An antibody consisting of a humanized hLA212_H2 type heavy chain and a humanized hLA212_L3 type light chain was designed and designated as “humanized hLA212_H2 / L3” (sometimes referred to as “hLA212_H2 / L3”).
- An antibody consisting of a humanized hLA212_H2 type heavy chain and a humanized hLA212_L4 type light chain was designed and designated as “humanized hLA212_H2 / L4” (sometimes called “hLA212_H2 / L4”).
- An antibody consisting of a humanized hLA212_H2 type heavy chain and a humanized hLA212_L5 type light chain was designed and designated as “humanized hLA212_H2 / L5” (sometimes called “hLA212_H2 / L5”).
- An antibody consisting of a humanized hLA212_H3 type heavy chain and a humanized hLA212_L1 type light chain was designed and named "humanized hLA212_H3 / L1" (sometimes called "hLA212_H3 / L1").
- An antibody consisting of a humanized hLA212_H3 type heavy chain and a humanized hLA212_L2 type light chain was designed and named "humanized hLA212_H3 / L2" (sometimes called “hLA212_H3 / L2").
- An antibody consisting of a humanized hLA212_H3 type heavy chain and a humanized hLA212_L3 type light chain was designed and designated as "humanized hLA212_H3 / L3" (sometimes referred to as "hLA212_H3 / L3").
- An antibody consisting of a humanized hLA212_H3 type heavy chain and a humanized hLA212_L4 type light chain was designed and named "humanized hLA212_H3 / L4" (sometimes called “hLA212_H3 / L4").
- An antibody consisting of a humanized hLA212_H3 type heavy chain and a humanized hLA212_L5 type light chain was designed and designated as “humanized hLA212_H3 / L5” (sometimes referred to as “hLA212_H3 / L5”).
- the antibody designed as described above can be prepared according to Example 6 and evaluated according to Example 7 and Example 8.
- Example 6 Expression and Purification of Humanized Anti-LAG-3 Antibody cLA212 Humanized Antibody (hLA212) 6) -1 Construction of hLA212 Heavy Chain Expression Vector 6) -1-1 Construction of hLA212_H2 Type Heavy Chain Expression Vector SEQ ID NO: 27 A DNA fragment containing a DNA sequence encoding the variable region of hLA212_H2 shown in nucleotide numbers 36 to 437 of the nucleotide sequence of hLA212_H2 was synthesized (GENEART, Inc., Strings DNA Fragments).
- HLA212_H2 expression vector by inserting the synthesized DNA fragment into the site where the chimeric and humanized antibody IgG1 type heavy chain expression vector pCMA-G1 was digested with restriction enzyme BlpI using In-Fusion HD PCR cloning kit (Clontech) Built. The obtained expression vector was designated as "pCMA / hLA212_H2".
- hLA212_H3 Type Heavy Chain Expression Vector
- hLA212_L2 Type Light Chain Expression Vector
- a DNA fragment containing a DNA sequence encoding the variable region of hLA212_L2 shown in nucleotide numbers 37 to 402 of the nucleotide sequence of hLA212_L2 shown in SEQ ID NO: 33 was synthesized (GENEART Company Strings DNA Fragments).
- hLA212_L3 type light chain expression vector A DNA fragment containing a DNA sequence encoding the variable region of hLA212_L3 shown in nucleotide numbers 37 to 402 of the nucleotide sequence of hLA212_L3 shown in SEQ ID NO Company Strings DNA Fragments).
- Example 6 An hLA212_L3 expression vector was constructed in the same manner as in -2-1. The obtained expression vector was named "pCMA / hLA212_L3".
- hLA212_L4 Type Light Chain Expression Vector
- a DNA fragment containing a DNA sequence encoding the variable region of hLA212_L4 shown in nucleotide numbers 37 to 402 of the nucleotide sequence of hLA212_L4 shown in SEQ ID NO: 37 was synthesized (GENEART Company Strings DNA Fragments).
- hLA212_L5 Type Light Chain Expression Vector A DNA fragment containing a DNA sequence encoding the variable region of hLA212_L5 shown in nucleotide numbers 37 to 402 of the nucleotide sequence of hLA212_L5 shown in SEQ ID NO: 39 was synthesized (GENEART Company Strings DNA Fragments).
- hLA212_H2 / L1 was obtained by the combination of pCMA / hLA212_H2 and pCMA / hLA212_L1.
- hLA212_H2 / L2 was obtained by the combination of pCMA / hLA212_H2 and pCMA / hLA212_L2.
- hLA212_H2 / L3 was obtained by the combination of pCMA / hLA212_H2 and pCMA / hLA212_L3.
- hLA212_H2 / L4 was obtained by the combination of pCMA / hLA212_H2 and pCMA / hLA212_L4.
- hLA212_H2 / L5 was obtained by the combination of pCMA / hLA212_H2 and pCMA / hLA212_L5.
- hLA212_H3 / L1 was obtained by the combination of pCMA / hLA212_H3 and pCMA / hLA212_L1.
- hLA212_H3 / L2 was obtained by the combination of pCMA / hLA212_H3 and pCMA / hLA212_L2.
- hLA212_H3 / L3 was obtained by the combination of pCMA / hLA212_H3 and pCMA / hLA212_L3.
- hLA212_H3 / L4 was obtained by the combination of pCMA / hLA212_H3 and pCMA / hLA212_L4.
- hLA212_H3 / L5 was obtained by the combination of pCMA / hLA212_H3 and pCMA / hLA212_L5. 6) Purification of hLA212 Antibody 6) The culture supernatant obtained in 6-3-1 was purified in the same manner as in Example 4) -6.
- Example 7 In vitro evaluation of humanized anti-human LAG-3 antibody (hLA212) 7) -1 Measurement of antigen binding activity of humanized anti-human LAG-3 antibody (hLA212) by Biacore: Four extracellular immunoglobulin-like components of human LAG-3 The protein LAG-3_D3D4-His in which a His tag was added to the C terminus of the N-terminal third and fourth (region # 263-450) of the domain was expressed in FreeStyle 293F cells (Invitrogen).
- the obtained culture supernatant was buffer-replaced (20 mM HEPES, 300 mM NaCl, pH 7.5), and HisTrap HP column (GE Healthcare) and Superdex 75 column (GE Healthcare) were used to carry out human LAG-3_D3D4-His.
- the protein was purified.
- the final buffer was PBS.
- LAG-3_D3D4-His Measurement of dissociation constant between antibody and antigen (LAG-3_D3D4-His) was performed using Biacore T200 (GE Healthcare) and immobilized anti-human IgG (Fc) antibody (Human Antibody Capture kit, GE Healthcare) To capture the antibody as a ligand and to measure the antigen as an analyte.
- the anti-human IgG (Fc) antibody was covalently bound to a sensor chip CM5 (GE Healthcare) with an amine coupling method to a target of about 1000 RU. It was fixed to the reference cell as well.
- Non-patent Document 1 N-terminal domains 1 and 2 are considered to be important for the binding of LAG-3 and MHC class II molecules (Non-patent document 4) ).
- the five clones of rat anti-human LAG-3 antibodies obtained by the method of Example 1 all recognize domain 3, and LAG-3 / MHC class II binding test and 293T-
- the human chimerized anti-human LAG-3 antibody IMP 731 which is a prior art antibody, did not show any inhibitory activity in hLAG-3 / Raji cell adhesion test, but recognized domain 1 and LAG-3 / MHC class II binding test It was revealed in Example 2 that they showed strong inhibitory activity in the 293T-hLAG-3 / Raji cell adhesion test.
- IMP 731 increased IL-2 production while the produced humanized anti-human LAG-3 antibody hLA212_H3 / L2 hardly affected IL-2 production.
- the humanized anti-human LAG-3 antibody hLA212_H3 / L2 produced does not affect the T cell suppressive function of LAG-3, whereas IMP 731 inhibits it to reversely immunize it. It has become clear that there is a risk of activating the system.
- Example 8 Preparation of Humanized Antibody with Modified Carbohydrate Modification
- a heavy chain comprising amino acid numbers 20 to 470 of the amino acid sequence shown in SEQ ID NO: 30 (FIG. 45) and an amino acid sequence shown in SEQ ID NO: 34 (FIG. 49)
- a humanized antibody comprising a light chain comprising amino acid numbers 21 to 234 is regulated by defucosifying a sugar chain modification that binds to the antibody protein according to a known method, and the obtained antibody is hLA212_H4 / L2 I named it.
- the modified form was subjected to mass spectrometry, and it was found that the peak of the fucose-containing heavy chain was below the detection limit.
- an antibody having a modified sugar chain such as hLA212_H4 / L2 is also referred to as "antibody” or "modified antibody”.
- Example 9 In vitro evaluation of humanized anti-human LAG-3 antibody hLA212_H4 / L2 9) -1 Binding activity of humanized anti-human LAG-3 antibody hLA212_H4 / L2 to LAG-3 expressing cells By the method described in Example 7) -2. Binding of humanized anti-human LAG-3 antibody hLA212_H4 / L2 to human LAG-3 expressing 293T-lacZ cells was examined by flow cytometry. As a result, as shown in FIG. 11, concentration dependent binding of hLA212_H4 / L2 was observed.
- Example 10 Generation of Human LAG-3 / Human Fc ⁇ RIIIA Double Transgenic Mice
- the humanized anti-human LAG-3 antibody hLA212_H4 / L2 binds to human LAG-3 as shown in Example 9, rodent LAG-3 It is clear that they do not cross. Therefore, in order to allow in vivo evaluation of hLA212_H4 / L2, a BAC (Bacterial Atrial Chromosome) transgenic mouse is generated, in which human LAG-3 is physiologically expressed using the expression regulation mechanism of mouse LAG-3. It was decided to.
- human Fc ⁇ IIIA is required to enhance ADCC activity by modulation of sugar chain modification such as hLA212_H4 / L2 (Junttila, T. T., et al., Cancer Res., Vol. 70 ( No. 11): pp 4481-9 (2010)), BAC containing the human Fc ⁇ RIIIA gene was also introduced according to the previous report (Non-patent document 10).
- BAC genomic clones RP11-101F21 and RP23-30O1, were obtained, containing human LAG-3 and mouse LAG-3 loci respectively.
- the sequence of intron 5 of the human LAG-3 gene, the sequence of both ends of the genomic DNA sequence from the translation initiation codon to the termination codon of the human LAG-3 gene, and LAG-3 of the mouse BAC clone The 3 'end and 5' end of the genomic DNA sequence from the translation initiation codon to the termination codon of the gene were used as key sequences for active homologous recombination reaction in E. coli.
- linearized LAG-3 pretransfer plasmid is introduced together with human LAG-3 Intermediate into an E. coli strain capable of Red / ET reaction, and Red / ET reaction is carried out in this host E. coli.
- the plasmid carrying the genomic DNA sequence of the human LAG-3 gene into which the Rpslkan cassette had been inserted was screened by inducing and picking up ampicillin and kanamycin resistant colonies (human LAG-3 transfer plasmid).
- the genomic DNA sequence of the human LAG-3 gene having the H5 and H6 sequences derived from the mouse genome sequence at both ends and the Rpsl-kan cassette inserted by restriction enzyme reaction It was excised from the plasmid vector (human LAG-3 transfer fragment).
- a human LAG-3 transfer fragment is introduced together with a mouse LAG-3 BAC clone into an E. coli strain capable of Red / ET reaction in the same manner as described above, and the Red / ET reaction is induced in this host E.
- the intron 5 sequence of the human LAG-3 locus was amplified by PCR and used as a DNA sequence for removing Rpsl-Kan inserted into intron 5 of the human LAG-3 gene by negative selection (human LAG-3 Repair fragment).
- a human LAG-3 repair fragment is introduced together with mouse LAG-3 / human LAG-3 RecBAC Intermediate into an E. coli strain capable of Red / ET reaction in the same manner as described above, and the Red / ET reaction is carried out in this host E. coli.
- the genomic DNA sequence from the translation initiation codon of the mouse LAG-3 gene to the termination codon is derived from the translation initiation codon of the human LAG-3 gene and the termination codon from the translation initiation codon of the human LAG-3 gene by The construction of a recombinant BAC clone of the mouse LAG-3 / human LAG-3 gene correctly substituted with the genomic DNA sequence up to (human LAG-3 RecBAC) was performed. Sequence analysis confirmed the genomic DNA sequences of H1-H6 joined in the Red / ET reaction.
- a linearized human LAG-3 RecBAC recombinant BAC clone is applied to 1% SeaKem GTG agarose gel (Takara Bio), and 6 v / cm, 0 using a pulse field electrophoresis apparatus (Bio-Rad, CHEF DR-II) The electrophoresis was performed under the conditions of 1-40 sec, 15 hr and 14 ° C.
- the linearized human LAG-3 RecBAC recombinant BAC clone separated in the agarose gel was excised with a razor without UV irradiation by visualizing a part of the sample as a guide marker with a UV transilluminator.
- the resulting long DNA fragment was extracted from the agarose gel by electroelution, and dialyzed at 4 ° C. for 2 hours with a TE buffer prepared for microinjection.
- the purified DNA fragment is applied to pulse field electrophoresis to confirm that the longer chain DNA fragment is highly purified without fragmentation, and its DNA concentration is measured by NanoDrop spectrophotometer (Asahi Techno Glass Co., Ltd.) It was determined.
- a solution of this DNA fragment was diluted to 0.5 ng / ⁇ l to prepare a solution of an expression construct for producing a transgenic mouse.
- the purified human LAG-3 RecBAC / human Fc ⁇ R BAC expression construct was directly injected into the male nucleus of pronuclear stage embryos of C57BL / 6J mice using a micromanipulator.
- the DNA-injected embryos were transferred into the oviduct of pseudopregnant-induced female recipient mice.
- Tail tissue of a candidate human LAG-3 RecBAC / human Fc ⁇ R BAC transgenic mouse stored at -80 ° C is thawed at room temperature, and 1 mg SDS (Wako Pure Chemical Industries, Ltd.), 1 mg / ml Actinase E (Kakken) Pharmaceuticals and Lysis buffer containing 0.15 mg / ml proteinase K (Merck) were added and shaken at 55 ° C. for 16 hours to solubilize the tissue. Phenol and phenol / chloroform extractions were performed to remove proteins that bind to solubilized genomic DNA from the tissue.
- RNA contaminating the genomic DNA was digested with RNase A (Sigma), high molecular weight genomic DNA was precipitated by isopropanol precipitation. The precipitated genomic DNA was washed with 70% ethanol, air-dried, and redissolved in 50 ⁇ l of TE.
- the DNA concentration of the genomic DNA solution prepared from each sample was determined by absorption method, and the volume of the genomic DNA solution corresponding to 5 ⁇ g of DNA was calculated from the value of the DNA concentration of each sample.
- genomic DNA prepared from each sample positive control DNA (genomic DNA of control mouse added with expression construct used for microinjection), and negative control DNA (genomic DNA of control mouse), 37 ° C., The reaction was carried out for 16 hours.
- the fragment of genomic DNA produced was precipitated by isopropanol precipitation, washed with 70% ethanol, air-dried and then redissolved in TE.
- These genomic DNA fragments were applied to a 1.2% agarose gel and electrophoresed, and the genomic DNA fragments separated in the agarose gel were visualized by a UV transilluminator and photographed with a scale.
- the agarose gel was immersed in 0.25 N hydrochloric acid and gently shaken for 10 minutes, then immersed in 0.4 N sodium hydroxide and gently shaken for another 10 minutes.
- the genomic DNA fragments separated in the agarose gel were transferred to a nylon membrane (Hybond-XL; GE Healthcare) for 16 hours at room temperature by capillary method using 0.4 N sodium hydroxide.
- the nylon membrane to which the genomic DNA fragment had been transferred was immersed in 2 ⁇ SSC, gently shaken for 10 minutes, air-dried, and stored at room temperature until it was used for hybridization.
- the DNA fragment was labeled with [32 P] by random prime method using DNA labeling kit (Megaprime DNA Labeling System; GE Healthcare).
- the [32P] -labeled fragment was purified using a Sephadex spin column (ProbeQuant G-50 Micro Columns; GE Healthcare) as a [32P] -labeled probe.
- the nylon membrane to which the genomic DNA fragment had been transferred was placed in a hybridization buffer and preincubated at 65 ° C. for 1 hour. Thereafter, the mixture was heated at 95 ° C. for 5 minutes, and immediately after that, ice-cold denatured [32 P] labeled probe was added for 5 minutes and incubated at 65 ° C. for 4 hours. After the incubation was completed, the nylon membrane was removed and washed with 0.1% SDS, 0.5 ⁇ SSC at 65 ° C. for about 15 minutes. The radioactivity derived from the probe bound to the membrane was monitored by a survey meter, and this washing was repeated until the radioactivity became almost constant.
- the washed membranes were covered with Saran Wrap® and overlaid in a dark room with X-ray film (BioMax MS; Kodak) and placed in an autoradiography cassette.
- the X-ray film was developed after one week exposure at 4 ° C.
- An individual that detects a specific signal derived from a human LAG-3 RecBAC / human Fc ⁇ R BAC expression construct by autoradiography and provides a specific signal by hybridization with a [32P] -labeled probe is human LAG-3.
- RecBAC / human Fc ⁇ R BAC transgenic mice were identified as founder individuals.
- mice Production and breeding of F1 mice
- the offspring of founder individuals were obtained, genotyping was performed, and Tg mice were lined.
- a Tg mouse founder identified by Southern analysis and a wild type C57BL / 6J mouse were subjected to in vitro fertilization or natural mating to produce an F1 individual.
- the transgenes were transferred to F1 individuals by genotyping, and the lines that were able to be organized were subjected to reproduction by in vitro fertilization or natural mating with wild-type C57BL / 6J mice, and both human LAG-3 and human Fc ⁇ RIIIA were genotyping. Heterozygous mice were used for experiments.
- PE-labeled anti-mouse LAG-3 antibody manufactured by BD
- ATTO 647-labeled anti-human LAG-3 antibody manufactured by Enzo Life Sciences
- FITC-labeled anti-mouse CD3 antibody manufactured by BD
- LIVE / DEAD Fixable Dead Cell Stain Kit-near-IR fluorescent reactive dye manufactured by Invitrogen was added and suspended, and allowed to stand at 4 ° C. for 30 minutes.
- a control without PE labeled anti-mouse LAG-3 antibody and ATTO 647 labeled anti-human LAG-3 antibody was prepared and treated in the same manner for use in identifying the position of the negative population.
- Con A-activated T cells derived from human LAG-3 / human Fc ⁇ RIIIA double transgenic mice show expression of both mouse LAG-3 and human LAG-3, and the dot plot dots representing individual cells are almost identical It was distributed diagonally. The expression of mouse LAG-3 and human LAG-3 was hardly observed in the non-activated resting T cells. From these results, in the prepared human LAG-3 / human Fc ⁇ RIIIA double transgenic mouse, as originally planned by using the technique of BAC transgenic, human LAG-3 expresses endogenous mouse LAG-3 It became clear to express according to the pattern.
- Example 11 In vivo evaluation of humanized anti-human LAG-3 antibody hLA212_H4 / L2 11-1) LAG-3 positive cell removing activity of humanized anti-human LAG-3 antibody hLA212_H4 / L2
- Example 10 human LAG-3 / human Fc ⁇ RIIIA double Using transgenic mice, it was examined whether the obtained humanized anti-human LAG-3 antibody hLA212_H4 / L2 has an activity of removing LAG-3 positive cells in vivo.
- Con A having polyclonal T cell activation activity (Sigma) was administered intravenously at a dose of 15 mg / kg.
- erythrocytes were hemolyzed from blood collected by Pharm Lyse (manufactured by BD) to obtain leukocytes, which were used for flow cytometry.
- FcBlock manufactured by BD
- PE-labeled anti-mouse LAG-3 antibody manufactured by BD
- ATTO 647-labeled anti-human LAG-3 antibody manufactured by Enzo Life Sciences
- FITC-labeled anti-mouse CD3 antibody BD
- LIVE / DEAD Fixable Dead Cell Stain Kit-near-IR fluorescent reactive dye manufactured by Invitrogen
- EAE pertussis toxin diluted with physiological saline.
- score 0 asymptomatic
- score 1 tail weakness
- score 2 gait abnormality
- loss of righting reflex
- score 3 hind limb paralysis
- score 4 partial paralysis of forelimb
- score 5 death or euthanasia.
- Humanized anti-human LAG-3 antibody hLA212_H4 / L2 and control antibody were intravenously administered at a dose of 30 mg / kg on Days 0 and 7, respectively.
- the average value of the clinical score of EAE is suppressed to 50% or less during the observation period as compared to the control antibody administration group.
- weight loss associated with EAE progression was also suppressed.
- the humanized anti-human LAG-3 antibody hLA212_H4 / L2 having the activity of removing LAG-3 positive cells in vivo suppresses EAE, which is a typical T-cell dependent autoimmune disease model. It became clear that it could be used as a therapeutic agent for human autoimmune diseases.
- Example 12 Relationship between LAG-3 and Perforin, CD28, and CD57 Expression in Human Activated T Cells
- PBMC peripheral blood by Ficoll centrifugation, and added to a 96-well U-bottom microplate at 4 ⁇ 10 5 cells / well.
- Human IL-2 (Peprotech, final concentration 100 ng / mL) and Dynabeads Human T-Activator CD3 / CD28 (Life Technologies, 4 ⁇ 10 5 / well) were added and cultured for 4 days to activate T cells.
- the obtained cells were collected, suspended in FACS buffer (PBS, 0.1% BSA, 0.1% sodium azide), and reacted with Human BD Fc Block (BD) at room temperature for 10 minutes.
- FACS buffer PBS, 0.1% BSA, 0.1% sodium azide
- the cell surface is stained by reacting it with a fluorescently labeled antibody diluted with a FACS buffer containing LIVE / DEAD Fixable Dead Cell Stain Kit-near-IR fluorescent reactive dye (manufactured by Invitrogen) at 4 ° C. for 30 minutes. Washed with FACS buffer.
- FITC labeled anti-human CD8 antibody As a fluorescent labeled antibody, FITC labeled anti-human CD8 antibody, PerCP-Cy5.5 labeled anti-human CD3 antibody, APC labeled anti-human CD28 antibody, PacificBlue labeled anti-human CD57 antibody (all are BD company), PE labeled anti-human CD28 antibody Anti-human LAG-3 antibody and isotype control antibody labeled using (Biolegend), PE labeling kit (Dojindo) were used in various combinations. For some samples, intracellular intracellular perforin was also stained using BD Cytofix / Cytoperm Fixation / Permeabilization Solution Kit (BD) and APC labeled anti-human perforin antibody (eBiosciences).
- BD Cytofix / Cytoperm Fixation / Permeabilization Solution Kit BD Cytofix / Cytoperm Fixation / Permeabilization Solution Kit (BD) and APC labeled anti-human perforin antibody (eBiosciences).
- the washed cells were resuspended in PBS containing 1% paraformaldehyde, and detection was performed with a flow cytometer (Canto II manufactured by BD or MACSQuant X manufactured by Miltenyi). Data analysis was performed by FlowJo (manufactured by TreeStar). LIVE / DEAD Fixable Dead Cell Stain Kit-near-IR fluorescent reactive dye-positive dead cells were gated out, then live cells alone were further gated and analyzed in CD3 positive CD8 positive CD8 T cells.
- FIG. 103 shows the results of analysis of the relationship between LAG-3 and CD28 expression.
- less than 50% of LAG-3 positive cells were found in CD28 positive cells, whereas in the case of CD28 negative cells, the cell population was generally LAG-3 positive compared to CD28 positive cells.
- expression of LAG-3 is more expressed in CD28 negative cells as compared to CD28 positive cells because Was found to be recognized.
- FIG. 104 shows the results of analysis of the relationship between LAG-3 and CD57 expression.
- 42% of the CD57-negative cells are LAG-3 positive, whereas the CD57-positive cells are generally LAG-3 positive compared to the CD57 negative cells.
- LAG-3 positive because of a large shift and a proportion of 79% of the cells became LAG-3 positive, in human activated CD8 T cells, expression of LAG-3 was more pronounced in CD57 positive cells compared to CD57 negative cells. It became clear that it was recognized.
- Example 13 Effect of LAG-3 Antibody on Perforin-Positive CD8 T Cells
- Humanized anti-human LAG-3 antibody hLA212_H4 / L2, calcineurin inhibitor tacrolimus, and corticosteroid dexamethasone in the experimental system of Example 12 were examined.
- Human PBMCs are hLA212_H4 / L2 (final concentration 10 ⁇ g / mL), control human IgG antibody (Jackson ImmunoResearch Laboratories, final concentration 10 ⁇ g / mL), tacrolimus (Focus, final concentration 10 nM), and dexamethasone (ENZO Life Sciences) After pre-incubation for 30 minutes at 37 ° C.
- the cells were cultured for 4 days with Dynabeads Human T-Activator CD3 / CD28 as in Example 12, and the obtained cells were subjected to flow cytometry.
- concentrations of these antibodies and compounds are as described previously (Henderson, DJ et al., Immunol., 1991; 73 (3): 316-321: Brunetti, M. et al., Pharmacol. Exp. Ther., 1998; 285 (2): 915-919), etc., the concentration is considered to be the concentration considered to exhibit the maximum efficacy.
- Example 14 Action of LAG-3 antibody on CD28 negative T cells and CD57 positive T cells Humanized anti-human LAG-3 antibody hLA212_H4 / L2 on calcineurin inhibitor on CD28 negative T cells and CD57 positive T cells in the assay system of Example 13 The effects of certain tacrolimus and corticosteroid dexamethasone were examined.
- Human PBMC were treated with hLA212_H4 / L2 (final concentrations 10, 1, and 0.1 ⁇ g / mL), control human IgG antibody (Jackson ImmunoResearch Laboratories, final concentration 10 ⁇ g / mL), tacrolimus (Focus, final concentration 10 nM), And pre-incubation with dexamethasone (ENZO Life Sciences, final concentration 1 ⁇ M) at 37 ° C. for 30 minutes, culture the cells with Dynabeads Human T-Activator CD3 / CD28 for 4 days as in Example 12, and flow the obtained cells Subject to cytometry. Among live cells, CD3 positive CD8 negative fractions were analyzed as CD4 T cells, and CD3 positive CD8 positive fractions as CD8 T cells.
- FIG. 106B The results of analyzing the effect on CD28 negative T cells are shown in FIG.
- the number of CD28 negative CD8 T cells was significantly reduced by hLA212_H4 / L2, as in the case of the perforin positive CD8 T cells of Example 13, as shown in FIG. 106B.
- This effect was dependent on the concentration of hLA212_H4 / L2, with similar results when using either PBMC from two donors.
- tacrolimus and dexamethasone were added, no significant decrease in the number of CD28 negative CD8 T cells as observed with the LAG-3 antibody was observed. Also, as shown in FIG.
- the CD28 negative CD4 T cells are not as remarkable as CD28 negative CD8 T cells
- the LAG-3 antibody hLA212_H4 / L2 shows a decrease in the number of cells
- tacrolimus and dexamethasone show little effect Or rather increased.
- FIG. 107B The result of analyzing the effect on CD57 positive T cells is shown in FIG.
- the number of CD57 positive CD8 T cells was markedly reduced by hLA212_H4 / L2, as in FIG. 107B.
- This effect was dependent on the concentration of hLA212_H4 / L2, with similar results when using either PBMC from two donors.
- tacrolimus and dexamethasone were added, the remarkable decrease in the number of CD57 positive CD8 T cells as observed with the LAG-3 antibody was not observed. Also, as shown in FIG.
- the LAG-3 antibody hLA212_H4 / L2 shows a decrease in the number of cells, and tacrolimus and dexamethasone have such an effect. was hardly observed.
- the humanized anti-human LAG-3 antibody hLA212_H3 / L2 the anti-human LAG-3 mouse-human chimeric antibody A9H12, and the anti-human LAG-3 rat-human chimeric antibody cLA212, which are not in the low fucose form, are in the low fucose form Although weak compared to hLA212_H4 / L2, it showed a tendency to reduce the number of CD28 negative T cells and CD57 positive T cells (data not shown).
- anti-LAG-3 antibody depletes CD28 negative T cells and CD57 positive T cells considered to be involved in steroid resistance in cytotoxic and immune system diseases, and such T cell depleting activity It has been revealed that hypofucosation is enhanced, and it has been shown that it may be a promising cytotoxic T cell depleting drug in the treatment of immunosuppressant-resistant cytotoxic T cell related diseases.
- compositions of the invention are useful for cytotoxic T cell depletion.
- SEQ ID NO: 1 Nucleotide sequence encoding amino acid sequence of heavy chain variable region of rLA204 antibody (FIG. 16)
- SEQ ID NO: 2 Amino acid sequence of heavy chain variable region of rLA204 antibody
- SEQ ID NO: 3 Nucleotide sequence encoding amino acid sequence of light chain variable region of rLA204 antibody (FIG. 18)
- SEQ ID NO: 4 Amino acid sequence of light chain variable region of rLA204 antibody (FIG. 19)
- SEQ ID NO: 5 Nucleotide sequence encoding amino acid sequence of heavy chain variable region of rLA212 antibody (FIG.
- SEQ ID NO: 6 Amino acid sequence of heavy chain variable region of rLA212 antibody
- SEQ ID NO: 7 Nucleotide sequence encoding amino acid sequence of light chain variable region of rLA212 antibody
- SEQ ID NO: 8 Amino acid sequence of light chain variable region of rLA212 antibody
- SEQ ID NO: 9 Nucleotide sequence encoding amino acid sequence of heavy chain variable region of rLA 225 antibody
- SEQ ID NO: 10 amino acid sequence of heavy chain variable region of rLA 225 antibody (FIG.
- SEQ ID NO: 11 Nucleotide sequence encoding amino acid sequence of light chain variable region of rLA 225 antibody
- SEQ ID NO: 12 Amino acid sequence of light chain variable region of rLA 225 antibody
- SEQ ID NO: 13 Nucleotide sequence encoding amino acid sequence of heavy chain variable region of rLA869 antibody
- SEQ ID NO: 14 Amino acid sequence of heavy chain variable region of rLA869 antibody
- SEQ ID NO: 15 Nucleotide sequence encoding amino acid sequence of light chain variable region of rLA869 antibody (FIG.
- SEQ ID NO: 16 Amino acid sequence of light chain variable region of rLA869 antibody
- SEQ ID NO: 17 Nucleotide sequence of cDNA encoding amino acid sequence of heavy chain variable region of rLA1264 antibody
- SEQ ID NO: 18 amino acid sequence of heavy chain variable region of rLA1264 antibody
- SEQ ID NO: 19 Nucleotide sequence encoding amino acid sequence of light chain variable region of rLA1264 antibody
- SEQ ID NO: 20 Amino acid sequence of light chain variable region of rLA1264 antibody (FIG.
- SEQ ID NO: 21 Nucleotide sequence encoding amino acid sequence of human light chain secretion signal and human ⁇ chain constant region
- SEQ ID NO: 22 Nucleotide sequence encoding amino acid sequence of human heavy chain secretion signal and human IgG1 constant region
- SEQ ID NO: 23 Nucleotide sequence encoding amino acid sequence of heavy chain of cLA212 antibody
- SEQ ID NO: 24 amino acid sequence of heavy chain of cLA212 antibody
- SEQ ID NO: 25 Nucleotide sequence encoding amino acid sequence of light chain of cLA212 antibody (FIG.
- SEQ ID NO: 26 Amino acid sequence of light chain of cLA212 antibody (FIG. 41)
- SEQ ID NO: 27 Nucleotide sequence encoding amino acid sequence of heavy chain H2 of hLA212 antibody (FIG. 42)
- SEQ ID NO: 28 Amino acid sequence of heavy chain H2 of hLA212 antibody (FIG. 43)
- SEQ ID NO: 29 Nucleotide sequence encoding amino acid sequence of heavy chain H3 of hLA212 antibody (FIG. 44)
- SEQ ID NO: 30 Amino acid sequence of heavy chain H3 of hLA212 antibody (FIG.
- SEQ ID NO: 31 Nucleotide sequence encoding amino acid sequence of light chain L1 of hLA212 antibody (FIG. 46)
- SEQ ID NO: 32 Amino acid sequence of light chain L1 of hLA212 antibody (FIG. 47)
- SEQ ID NO: 33 Nucleotide sequence encoding amino acid sequence of light chain L2 of hLA212 antibody (FIG. 48)
- SEQ ID NO: 34 Amino acid sequence of light chain L2 of hLA212 antibody (FIG. 49)
- SEQ ID NO: 35 Nucleotide sequence encoding amino acid sequence of light chain L3 of hLA212 antibody (FIG.
- SEQ ID NO: 36 Amino acid sequence of light chain L3 of hLA212 antibody (FIG. 51)
- SEQ ID NO: 37 Nucleotide sequence encoding amino acid sequence of light chain L4 of hLA212 antibody (FIG. 52)
- SEQ ID NO: 38 Amino acid sequence of light chain L4 of hLA212 antibody (FIG. 53)
- SEQ ID NO: 39 Nucleotide sequence encoding amino acid sequence of light chain L5 of hLA212 antibody (FIG. 54)
- SEQ ID NO: 40 Amino acid sequence of light chain L5 of hLA212 antibody (FIG. 55)
- SEQ ID NO: 42 Amino acid sequence of heavy chain CDRH2 of rLA204 antibody (FIG. 57)
- SEQ ID NO: 43 amino acid sequence of heavy chain CDRH3 of rLA204 antibody
- SEQ ID NO: 44 Amino acid sequence of light chain CDRL1 of rLA204 antibody (FIG. 59)
- SEQ ID NO: 45 Amino acid sequence of light chain CDRL2 of rLA204 antibody (FIG. 60)
- SEQ ID NO: 47 amino acid sequence of heavy chain CDRH1 of rLA212 antibody (FIG.
- SEQ ID NO: 48 amino acid sequence of heavy chain CDRH2 of rLA212 antibody
- SEQ ID NO: 49 amino acid sequence of heavy chain CDRH3 of rLA212 antibody
- SEQ ID NO: 50 Amino acid sequence of light chain CDRL1 of rLA212 antibody
- SEQ ID NO: 51 amino acid sequence of light chain CDRL2 of rLA212 antibody
- SEQ ID NO: 52 Amino acid sequence of light chain CDRL3 of rLA212 antibody
- SEQ ID NO: 53 amino acid sequence of heavy chain CDRH1 of rLA225 antibody
- SEQ ID NO: 54 amino acid sequence of heavy chain CDRH2 of rLA225 antibody (FIG. 69)
- SEQ ID NO: 55 amino acid sequence of heavy chain CDRH3 of rLA225 antibody
- SEQ ID NO: 56 Amino acid sequence of light chain CDRL1 of rLA225 antibody (FIG. 71)
- SEQ ID NO: 57 Amino acid sequence of light chain CDRL2 of rLA225 antibody (FIG. 72)
- SEQ ID NO: 58 amino acid sequence of light chain CDRL3 of rLA225 antibody (FIG. 73)
- SEQ ID NO: 60 amino acid sequence of heavy chain CDRH2 of rLA869 antibody (FIG. 75)
- SEQ ID NO: 61 Amino acid sequence of heavy chain CDRH3 of rLA869 antibody (FIG. 76)
- SEQ ID NO: 62 Amino acid sequence of light chain CDRL1 of rLA869 antibody (FIG. 77)
- SEQ ID NO: 63 Amino acid sequence of light chain CDRL2 of rLA869 antibody (FIG. 78)
- SEQ ID NO: 65 amino acid sequence of heavy chain CDRH1 of rLA1264 antibody (FIG. 80)
- SEQ ID NO: 66 amino acid sequence of heavy chain CDRH2 of rLA1264 antibody (FIG. 81)
- SEQ ID NO: 67 amino acid sequence of heavy chain CDRH3 of rLA1264 antibody (FIG. 82)
- SEQ ID NO: 68 Amino acid sequence of light chain CDRL1 of rLA1264 antibody (FIG. 83)
- SEQ ID NO: 71 Primer RG2AR3
- SEQ ID NO: 72 Primer RKR5
- SEQ ID NO: 73 Primer 3.3-F1
- SEQ ID NO: 74 Primer 3.3-R1
- SEQ ID NO: 75 Primer 212H-F
- SEQ ID NO: 76 Primer 212H-R
- SEQ ID NO: 77 Primer 212L-F
- Figure 93 SEQ ID NO: 79: oligonucleotide LAG-3-H1 (FIG.
- SEQ ID NO: 80 oligonucleotide LAG-3-H2 (FIG. 95)
- SEQ ID NO: 81 oligonucleotide LAG-3-H3 (FIG. 96)
- SEQ ID NO: 82 oligonucleotide LAG-3-H4 (FIG. 97)
- SEQ ID NO: 83 oligonucleotide LAG-3-H5 (FIG. 98)
- SEQ ID NO: 84 oligonucleotide LAG-3-H6 (FIG. 99)
- SEQ ID NO: 86 Amino acid sequence of human LAG-3 (FIG. 101)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
(1)
下記(i)乃至(iii)記載の性質を有する抗LAG-3抗体又はその結合断片を含む、細胞傷害性T細胞枯渇用組成物:
(i)イン・ビトロADCC活性を有する;
(ii)低フコース形態で、イン・ビボでLAG-3陽性細胞数を低減させる;及び、
(iii)ヒト活性化T細胞に結合する、
(2)
細胞傷害性T細胞が、パーフォリン陽性T細胞、グランザイムB陽性T細胞、CD28陰性CD4陽性T細胞、CD28陰性CD8陽性T細胞、CD57陽性CD4陽性T細胞及びCD57陽性CD8陽性T細胞よりなる群から選択される、(1)記載の組成物、
(3)
細胞傷害性T細胞がLAG-3陽性である、(1)又は(2)に記載の組成物、
(4)
抗LAG-3抗体又はその結合断片が、ヒトLAG-3のドメイン3に結合し、下記(i)乃至(iii)記載の性質を有する、(1)乃至(3)のいずれか一つに記載の組成物:
(i)低フコース形態で、イン・ビボで実験的自己免疫性脳脊髄炎を抑制する;
(ii)該抗体又はその結合断片存在下で、ヒトLAG-3とヒト主要組織適合遺伝子複合体クラスII分子は結合する;及び
(iii)該抗体又はその結合断片存在下で、ヒトLAG-3はヒトT細胞抑制機能を奏する、
(5)
免疫抑制剤抵抗性の細胞傷害性T細胞関連疾患の治療又は予防に使用される、(1)乃至(4)のいずれか一つに記載の組成物、
(6)
免疫抑制剤がステロイドである、(5)記載の組成物、
(7)
免疫抑制剤がカルシニューリン阻害剤である、(5)又は(6)記載の組成物、
(8)
該抗体又はその結合断片が、キメラ抗体、ヒト化抗体若しくはヒト抗体又はその結合断片である、(1)乃至(7)のいずれか一つに記載の組成物、
(9)
該抗体又はその結合断片が、配列番号50又は図65で示されるアミノ酸配列を有するCDRL1、配列番号51又は図66で示されるアミノ酸配列を有するCDRL2及び配列番号52又は図67で示されるアミノ酸配列を有するCDRL3を含む軽鎖、ならびに、配列番号47又は図62で示されるアミノ酸配列を有するCDRH1、配列番号48又は図63で示されるアミノ酸配列を有するCDRH2及び配列番号49又は図64で示されるアミノ酸配列を有するCDRH3を含む重鎖、を含んでなる、(4)記載の組成物、
(10)
該抗体又はその結合断片が、ヒト化抗体又はその結合断片である、(9)記載の組成物、
(11)
該抗体又はその結合断片が、配列番号28又は図43で示されるアミノ酸配列において、第68番の位置に相当するアミノ酸がGlyであるか又はAlaに置換され、第103番の位置に相当するアミノ酸がAsnであるか又はAspに置換されてなるアミノ酸配列を含む重鎖、並びに、配列番号32又は図47で示されるアミノ酸配列において、第21番の位置に相当するアミノ酸がAspであるか又はAsnに置換され、第31番の位置に相当するアミノ酸がLeuであるか又はMetに置換され、第33番の位置に相当するアミノ酸がAlaであるか又はIleに置換され、第41番の位置に相当するアミノ酸がIleであるか又はMetに置換され、第58番の位置に相当するアミノ酸がGlnであるか又はLysに置換され、第63番の位置に相当するアミノ酸がAlaであるか又はSerに置換され、第80番の位置に相当するアミノ酸がSerであるか又はAspに置換され、第85番の位置に相当するアミノ酸がSerであるか又はGlyに置換され、第87番の位置に相当するアミノ酸がSerであるか又はTyrに置換され、第98番の位置に相当するアミノ酸がLeuであるか又はValに置換され、第103番の位置に相当するアミノ酸がPheであるか又はAlaに置換され、第105番の位置に相当するアミノ酸がThrであるか又はPheに置換され、第124番の位置に相当するアミノ酸がValであるか又はLeuに置換され、126番の位置に相当するアミノ酸がIleであるか又はLeuに置換されてなるアミノ酸配列を含む軽鎖、を含んでなる、(10)記載の組成物、
(12)
該抗体又はその結合断片の、軽鎖可変領域のアミノ酸配列が配列番号32、34、36、38及び40からからなる群より選択されるアミノ酸配列の第21番アミノ酸乃至第129番アミノ酸を含み、重鎖可変領域のアミノ酸配列が配列番号28及び30からなる群より選択されるアミノ酸配列の第20番アミノ酸乃至第140番アミノ酸を含む、(10)又は(11)記載の組成物、
(13)
該抗体又はその結合断片の、軽鎖のアミノ酸配列が配列番号32、34、36、38及び40からからなる群より選択されるアミノ酸配列の第21番アミノ酸乃至第234番アミノ酸を含み、重鎖のアミノ酸配列が配列番号28及び30からなる群より選択されるアミノ酸配列の第20番アミノ酸乃至第470番アミノ酸を含む、(10)乃至(12)のいずれか一つに記載の組成物、
(14)
該抗体又はその結合断片が、下記[i]乃至[x]よりなる群から選択される、(10)乃至(13)のいずれか一つに記載の組成物:
[i]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号34(図49)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[ii]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号32(図47)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[iii]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号36(図51)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[iv]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号34(図49)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[v]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号36(図51)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[vi]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号38(図53)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[vii]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号40(図55)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[viii]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号32(図47)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[ix]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号38(図53)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;及び、
[x]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号40(図55)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片、
(15)
該抗体又はその結合断片の有する軽鎖可変領域及び重鎖可変領域のアミノ酸配列と、それぞれ95%以上同一なアミノ酸配列を含む軽鎖可変領域と重鎖可変領域を有する抗体又はその結合断片を含んでなる、(14)記載の組成物、
(16)
該抗体又はその結合断片の有する軽鎖可変領域のアミノ酸配列をコードするヌクレオチド配列又はそれに相補的なヌクレオチド配列を有する第1の核酸分子とストリンジェントな条件下でハイブリダイズする第2の核酸分子が含むヌクレオチド配列によりコードされる軽鎖可変領域アミノ酸配列、および、該抗体又はその結合断片の有する重鎖可変領域のアミノ酸配列をコードするヌクレオチド配列又はそれに相補的なヌクレオチド配列を有する第3の核酸分子とストリンジェントな条件下でハイブリダイズする第4の核酸分子が含むヌクレオチド配列によりコードされる重鎖可変領域アミノ酸配列、を含む抗体又はその結合断片を含んでなる、(14)記載の組成物、
(17)
下記(i)又は(ii)記載の性質を有する抗体又はその結合断片を含んでなる、(14)記載の組成物:
(i)該抗体又はその結合断片が認識するヒトLAG-3のドメイン3上の部位に結合する;
(ii)該抗体又はその結合断片と、ヒトLAG-3のドメイン3への結合において競合する、
(18)
該抗体又はその結合断片が、低フコース形態にある、(1)乃至(17)のいずれか一つに記載の組成物、
(19)
該抗体又はその結合断片が、そのアミノ酸配列をコードするヌクレオチド配列を含む核酸分子若しくは該核酸分子を含むベクターを含む細胞、又は、該抗体又はその結合断片を生産する細胞を培養する工程を含んでなる、該抗体又はその結合断片の製造方法により得られる、(1)乃至(18)のいずれか一つに記載の組成物、
(20)
該抗体又はその結合断片存在下で、ヒトLAG-3はヒトT細胞抑制機能を奏しない、(1)乃至(3)のいずれか一つに記載の組成物、
(21)
該抗体又はその結合断片存在下で、ヒトLAG-3とヒト主要組織適合遺伝子複合体クラスII分子は結合しない、(1)乃至(3)及び(20)のいずれか一つに記載の組成物、
(22)
該抗体又はその結合断片が、低フコース形態にある、(20)又は(21)に記載の組成物、
(23)
細胞傷害性T細胞枯渇に使用される、下記(i)乃至(iii)記載の性質を有する抗LAG-3抗体又はその結合断片:
(i)イン・ビトロADCC活性を有する;
(ii)低フコース形態で、イン・ビボでLAG-3陽性細胞数を低減させる;及び、
(iii)ヒト活性化T細胞に結合する、
(24)
細胞傷害性T細胞枯渇のための、下記(i)乃至(iii)記載の性質を有する抗LAG-3抗体又はその結合断片の使用:
(i)イン・ビトロADCC活性を有する;
(ii)低フコース形態で、イン・ビボでLAG-3陽性細胞数を低減させる;及び、
(iii)ヒト活性化T細胞に結合する、
(25)
下記(i)乃至(iii)記載の性質を有する抗LAG-3抗体又はその結合断片を投与することを含む、細胞傷害性T細胞を枯渇させる方法:
(i)イン・ビトロADCC活性を有する;
(ii)低フコース形態で、イン・ビボでLAG-3陽性細胞数を低減させる;及び、
(iii)ヒト活性化T細胞に結合する、
(26)
他の医薬と組み合わせて使用される、(1)乃至(22)のいずれか一つに記載の組成物、
(27)
下記(i)乃至(iii)記載の性質を有する抗LAG-3抗体又はその結合断片を含む、 パーフォリン陽性、グランザイムB陽性、CD28陰性CD4陽性、CD28陰性CD8陽性、CD57陽性CD4陽性、及び/又は、CD57陽性CD8陽性の細胞傷害性T細胞関連疾患の治療用又は予防用医薬組成物:
(i)イン・ビトロADCC活性を有する;
(ii)低フコース形態で、イン・ビボでLAG-3陽性細胞数を低減させる;及び、
(iii)ヒト活性化T細胞に結合する、
(28)
パーフォリン陽性、グランザイムB陽性、CD28陰性CD4陽性、CD28陰性CD8陽性、CD57陽性CD4陽性、及び/又は、CD57陽性CD8陽性が、細胞傷害性T細胞又はその細胞膜画分を含む生物学的サンプルについて判定されることを特徴とする、(27)記載の医薬組成物、
(29)
該生物学的サンプルが、細胞傷害性T細胞関連疾患に罹患しているか又は罹患を回避することが望ましい個体に由来することを特徴とする、(28)記載の医薬組成物、
(30)
細胞傷害性T細胞関連疾患が、特発性肺線維症、慢性閉塞性肺疾患(COPD)、多発性硬化症、バセドウ病、強直性脊椎炎、扁平部炎、喘息、関節リウマチ、多発性筋炎・皮膚筋炎、封入体筋炎、急性冠症候群、全身性エリテマトーデス、ループス腎炎、強皮症、クローン病、潰瘍性大腸炎、再生不良性貧血、骨髄異形成症候群、シェーグレン症候群、ヴェゲナー肉芽腫症、乾癬、2型糖尿病、宿主対移植片反応、慢性B型肝炎、及び/又は、サルコイドーシスである、(27)乃至(29)のいずれか一つに記載の医薬組成物、
(31)
細胞傷害性T細胞関連疾患がLAG-3陽性である、(27)乃至(30)のいずれか一つに記載の医薬組成物、
(32)
抗LAG-3抗体又はその結合断片が、ヒトLAG-3のドメイン3に結合し、下記(i)乃至(iii)記載の性質を有する、(27)乃至(31)のいずれか一つに記載の医薬組成物:
(i)低フコース形態で、イン・ビボで実験的自己免疫性脳脊髄炎を抑制する;
(ii)該抗体又はその結合断片存在下で、ヒトLAG-3とヒト主要組織適合遺伝子複合体クラスII分子は結合する;及び
(iii)該抗体又はその結合断片存在下で、ヒトLAG-3はヒトT細胞抑制機能を奏する、
(33)
細胞傷害性T細胞関連疾患が免疫抑制剤抵抗性である、(27)乃至(32)のいずれか一つに記載の医薬組成物、
(34)
免疫抑制剤がステロイドである、(33)記載の医薬組成物、
(35)
免疫抑制剤がカルシニューリン阻害剤である、(33)又は(34)記載の医薬組成物、
(36)
該抗体又はその結合断片が、キメラ抗体、ヒト化抗体若しくはヒト抗体又はその結合断片である、(27)乃至(35)のいずれか一つに記載の医薬組成物、
(37)
該抗体又はその結合断片が、配列番号50で示されるアミノ酸配列を有するCDRL1、配列番号51で示されるアミノ酸配列を有するCDRL2及び配列番号52で示されるアミノ酸配列を有するCDRL3を含む軽鎖、ならびに、配列番号47で示されるアミノ酸配列を有するCDRH1、配列番号48で示されるアミノ酸配列を有するCDRH2及び配列番号49で示されるアミノ酸配列を有するCDRH3を含む重鎖、を含んでなる、(27)乃至(36)のいずれか一つに記載の医薬組成物、
(38)
該抗体又はその結合断片が、ヒト化抗体又はその結合断片である、(37)記載の医薬組成物、
(39)
該抗体又はその結合断片が、配列番号28で示されるアミノ酸配列において、第68番の位置に相当するアミノ酸がGlyであるか又はAlaに置換され、第103番の位置に相当するアミノ酸がAsnであるか又はAspに置換されてなるアミノ酸配列を含む重鎖、並びに、配列番号32で示されるアミノ酸配列において、第21番の位置に相当するアミノ酸がAspであるか又はAsnに置換され、第31番の位置に相当するアミノ酸がLeuであるか又はMetに置換され、第33番の位置に相当するアミノ酸がAlaであるか又はIleに置換され、第41番の位置に相当するアミノ酸がIleであるか又はMetに置換され、第58番の位置に相当するアミノ酸がGlnであるか又はLysに置換され、第63番の位置に相当するアミノ酸がAlaであるか又はSerに置換され、第80番の位置に相当するアミノ酸がSerであるか又はAspに置換され、第85番の位置に相当するアミノ酸がSerであるか又はGlyに置換され、第87番の位置に相当するアミノ酸がSerであるか又はTyrに置換され、第98番の位置に相当するアミノ酸がLeuであるか又はValに置換され、第103番の位置に相当するアミノ酸がPheであるか又はAlaに置換され、第105番の位置に相当するアミノ酸がThrであるか又はPheに置換され、第124番の位置に相当するアミノ酸がValであるか又はLeuに置換され、126番の位置に相当するアミノ酸がIleであるか又はLeuに置換されてなるアミノ酸配列を含む軽鎖、を含んでなる、(38)記載の医薬組成物、
(40)
該抗体又はその結合断片の、軽鎖可変領域のアミノ酸配列が配列番号32、34、36、38及び40からからなる群より選択されるアミノ酸配列の第21番アミノ酸乃至第129番アミノ酸を含み、重鎖可変領域のアミノ酸配列が配列番号28及び30からなる群より選択されるアミノ酸配列の第20番アミノ酸乃至第140番アミノ酸を含む、(38)又は(39)記載の医薬組成物、
(41)
該抗体又はその結合断片の、軽鎖のアミノ酸配列が配列番号32、34、36、38及び40からからなる群より選択されるアミノ酸配列の第21番アミノ酸乃至第234番アミノ酸を含み、重鎖のアミノ酸配列が配列番号28及び30からなる群より選択されるアミノ酸配列の第20番アミノ酸乃至第470番アミノ酸を含む、(38)乃至(40)のいずれか一つに記載の医薬組成物、
(42)
該抗体又はその結合断片が、下記[i]乃至[x]よりなる群から選択される、(38)乃至(41)のいずれか一つに記載の医薬組成物:
[i]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号34(図49)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[ii]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号32(図47)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[iii]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号36(図51)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[iv]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号34(図49)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[v]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号36(図51)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[vi]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号38(図53)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[vii]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号40(図55)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[viii]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号32(図47)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[ix]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号38(図53)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;及び、
[x]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号40(図55)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片、
(43)
該抗体又はその結合断片の有する軽鎖可変領域及び重鎖可変領域のアミノ酸配列と、それぞれ95%以上同一なアミノ酸配列を含む軽鎖可変領域と重鎖可変領域を有する抗体又はその結合断片を含んでなる、(42)記載の医薬組成物、
(44)
該抗体又はその結合断片の有する軽鎖可変領域のアミノ酸配列をコードするヌクレオチド配列又はそれに相補的なヌクレオチド配列を有する第1の核酸分子とストリンジェントな条件下でハイブリダイズする第2の核酸分子が含むヌクレオチド配列によりコードされる軽鎖可変領域アミノ酸配列、および、該抗体又はその結合断片の有する重鎖可変領域のアミノ酸配列をコードするヌクレオチド配列又はそれに相補的なヌクレオチド配列を有する第3の核酸分子とストリンジェントな条件下でハイブリダイズする第4の核酸分子が含むヌクレオチド配列によりコードされる重鎖可変領域アミノ酸配列、を含む抗体又はその結合断片を含んでなる、(42)記載の医薬組成物、
(45)
下記(i)又は(ii)記載の性質を有する抗体又はその結合断片を含んでなる、(42)記載の医薬組成物:
(i)該抗体又はその結合断片が認識するヒトLAG-3のドメイン3上の部位に結合する;
(ii)該抗体又はその結合断片と、ヒトLAG-3のドメイン3への結合において競合する、
(46)
該抗体又はその結合断片が、低フコース形態にある、(27)乃至(45)のいずれか一つに記載の医薬組成物、
(47)
該抗体又はその結合断片が、そのアミノ酸配列をコードするヌクレオチド配列を含む核酸分子若しくは該核酸分子を含むベクターを含む細胞、又は、該抗体又はその結合断片を生産する細胞を培養する工程を含んでなる、該抗体又はその結合断片の製造方法により得られる、(27)乃至(46)のいずれか一つに記載の医薬組成物。
(48)
該抗体又はその結合断片存在下で、ヒトLAG-3はヒトT細胞抑制機能を奏しない、(27)乃至(31)のいずれか一つに記載の医薬組成物、
(49)
該抗体又はその結合断片存在下で、ヒトLAG-3とヒト主要組織適合遺伝子複合体クラスII分子は結合しない、(27)乃至(31)及び(48)のいずれか一つに記載の医薬組成物、
(50)
該抗体又はその結合断片が、低フコース形態にある、(48)又は(49)に記載の医薬組成物、
(51)
他の医薬と組み合わせて使用される、(27)乃至(50)のいずれか一つに記載の医薬組成物、
(52)
パーフォリン陽性、グランザイムB陽性、CD28陰性CD4陽性、CD28陰性CD8陽性、CD57陽性CD4陽性、及び/又は、CD57陽性CD8陽性の細胞傷害性T細胞関連疾患に罹患しているか又は罹患を回避することが望ましい個体に(1)乃至(22)のいずれか一つに記載の組成物、又は(27)乃至(51)のいずれか一つに記載の医薬組成物を投与する工程を含む、細胞傷害性T細胞関連疾患を治療又は予防する方法、
(53)
細胞傷害性T細胞関連疾患が、免疫抑制剤抵抗性である、(52)記載の方法、
(54)
免疫抑制剤がステロイドである、(53)記載の方法、
(55)
免疫抑制剤がカルシニューリン阻害剤である、(53)又は(54)記載の方法、
(56)
細胞傷害性T細胞又はその細胞膜画分を含む生物学的サンプルについて、パーフォリン陽性、グランザイムB陽性、CD28陰性CD4陽性、CD28陰性CD8陽性、CD57陽性CD4陽性、及び/又は、CD57陽性CD8陽性か否かを判定する工程を含む、(52)乃至(55)のいずれか一つに記載の方法、
(57)
該生物学的サンプルが、細胞傷害性T細胞関連疾患に罹患しているか又は罹患を回避することが望ましい個体に由来する、(56)記載の方法、
等に関する。
本発明において、「遺伝子」とは、蛋白質のアミノ酸をコードするヌクレオチド配列が含まれる核酸分子またはその相補鎖を意味し、例えば、蛋白質のアミノ酸をコードするヌクレオチド配列またはその配列に相補的なヌクレオチド配列を有するポリヌクレオチド、オリゴヌクレオチド、DNA、mRNA、cDNA、cRNA等は「遺伝子」の意味に含まれる。かかる遺伝子は一本鎖、二本鎖又は三本鎖以上のヌクレオチドであり、DNA鎖とRNA鎖の会合体、一本のヌクレオチド鎖上にリボヌクレオチド(RNA)とデオキシリボヌクレオチド(DNA)が混在するもの及びそのようなヌクレオチド鎖を含む二本鎖又は三本鎖以上のヌクレオチドも「遺伝子」の意味に含まれる。本発明の「LAG-3遺伝子」としては、例えば、LAG-3蛋白質のアミノ酸配列をコードするヌクレオチド配列が含まれるDNA、mRNA、cDNA、cRNA等をあげることができる。
(2-1)特性
LAG-3蛋白質(以下単に「LAG-3」とも記す)は膜貫通型受容体蛋白質で、免疫グロブリン様ドメイン(IgD1乃至4)から成るリガンド結合部位を含む細胞外領域、I型1回膜貫通領域、および細胞内領域から構成されている。LAG-3はCD223と同義である。
LAG-3蛋白質は以下の性質を有する。
(i)抗原提示細胞上の主要組織適合遺伝子複合体(MHC)クラスII分子に結合する。
(ii)MHCクラスII分子に結合して、当該分子を発現するT細胞に抑制性のシグナルを伝達し、該T細胞の機能を負に制御する。
(iii)本発明においてLAG-3蛋白質は、次の(a)乃至(d)のいずれか一つに記載のアミノ酸配列(以下、「LAG-3アミノ酸配列」という)を含んでなるか、LAG-3アミノ酸配列を含むアミノ酸配列からなるか、またはLAG-3アミノ酸配列からなる:
(a)配列番号86(図101)で示されるアミノ酸配列;
(b)配列番号86(図101)で示されるアミノ酸配列と80%以上、82%以上、84%以上、86%以上、88%以上、90%以上、92%以上、94%以上、96%以上、98%以上又は99%以上の配列同一性を示し且つMHCクラスII分子結合活性を有するポリペプチドのアミノ酸配列;
(c)配列番号86(図101)で示されるアミノ酸配列において1乃至50個、1乃至45個、1乃至40個、1乃至35個、1乃至30個、1乃至25個、1乃至20個、1乃至15個、1乃至10個、1乃至8個、1乃至6個、1乃至5個、1乃至4個、1乃至3個、1若しくは2個、または1個のアミノ酸が置換、欠失、付加または挿入してなり且つMHCクラスII分子結合活性を有するポリペプチドのアミノ酸配列;及び、
(d)配列番号86(図101)で示されるアミノ酸配列をコードするヌクレオチド配列に相補的なヌクレオチド配列を有するポリヌクレオチド(核酸分子)とストリンジェントな条件下でハイブリダイズするポリヌクレオチド(核酸分子)の有するヌクレオチド配列によりコードされ、且つ、MHCクラスII分子結合活性を有するポリペプチドのアミノ酸配列。
(iv)LAG-3蛋白質は、脊椎動物、好適には哺乳動物、より好適にはマウス、ラット等のげっ歯類及びヒト、より一層好適にはヒト、ラット又はマウスの、LAG-3を発現している細胞、組織又は癌組織、かかる組織由来の細胞、かかる細胞の培養物等より得ることができる。
LAG-3は、生体内では炎症部位の活性化T細胞等に発現が認められ、正常組織の細胞においてはほとんど発現していないか又は発現レベルが非常に低い。
本発明においてLAG-3遺伝子は、次の(a)乃至(c)のいずれか一つに記載のヌクレオチド配列(以下、「LAG-3遺伝子配列」という)を含んでなるか、LAG-3遺伝子配列を含むヌクレオチド配列からなるか、またはLAG-3遺伝子配列からなる:
(a)配列番号86(図101)で示されるアミノ酸配列をコードするヌクレオチド配列;
(b)配列番号86(図101)で示されるアミノ酸配列をコードするヌクレオチド配列に相補的なヌクレオチド配列からなるポリヌクレオチド(核酸分子)とストリンジェントな条件下でハイブリダイズし且つMHCクラスII分子結合活性を有するポリペプチドのアミノ酸配列をコードするポリヌクレオチド(核酸分子)が有するヌクレオチド配列;及び
(c)配列番号86(図101)で示されるアミノ酸配列において1乃至50個、1乃至45個、1乃至40個、1乃至30個、1乃至25個、1乃至20個、1乃至15個、1乃至10個、1乃至8個、1乃至6個、1乃至5個、1乃至4個、1乃至3個、1若しくは2個、または1個の塩基が置換、欠失、付加または挿入してなるアミノ酸配列をコードし且つMHCクラスII分子結合活性を有するポリペプチドのアミノ酸配列をコードするヌクレオチド配列。
LAG-3蛋白質は、動物組織(体液を含む)、該組織由来の細胞もしくは該細胞培養物からの精製及び単離、遺伝子組換え、インビトロ翻訳、化学合成等により調製することができる。
(2-3-1)非組換型LAG-3の精製、単離
非組換型LAG-3蛋白質は、LAG-3を発現している細胞より精製、単離することができる。LAG-3を発現している細胞としては(2-1)の(iv)記載のものを例示することができるが、非組換型LAG-3蛋白質の由来はそれらに限定されるものではない。
(2-3-2)組換型LAG-3蛋白質の調製
LAG-3蛋白質は、組換型としても調製することができる。すなわち、LAG-3蛋白質又はLAG-3蛋白質断片のアミノ酸配列をコードする遺伝子を宿主細胞に導入し、かかる細胞の培養物からLAG-3蛋白質を回収することができる。また、アミノ末端(N末)及び/又はカルボキシ末端(C末)が天然型と同一の分子のみならず、分泌シグナル、細胞内局在化シグナル、アフィニティー精製用タグ、パートナーペプチドとの融合蛋白質として発現させることもできる。かかる組換え細胞培養物からのLAG-3蛋白質の精製、単離は、(2-3-1)記載の非組換型LAG-3蛋白質の精製、単離に記載の分画、クロマトグラフィー等の操作を適宜組み合わせることにより行うことができる。また、LAG-3蛋白質含有溶液は、ゲルろ過やCentriprep等の濃縮装置でバッファー交換及び/又は濃縮することができる。
LAG-3蛋白質はインビトロ翻訳によっても調製することができる。かかる翻訳法としては、転写及び翻訳に必要な酵素、基質並びにエネルギー物質を含む無細胞翻訳系を利用した方法であれば特に限定されるものではないが、例えば、ロシュ・ダイアグノスティックス社製のラピッドトランスレーションシステム(RTS)を利用する方法をあげることができる。
(2-3-4)化学合成
LAG-3蛋白質は化学合成によっても調製することができる。化学合成法としては、例えば、Fmoc合成法、Boc合成法などのペプチド固相合成法をあげることができる。
(3-1)抗体の分類
本発明においてLAG-3抗体は、モノクローナル抗体およびポリクローナル抗体のいずれであってもよい。モノクローナル抗体としては、非ヒト動物由来の抗体(非ヒト動物抗体)、ヒト由来の抗体(ヒト抗体)、キメラ化抗体(「キメラ抗体」ともいう)、ヒト化抗体等をあげることができる。
本発明においてLAG-3抗体はLAG-3蛋白質を認識する。言い換えれば、LAG-3抗体はLAG-3蛋白質に結合する。かかる抗体は「抗LAG-3抗体」とも表記される。また、本発明に使用される好適な抗体はLAG-3蛋白質を特異的に認識する。言い換えれば、本発明に使用される好適な抗体はLAG-3蛋白質に特異的に結合する(以上、まとめて抗体の「LAG-3結合活性という)。さらに、本発明に使用されるより好適な抗体はLAG-3蛋白質の細胞外領域に特異的に結合し、より一層好適な抗体はLAG-3蛋白質の有する免グロブリン様ドメイン(以下、「Ig様ドメイン」という)に特異的に結合し、さらにより一層好適な抗体はかかるIg様ドメイン3に特異的に結合する。
本発明に使用される抗LAG-3抗体は、そのある態様において、抗体依存性細胞傷害(ADCC)活性を有し、好適にはイン・ビトロでADCC活性を有し、より好適にはLAG-3を発現するT細胞に対してADCC活性を有する。本発明に使用される抗LAG-3抗体は、ADCC活性に加え、補体依存性細胞傷害(CDC)活性及び/又は抗体依存性細胞媒介食活性(ADCP)活性を有していてもよい。本発明においては「イン・ビトロのADCC活性」を単に「ADCC活性」ということがある。
本発明においてLAG-3抗体は、そのある態様において、LAG-3陽性細胞数を低減させ、好適にはイン・ビボ(in vivo)でLAG-3陽性細胞数を低減させ、より好適には低フコース形態で、イン・ビボ(in vivo)でLAG-3陽性細胞数を低減させる。
本発明においてLAG-3抗体は、そのある態様において、脳脊髄炎抑制活性を有し、好適にはイン・ビボ(in vivo)で実験的自己免疫性脳脊髄炎抑制活性を有し、より好適には低フコース形態で、イン・ビボ(in vivo)で実験的自己免疫性脳脊髄炎抑制活性を有する。
本発明においてLAG-3抗体は、そのある態様において、ヒト活性化T細胞に結合し、好適にはLAG-3陽性ヒト活性化T細胞に結合する。
抗体と活性化ヒト活性化T細胞の結合は、例えば、フローサイトメトリー法により測定又は検出することができる。
本発明のある態様では、抗体の存在下において、ヒトLAG-3とヒトMHCクラスII分子は結合することができるか、又は、本発明においてLAG-3抗体は、ヒトLAG-3とヒトMHCクラスII分子の結合を阻害しない。
また他の態様において、本発明におけるLAG-3抗体の存在下で、ヒトLAG-3はヒトT細胞抑制機能を奏する。
サイトカインとしては、例えば、活性化T細胞から産生されるサイトカイン、好適には各種インターローキンおよびインターフェロン、より好適にはインターロイキン2(IL-2)およびインターフェロンγ等をあげることができる。
本発明は抗LAG-3モノクローナル抗体及びその結合断片を提供する。モノクローナル抗体には、ラット抗体、マウス抗体、ウサギ抗体、ニワトリ抗体、魚類抗体等の非ヒト動物由来のモノクローナル抗体、キメラ抗体、ヒト化抗体、ヒト抗体、それらの結合断片、それらの修飾体等が含まれる。このうち、ラットモノクローナル抗体の例としては、rLA204、rLA212、rLA225、rLA869、rLA1264等をあげることができる。
また、複数の抗体に由来するCDRH1乃至CDRH3およびCDRL1乃至CDRL3を有する抗体も、抗体変異体に含まれる。そのような変異体の例として、CDRH3のみある抗体に由来し、CDRH1及びCDRH2ならびにCDRL1乃至CDRL3は別の抗体に由来する抗体変異体をあげることができる。
本発明においては抗体変異体も「抗体」に包含される。
本発明における抗体の定常領域としては、特に限定されるものではないが、細胞傷害性T細胞枯渇のためのLAG-3抗体としては、好適にはヒト抗体のものが使用される。ヒト抗体の重鎖定常領域としては、例えば、Cγ1、Cγ2、Cγ3、Cγ4、Cμ、Cδ、Cα1、Cα2、Cε等をあげることができる。ヒト抗体の軽鎖定常領域としては、例えば、Cκ、Cλ等をあげることができる。
本発明に使用される抗LAG-3キメラ化抗体又はその結合断片は、(3-2)および(3-3)、好適にはそれらに加えて(3-4)、より好適にはそれらに加えて(3-5)、より一層好適には(3-2)乃至(3-8)全て、に記載の性質、機能、活性等をそれぞれ有する。
本発明のラット-ヒトキメラ化抗体として例示されるcLA212の重鎖ヌクレオチド配列及びアミノ酸配列ならびに軽鎖ヌクレオチド配列及びアミノ酸配列は、配列番号23、24、25及び26(図38、39、40及び41)にそれぞれ示される。重鎖のヌクレオチド配列におけるヌクレオチド番号1乃至57、ならびに、重鎖のアミノ酸配列におけるアミノ酸番号1乃至19は、シグナル配列であり、通常大部分の成熟重鎖のヌクレオチド配列およびアミノ酸配列にはそれぞれ含まれない。同様に、軽鎖のヌクレオチド配列におけるヌクレオチド番号1乃至60、ならびに、軽鎖のアミノ酸配列におけるアミノ酸番号1乃至20は、シグナル配列であり、通常大部分の成熟軽鎖のヌクレオチド配列およびアミノ酸配列にはそれぞれ含まれない。
本発明に使用される抗体は一つの態様として、抗LAG-3抗体の結合断片であってよい。抗体の結合断片とは、該抗体の有する機能の少なくとも一部を保持する断片を意味する。かかる抗体の機能としては、一般的には、抗原結合活性、抗原の活性を調節する活性、抗体依存性細胞傷害(ADCC)活性等を挙げることができる。本発明に使用される好適な抗LAG-3抗体の結合断片は、(3-2)および(3-3)、好適にはそれらに加えて(3-4)、より好適にはそれらに加えて(3-5)、より一層好適には(3-2)乃至(3-8)全て、に記載の性質、機能、活性等をそれぞれ有する。
抗体の結合断片としては、該抗体の有する活性の少なくとも一部を保持している該抗体の断片であれば特に限定されないが、例えば、Fab、F(ab’)2、Fv、重鎖及び軽鎖のFvを適当なリンカーで連結させたシングルチェインFv(scFv)、diabody(diabodies)、線状抗体、及び抗体断片より形成された多特異性抗体、F(ab’)2を還元条件下で処理した抗体の可変領域の一価の断片であるFab’等をあげることができるが、それらに限定されるものではない。リンカー部分を保有するscFvのように、抗体の断片以外の部分を含む分子も、抗体の結合断片の意味に包含される。
本発明はその一つの態様において、ヒト化抗体又はその結合断片を提供する。
本発明のヒト化抗LAG-3抗体又はその結合断片としては、例えば、配列番号41(図56)に示されるアミノ酸配列からなるCDRH1、配列番号42(図57)に示されるアミノ酸配列からなるCDRH2及び配列番号43(図58)に示されるアミノ酸配列からなるCDRH3を含む可変領域を有する重鎖、並びに、配列番号44(図59)に示されるアミノ酸配列からなるCDRL1、配列番号45(図60)に示されるアミノ酸配列からなるCDRL2及び配列番号46(図61)に示されるアミノ酸配列からなるCDRL3を含む可変領域を有する軽鎖からなり、LAG-3蛋白質を認識するヒト化抗体もしくはその結合断片、またはその変異体等をあげることができる。
また、他のヒト化抗LAG-3抗体又はその結合断片としては、例えば、配列番号47(図62)に示されるアミノ酸配列からなるCDRH1、配列番号48(図63)に示されるアミノ酸配列からなるCDRH2及び配列番号49(図64)に示されるアミノ酸配列からなるCDRH3を含む可変領域を有する重鎖、並びに、配列番号50(図65)に示されるアミノ酸配列からなるCDRL1、配列番号51(図66)に示されるアミノ酸配列からなるCDRL2及び配列番号52(図67)に示されるアミノ酸配列からなるCDRL3を含む可変領域を有する軽鎖からなり、LAG-3蛋白質を認識するヒト化抗体もしくはその結合断片、またはその変異体等をあげることができる。
さらに、他のヒト化抗LAG-3抗体又はその結合断片としては、例えば、配列番号53(図68)に示されるアミノ酸配列からなるCDRH1、配列番号54(図69)に示されるアミノ酸配列からなるCDRH2及び配列番号55(図70)に示されるアミノ酸配列からなるCDRH3を含む可変領域を有する重鎖、並びに、配列番号56(図71)に示されるアミノ酸配列からなるCDRL1、配列番号57(図72)に示されるアミノ酸配列からなるCDRL2及び配列番号58(図73)に示されるアミノ酸配列からなるCDRL3を含む可変領域を有する軽鎖からなり、LAG-3蛋白質を認識するヒト化抗体もしくはその結合断片、またはその変異体等をあげることができる。
さらに、他のヒト化抗LAG-3抗体又はその結合断片としては、例えば、配列番号59(図74)に示されるアミノ酸配列からなるCDRH1、配列番号60(図75)に示されるアミノ酸配列からなるCDRH2及び配列番号61(図76)に示されるアミノ酸配列からなるCDRH3を含む可変領域を有する重鎖、並びに、配列番号62(図77)に示されるアミノ酸配列からなるCDRL1、配列番号63(図78)に示されるアミノ酸配列からなるCDRL2及び配列番号64(図79)に示されるアミノ酸配列からなるCDRL3を含む可変領域を有する軽鎖からなり、LAG-3蛋白質を認識するヒト化抗体もしくはその結合断片、またはその変異体等をあげることができる。
さらに、他のヒト化抗LAG-3抗体又はその結合断片としては、例えば、配列番号65(図80)に示されるアミノ酸配列からなるCDRH1、配列番号66(図81)に示されるアミノ酸配列からなるCDRH2及び配列番号67(図82)に示されるアミノ酸配列からなるCDRH3を含む可変領域を有する重鎖、並びに、配列番号68(図83)に示されるアミノ酸配列からなるCDRL1、配列番号69(図84)に示されるアミノ酸配列からなるCDRL2及び配列番号70(図85)に示されるアミノ酸配列からなるCDRL3を含む可変領域を有する軽鎖からなり、LAG-3蛋白質を認識するヒト化抗体もしくはその結合断片、またはその変異体等をあげることができる。
A9H12抗体又はH5L7抗体に含まれるCDRH1乃至CDRH3およびCDRL1乃至CDRL3を含み、LAG-3蛋白質を認識するヒト化抗体もしくはその結合断片、またはその変異体等をあげることができる。
[iの1]hLA212_H3/L2は実施例6において得られたヒト化抗体である。当該抗体の重鎖のヌクレオチド配列は配列番号29(図44)のヌクレオチド番号58乃至1410(うち可変領域は58乃至420)を、アミノ酸配列は配列番号30(図45)のアミノ酸番号20乃至470(うち可変領域は20乃至140)を、軽鎖のヌクレオチド配列は配列番号33(図48)のヌクレオチド番号61乃至702(うち可変領域は61乃至387)を、アミノ酸配列は配列番号34(図49)のアミノ酸番号21乃至234(うち可変領域は21乃至129)を、それぞれ含んでいる。該抗体は本発明の細胞傷害性T細胞枯渇用組成物、細胞傷害性T細胞関連疾患の治療又は予防の方法、治療又は予防のための使用等に適した物性(データ示さず)、(3-2)、及び(3-3)記載のLAG-3結合活性及びイン・ビトロADCC活性を有し且つ(3-8)記載の性質すなわち該抗体存在下でヒトLAG-3はヒトT細胞抑制機能を奏し(実施例参照)、(3-4)乃至(3-7)記載の活性、性質等を有していることは、例えば、実施例記載の方法により評価することができる。
本発明において「物性」とは、本発明に使用される抗体及びその結合断片等のモノとしての安定性を意味し、公知の指標を用いて評価することができる。モノとしての安定性として熱安定性、保存安定性等をあげることができ、それらの指標としてはサーモグラムから導き出されるTm値、保存条件下又は加速劣化条件下での抗原結合活性の変化又は経時的変化等をあげることができる。
上述の、本発明に使用される好適なヒト化抗LAG-3抗体及びその結合断片のうち、より一層好適なものはhLA212_H3/L2、hLA212_H2/L1、hLA212_H3/L3、hLA212_H3/L6、hLA212_H4/L2、H5L7およびH5L7BWである。
本発明に使用される抗体と「同一の部位に結合する抗体」も本発明に使用することができる。ある抗体と「同一の部位に結合する抗体」とは、該抗体が認識する抗原分子上の部位に結合する他の抗体を意味する。第一抗体が結合する抗原分子上の部分ペプチド又は部分立体構造に第二抗体が結合すれば、第一抗体と第二抗体は同一の部位に結合すると判定することができる。また、第一抗体の抗原に対する結合に対して第二抗体が競合する、すなわち、第二抗体が第一抗体と抗原の結合を妨げることを確認することによって、具体的な結合部位のペプチド配列又は立体構造が決定されていなくても、第一抗体と第二抗体が同一の部位に結合すると判定することができる。さらに、第一抗体と第二抗体が同一の部位に結合し、且つ第一抗体がADCC活性などの効果を有する場合、第二抗体も同様の活性を有する蓋然性は極めて高い。従って、第一の抗LAG-3抗体の結合する部位に第二の抗LAG-3抗体が結合すれば、第一抗体と第二抗体がLAG-3蛋白質上の同一の部位に結合すると判定することができる。また、第一の抗LAG-3抗体のLAG-3蛋白質への結合に対して第二の抗LAG-3抗体が競合することを確認できれば、第一抗体と第二抗体がLAG-3蛋白質上の同一の部位に結合する抗体と判定することができる。
本発明は、抗体又はその結合断片の修飾体を含む組成物を提供する。抗体又はその結合断片の修飾体とは、抗体又はその結合断片に化学的又は生物学的な修飾が施されてなるものを意味する。化学的な修飾体には、アミノ酸骨格への化学部分の結合、N-結合またはO-結合炭水化物鎖の化学修飾体等が含まれる。生物学的な修飾体には、翻訳後修飾(例えば、N-結合またはO-結合 への糖鎖付加、N末またはC末のプロセッシング、脱アミド化、アスパラギン酸の異性化、メチオニンの酸化)されたもの、原核生物宿主細胞を用いて発現させることによりN末にメチオニン残基が付加したもの等が含まれる。また、抗体または抗原の検出または単離を可能にするために標識されたもの、例えば、酵素標識体、蛍光標識体、アフィニティ標識体もかかる修飾物の意味に含まれる。このような抗体又はその結合断片の修飾物は、元の抗体又はその結合断片の安定性および血中滞留性の改善、抗原性の低減、かかる抗体又は抗原の検出又は単離等に有用である。
前述の通り、hLA212_H4/L2は実施例8において得られた、糖鎖修飾が調節されたヒト化抗体である。該ヒト化抗体も、本発明に使用可能な抗体に包含される。
細胞傷害性T細胞枯渇用に供し得るLAG-3抗体は、好適には、LAG-3発現細胞に対してADCC活性、CDC活性及び/又はADCP活性などの細胞傷害活性を示す抗体であり、より好適には、ADCC活性、CDC活性及び/又はADCP活性が増強されたLAG-3抗体である。低フコース化、脱フコース化(afucosylation)等によりADCC活性が増強されたLAG-3抗体、すなわち低フコース形態にあるLAG-3抗体としては、例えば、hLA212_H4/L2、H5L7BW等をあげることができる。
(4-1)ハイブリドーマを用いる方法
抗LAG-3抗体は、コーラーとミルスタインの方法(Kohler and Milstein,Nature (1975)256,p.495-497、Kennet,R.ed.,Monoclonal Antibody,p.365-367,Prenum Press,N.Y.(1980))に従って、LAG-3蛋白質又はその可溶型フォームで免疫した動物の脾臓より抗LAG-3抗体の産生細胞を単離し、該細胞とミエローマ細胞とを融合させることによりハイブリドーマを樹立し、かかるハイブリドーマの培養物からモノクローナル抗体を取得することができる。
抗LAG-3抗体を作製するための抗原は、本発明の他の部分に記載された天然型または組換え型のLAG-3蛋白質の調製法等に従って、取得することができる。そのようにして調製し得る抗原としては、LAG-3蛋白質若しくはその少なくとも6個の連続した部分アミノ酸配列を含むことからなるLAG-3蛋白質断片、またはそれらに任意のアミノ酸配列や担体が付加された誘導体等(以下、まとめて「LAG-3抗原」とよぶ:「LAG-3蛋白質」と同義)を挙げることができる。
モノクローナル抗体の製造は、通常、下記のような工程を経る。
(a)抗原を調製する工程、
(b)抗体産生細胞を調製する工程、
(c)骨髄腫細胞(以下、「ミエローマ」という)を調製する工程、
(d)抗体産生細胞とミエローマとを融合させる工程、
(e)目的とする抗体を産生するハイブリドーマ群を選別する工程、及び
(f)単一細胞クローンを得る工程(クローニング)。
前記(2-3)記載のLAG-3蛋白質の調製法に準ずる。
工程(a)で得られた抗原と、フロインドの完全又は不完全アジュバント、又はカリミョウバンのような助剤とを混合し、免疫原として実験動物に免疫する。実験動物は公知のハイブリドーマ作製法に用いられる動物を支障なく使用することができる。具体的には、たとえばマウス、ラット、ヤギ、ヒツジ、ウシ、ウマ等を使用することができる。ただし、摘出した抗体産生細胞と融合させるミエローマ細胞の入手容易性等の観点から、マウス又はラットを被免疫動物とするのが好ましい。
細胞融合に用いるミエローマ細胞には特段の限定はなく、公知の細胞株から適宜選択して用いることができるが、融合細胞からハイブリドーマを選択する際の利便性を考慮して、その選択手続が確立しているHGPRT(Hipoxanthine-guanine phosphoribosyl transferase)欠損株、すなわちマウス由来のX63-Ag8(X63)、NS1-ANS/1(NS1)、P3X63-Ag8.Ul(P3Ul)、X63-Ag8.653(X63.653)、SP2/0-Ag14(SP2/0)、MPC11-45.6TG1.7(45.6TG)、FO、S149/5XXO、BU.1等、ラット由来の210.RSY3.Ag.1.2.3(Y3)等、ヒト由来のU266AR(SKO-007)、GM1500・GTG-A12(GM1500)、UC729-6、LICR-LOW-HMy2(HMy2)、8226AR/NIP4-1(NP41)等を用いるのが好ましい。これらのHGPRT欠損株は例えば、American Type Culture Collection (ATCC)等から入手することができる。
抗体産生細胞とミエローマ細胞との融合は、公知の方法(Weir,D.M.,Handbookof Experimental Immunology Vol.I.II.III.,Blackwell Scientific Publications,Oxford(1987)、Kabat,E.A.and Mayer,M.M.,Experimental Immunochemistry,Charles C Thomas Publisher Spigfield,Illinois(1964)等)に従い、細胞の生存率を極度に低下させない程度の条件下で実施することができる。例えば、ポリエチレングリコール等の高濃度ポリマー溶液中で抗体産生細胞とミエローマ細胞とを混合する化学的方法、電気的刺激を利用する物理的方法等を用いることができる。
細胞融合により得られるハイブリドーマの選択方法は特に制限はないが、通常HAT(ヒポキサンチン・アミノプテリン・チミジン)選択法(Kohler et al., Nature(1975)256,p.495;Milstein et al.,Nature(1977)266,p.550)が用いられる。この方法は、アミノプテリンで生存し得ないHGPRT欠損株のミエローマ細胞を用いてハイブリドーマを得る場合に有効である。すなわち、未融合細胞及びハイブリドーマをHAT培地で培養することにより、アミノプテリンに対する耐性を持ち合わせたハイブリドーマのみを選択的に残存させ、かつ増殖させることができる。
ハイブリドーマのクローニング法としては、例えば、メチルセルロース法、軟アガロース法、限界希釈法等の公知の方法を用いることができるが(例えば、Barbara, B.M. and Stanley, M.S.:Selected Methods in Cellular Immunology,W.H. Freeman and Company,San Francisco(1980)参照)、好適には限界希釈法である。
選択されたハイブリドーマを培養することにより、モノクローナル抗体を産生することができるが、好適には所望のハイブリドーマをクローニングしてから抗体の産生に供する。
(h)モノクローナル抗体の生物活性の測定工程・判定工程
各種生物試験を目的に応じて選択し、適用することができる。
天然型のLAG-3蛋白質を発現する細胞、組換え型LAG-3蛋白質またはその断片を発現する細胞等を免疫原として使用することにより、前記のハイブリドーマ法により抗LAG-3抗体を調製することができる。
LAG-3を発現している細胞は、1×105乃至1×109個、好適には1×106乃至1×108個、より好適には0.5乃至2×107個、より一層好適には1×107個を1回の免疫に用いるが、LAG-3蛋白質の発現量に応じて免疫に供する細胞数を変えることができる。かかる免疫源は、一般的には腹腔内に投与するが、皮内等に投与することもできる。ハイブリドーマの作製手法としては(4-1-2)記載の方法を適用することができる。
本発明に使用される抗体は、その重鎖アミノ酸配列をコードするヌクレオチド配列が含まれるヌクレオチド(重鎖ヌクレオチド)及びその軽鎖アミノ酸配列をコードするヌクレオチド配列が含まれるヌクレオチド(軽鎖ヌクレオチド)、又は、かかる重鎖ヌクレオチドが挿入されたベクター及び軽鎖ヌクレオチドが挿入されたベクターを宿主細胞に導入し、該細胞を培養した後その培養物からかかる抗体を回収することにより調製することができる。一つのベクターに重鎖ヌクレオチド及び軽鎖ヌクレオチドが挿入されていてもよい。
ヒト化抗体としては、非ヒト動物抗体のCDRのみがヒト由来の抗体に組込まれ抗体(Nature(1986)321,p.522-525参照)、CDR移植法によりCDRの配列に加え一部のフレームワークのアミノ酸残基もヒト抗体に移植した抗体(WO90/07861号、US6972323号公報参照)、それらのいずれかにおける非ヒト動物抗体の1つまたは2つ以上のアミノ酸がヒト型のアミノ酸で置換されてなる抗体等を挙げることができるが、それらに限定されるものではない。
本発明に使用可能な抗体としては、さらに、ヒト抗体を挙げることができる。抗LAG-3ヒト抗体とは、ヒト由来の抗体のアミノ酸配列からなる抗LAG-3抗体を意味する。抗LAG-3ヒト抗体は、ヒト抗体の重鎖と軽鎖の遺伝子を含むヒトゲノムDNA断片を有するヒト抗体産生マウスを用いた方法(Tomizuka,K.et al.,Nature Genetics(1997)16,p.133-143,; Kuroiwa,Y.et.al.,Nuc.Acids Res.(1998)26,p.3447-3448;Yoshida, H.et.al.,Animal Cell Technology:Basic and Applied Aspects vol.10,p.69-73(Kitagawa, Y.,Matuda,T.and Iijima,S.eds.),Kluwer Academic Publishers,1999.;Tomizuka,K.et.al.,Proc.Natl.Acad.Sci.USA(2000)97,p.722-727等を参照。)によって取得することができる。
一本鎖抗体を作成する方法は当技術分野において周知である(例えば、米国特許第4,946,778号、米国特許第5,260,203号、米国特許第5,091,513号、米国特許第5,455,030号等を参照)。このscFvにおいて、重鎖可変領域と軽鎖可変領域は、コンジュゲートを作らないようなリンカー、好ましくはポリペプチドリンカーを介して連結される(Huston,J.S.et al.,Proc.Natl.Acad.Sci.U.S.A.(1988),85,p.5879-5883)。scFvにおける重鎖可変領域及び軽鎖可変領域は、同一の抗体に由来してもよく、別々の抗体に由来してもよい。
得られた抗体は、均一にまで精製することができる。抗体の分離、精製は通常の蛋白質で使用されている分離、精製方法を使用すればよい。
抗体もしくはその結合断片またはその修飾体をコードするヌクレオチド(「抗体遺伝子」という)、該遺伝子が挿入された組換えベクター、該遺伝子又はベクターが導入された細胞(「抗体遺伝子導入細胞」という)、その他抗体もしくは結合断片またはその修飾体を産生する細胞(「抗体産生細胞」という)も本発明の組成物を調製するために使用される。
(a)ラット抗体rLA204、rLA212、rLA225,rLA869、及びrLA1264並びにマウス抗体A9H12、それらの重鎖及び軽鎖の定常領域をヒト抗体のもので置き換えたキメラ体であるcLA204、cLA212、cLA225、cLA869、cLA1264及びキメラ型A9H12(IMP731)、ならびに、それらのヒト化体であるhLA212_H2/L1乃至hLA212_H2/L5、LA212_H3/L1乃至hLA212_H3/L5、H5L7及びH5L7BWのいずれか一つの抗体の重鎖アミノ酸配列をコードするヌクレオチド配列と軽鎖アミノ酸配列をコードするヌクレオチド配列の組合せ;
(b)ラット抗体rLA204、rLA212、rLA225,rLA869及びrLA1264並びにマウス抗体A9H12、それらの重鎖及び軽鎖の定常領域をヒト抗体のもので置き換えたキメラ体であるcLA204、cLA212、cLA225、cLA869、cLA1264及びキメラ型A9H12(IMP731)、ならびに、それらのヒト化体であるhLA212_H2/L1乃至hLA212_H2/L5、LA212_H3/L1乃至hLA212_H3/L5、H5L7及びH5L7BWのいずれか一つの抗体のCDRH1乃至CDRH3を含む重鎖のアミノ酸配列をコードするヌクレオチド配列とCDRL1乃至CDRL3を含む軽鎖のアミノ酸配列をコードするヌクレオチド配列の組合せ;
(c)ラット抗体rLA204、rLA212、rLA225,rLA869及びrLA1264並びにマウス抗体A9H12、それらの重鎖及び軽鎖の定常領域をのヒト抗体のもので置き換えたキメラ体であるcLA204、cLA212、cLA225、cLA869及びcLA1264及びキメラ型A9H12(IMP731)、ならびに、それらのヒト化体であるhLA212_H2/L1乃至hLA212_H2/L5、LA212_H3/L1乃至hLA212_H3/L5、H5L7及びH5L7BWのいずれか一つの抗体の重鎖可変領域のアミノ酸配列を含む重鎖アミノ酸配列をコードするヌクレオチド配列と軽鎖可変領域のアミノ酸配列を含む軽鎖アミノ酸配列コードするヌクレオチド配列の組合せ;
(d)(a)乃至(c)のいずれか一つに記載のヌクレオチド配列に相補的なヌクレオチド配列からなるヌクレオチドとストリンジェントな条件下でハイブリダイズし且つLAG-3に結合する抗体のアミノ酸配列をコードするヌクレオチド配列;および、
(e)(a)乃至(c)のいずれか一つに記載のアミノ酸配列において1乃至50個、1乃至45個、1乃至40個、1乃至30個、1乃至25個、1乃至20個、1乃至15個、1乃至10個、1乃至8個、1乃至6個、1乃至5個、1乃至4個、1乃至3個、1若しくは2個、または1個の塩基が置換、欠失、付加及び/又は挿入してなるアミノ酸配列をコードし且つLAG-3に結合する抗体のアミノ酸配列をコードするヌクレオチド配列;
(d)又は(e)記載のヌクレオチド配列によりコードされるアミノ酸配列を有する抗体は、(3-2)および(3-3)、好適にはそれらに加えて(3-4)、より好適にはそれらに加えて(3-5)、より一層好適には(3-2)乃至(3-8)全て、に記載の性質、機能、活性等をそれぞれ有する。
本発明は抗LAG-3抗体もしくはその結合断片またはその修飾体を含む細胞傷害性T細胞枯渇用組成物を提供する。
本発明において、疾患の治療または予防には、かかる疾患、好適にはLAG-3蛋白質を発現している個体におけるかかる疾患の発症の予防、増悪化又は進行の抑制又は阻害、かかる疾患に罹患した個体が呈する一つ又は二つ以上の症状の軽減、増悪化若しくは進行の抑制または寛解、二次性疾患の治療又は予防等が含まれるが、それらに限定されるものではない。
1)-1 免疫
ヒトLAG-3(配列番号86:図101)の細胞外の4つの免疫グロブリン様ドメインのうちN末端から1および2番目(23-262番の領域)を欠失させた変異体をpcDNA3.1(Life Technologies社)にクローニングした発現プラスミドpcDNA3.1-hLAG-3_D3D4を、EndoFree Plasmid Giga Kit(QIAGEN社)を用い大量調製した。WKY/Izmラットの雌(日本エスエルシー社)両足下腿部をHyaluronidase(Sigma社)にて前処理後、同部位にpcDNA3.1-hLAG-3_D3D4を筋注した。続けて、ECM830(BTX社)を使用し、2ニードル電極を用いて、同部位にインビボエレクトロポレーションを実施した。二週間に一度、同様のインビボエレクトロポレーションを合計3あるいは5回繰り返した後、ラットのリンパ節を採取しハイブリドーマ作製に用いた。
リンパ節細胞あるいは脾臓細胞とマウスミエローマSP2/0-ag14細胞とをHybrimune Hybridoma Production System(Cyto Pulse Sciences社製)を用いて電気細胞融合し、ClonaCell-HY Selection Medium D(StemCell Technologies社製)に希釈して培養した。出現したハイブリドーマコロニーを回収することでモノクローンハイブリドーマを作製した。回収された各ハイブリドーマコロニーを培養し、得られたハイブリドーマ培養上清用いて抗LAG-3抗体産生ハイブリドーマのスクリーニングを行った。
HEK293細胞に、Lipofectamine 2000(Life Technologies社製)を用いて、pcDNA3.1にヒトあるいはカニクイザルのLAG-3をクローニングして作製した発現プラスミド(pcDNA3.1/hLAG-3およびpcDNA3.1/cynoLAG-3)もしくはコントロールのプラスミドを導入し、96穴マイクロプレート(Corning社製)にて、10%FBS含有DMEM培地中で37℃、5%CO2の条件下で一晩培養した。培養上清を除去後、ハイブリドーマ培養上清を添加し、4℃で1時間静置した。ウェル中の細胞を5% FBS含有PBSで1回洗浄後、5% FBS含有PBSで500倍に希釈したAnti-Rat IgG-Peroxidase antibody produced in rabbit(Sigma社製)を加えて、4℃で1時間静置した。ウェル中の細胞を5% FBS含有PBSで5回洗浄した後、OPD発色液(OPD溶解液(0.05 M クエン酸3ナトリウム、0.1M リン酸水素2ナトリウム・12水 pH4.5)にo-フェニレンジアミン二塩酸塩(和光純薬社製)、H2O2をそれぞれ0.4mg/mL、0.6%(v/v)になるように溶解)を25μL/ウェルで添加した。時々攪拌しながら発色反応を行い、1M HClを25μL/ウェルを添加して発色反応を停止させた後、プレートリーダー(ENVISION:PerkinElmer社)で490nmの吸光度を測定した。細胞膜表面上に発現するLAG-3に特異的に結合する抗体を産生するハイブリドーマを選択するため、LAG-3遺伝子を含まないコントロールのプラスミドを導入したHEK293細胞と比較し、LAG-3発現ベクター導入HEK293細胞の方でより高い吸光度を示す培養上清を産生するハイブリドーマを抗LAG-3抗体産生陽性として選択した。
実施例1)-3のCell-ELISAで陽性と判定されたハイブリドーマが産生する抗体が、より生理的なLAG-3発現細胞であるPHA(phytohemagglutinin)活性化ヒトT細胞(PHA blast)に結合することを、フローサイトメトリー法によりさらに確認した。ヒトPBMCを2μg/mLのPHA(Sigma社製)で3日間刺激した細胞に対しハイブリドーマ培養上清を加えて懸濁し、4℃で30分間反応させた。FACSバッファー(PBS、0.1%BSA、0.1%アジ化ナトリウム)で洗浄した後、LIVE/DEAD Fixable Dead Cell Stain Kit-near-IR fluorescent reactive dye(Invitrogen社製)を含むFACSバッファーで200倍に希釈したAnti-Rat IgG PE conjugate(Jackson ImmunoResearch Laboratories社製)等の二次抗体を加えて懸濁し、4℃で30分間静置した。FACSバッファーで洗浄した後、1ないし2%パラホルムアルデヒド含有PBSに再懸濁し、フローサイトメーター(CantoII:BD社製あるいはFC500:BeckmanCoulter社製)で検出を行った。データ解析はFlowJo(TreeStar社製)で行った。LIVE/DEAD Fixable Dead Cell Stain Kit-near-IR fluorescent reactive dye陽性の死細胞をゲートで除外した後、生細胞の蛍光強度のヒストグラムを作成した。
1)-5-1 標的細胞の作製
pLenti6/V5-GW/lacZ、およびViraPowerTM Packaging Mix(Invitorogen社)を添付プロトコールに従って293FT細胞(Invitrogen社)にトランスフェクションすることにより、β-ガラクトシダーゼ遺伝子を発現する組み換えレンチウイルスを作製した。得られた組み換えレンチウイルスをViraPower Lentiviral Expression Systems(Invitrogen社)のプロトコールに従って293T細胞に感染させ、10μg/mLのブラストサイジン(Invitrogen社)でウイルス感染細胞を選択することにより、β-ガラクトシダーゼの安定発現株を取得した。このβ-ラクトシダーゼを安定発現する293T細胞(以下293T-lacZと表記)に、ヒトLAG-3全長の発現プラスミドをLipofectamine 2000(Invitrogen社製)を用いて導入し、1日間培養した後、TrypLExpress(Invitrogen社製)を用いて剥離・回収した。5% FBSを含むフェノールレッド不含RPMI1640(以下「ADCC用培地」と略す)にて2回洗浄し、生細胞数をトリパンブルー色素排除試験にて計測し、ADCC用培地で1×105 細胞/mlになるよう再懸濁したものを標的細胞として用いた。
ヒト末梢血からフィコール遠心分離にてPBMCを分離し、ADCC用培地にて生細胞密度で1.2×106 細胞/mLになるように懸濁したものを、エフェクター細胞として使用した。
ハイブリドーマ培養上清50μL/ウェルを含む96穴U底マイクロプレートに、1)-5-1の標的細胞を50μL/ウェル添加し、4℃で30分間静置した。ADCC用培地150μL/ウェルを添加して撹拌した後、室温で1200rpm×5分間遠心し、上清200μL/ウェルを除いた。そこに、1)-5-2のエフェクター細胞を125μL/ウェル添加し、室温で1200rpm×5分間遠心の後、37℃、5% CO2の条件下で一晩培養した。翌日、上清50μLを黒色プレート(Corning社製)に回収し、β-Gloアッセイシステム(Promega社製)溶液50μLを添加し、発光量をプレートリーダー(ENVISION:PerkinElmer社製)で測定した。ADCC活性による細胞溶解率は次式で算出した。
A:サンプルウェルのカウント
B:自然放出(抗体非添加ウェル)カウントの平均値(n=3)。抗体添加時にADCC用培地を50μL添加した。それ以外はサンプルウェルと同様の操作を行った。
C:最大放出(標的細胞を界面活性剤で溶解させたウェル)カウントの平均値(n=3)。抗体添加時およびエフェクター細胞添加時にADCC用培地を50μLおよび75μLそれぞれ添加した。測定時には、細胞を含むウェルに175μlのβ-Gloアッセイシステム溶液を添加して混和し、そのうち100μl分を黒色プレートに加えて測定を実施した。
既報(非特許文献8)に準じて実施した。すなわち、96穴U底マイクロプレートに10%FBSを含むRPMI1640で25nMに希釈したLAG-3-Fc(R&D Systems社製)を20μL/ウェル加え、そこにハイブリドーマ培養上清20μL/ウェルを加えて撹拌し、4℃で20分間静置した。そこに内因性にMHCクラスII分子を高発現するRaji細胞を10μL/ウェル(2.5×105 細胞/ウェル)添加して撹拌し、4℃でさらに30分間静置した。細胞をPBSもしくはFACSバッファーで2回洗浄した後、FACSバッファーで200倍に希釈したAnti-Human IgG PE conjugate(Jackson ImmunoResearch Laboratories社製)を加えて懸濁し、4℃で20分間静置した。細胞をPBSもしくはFACSバッファーで洗浄した後、1ないし2%パラホルムアルデヒド含有PBSに再懸濁し、フローサイトメーター(CantoII:BD社製あるいはFC500:BeckmanCoulter社製)で検出を行った。データ解析はFlowJo(TreeStar社製)で行い、阻害率は次式で算出した。
B:バックグラウンドの平均蛍光強度。LAG-3-Fcおよび抗体添加時に培地をそれぞれ20μL添加した。それ以外はサンプルウェルと同様の操作を行った。
C:最大結合の平均蛍光強度。抗体添加時に培地を20μL添加した。
ラット抗ヒトLAG-3モノクローナル抗体は、ハイブリドーマ培養上清から精製した。すなわち、まずPBSで平衡化したProteinGカラム(GEヘルスケア社製)にハイブリドーマの培養上清をアプライした。PBSでカラムを洗浄した後、0.1 Mグリシン/塩酸水溶液(pH2.7)で溶出し、抗体の含まれる画分を集めた。集めた画分に1M Tris-HCl(pH9.0)を加えてpH7.0~7.5に調製した後に、Centrifugal UF Filter Device VIVASPIN20(分画分子量UF30K、Sartorius社製)にてPBSへのバッファー置換を行うとともに抗体の濃縮を行い、抗体濃度を2mg/mL以上に調製した。最後にMinisart-Plus filter(Sartorius社製)でろ過し、精製サンプルとした。
2)-1 取得ラット抗LAG-3抗体(rLA204、rLA212、rLA225、rLA869およびrLA1264)のヒト活性化T細胞への結合性
実施例1)-7に記載の方法により、精製したラット抗ヒトLAG-3抗体rLA204、rLA212、rLA225、rLA869およびrLA1264の、ヒト活性化T細胞への結合性を検討した。図1に示すとおり、これらのラット抗ヒトLAG-3抗体はいずれもin vitro活性化ヒトT細胞として調製したPHA blastに濃度依存的に結合した。
精製したラット抗ヒトLAG-3抗体rLA204、rLA212、rLA225、rLA869およびrLA1264のADCC活性を、以下の方法により検討した。抗体溶液50μL/ウェルを含む96穴U底マイクロプレートに、実施例1)-5-1の標的細胞(以下、293T-lacZ/hLAG-3細胞と記載)を50μL/ウェル添加し、4℃で30分間静置した。そこに、実施例1)-5-2のように調製したエフェクター細胞(ただし、2×106 細胞/mLになるように懸濁したもの)を75μL/ウェル添加し、室温で1200rpm×5分間遠心の後、37℃、5% CO2の条件下で一晩培養した。翌日、上清50μLを黒色プレート(Corning社製)に回収し、β-Gloアッセイシステム(Promega社製)溶液50μLを添加し、発光量をプレートリーダー(ENVISION:PerkinElmer社製)で測定した。ADCC活性による細胞溶解率は次式で算出した。
A:サンプルウェルのカウント
B:自然放出(抗体非添加ウェル)カウントの平均値(n=3)。抗体添加時にADCC用培地を50μL添加した。それ以外はサンプルウェルと同様の操作を行った。
C:最大放出(標的細胞を界面活性剤で溶解させたウェル)カウントの平均値(n=3)。抗体添加時およびエフェクター細胞添加時にADCC用培地を50μLおよび75μLそれぞれ添加した。測定時には、細胞を含むウェルに175μlのβ-Gloアッセイシステム溶液を添加して混和し、そのうち100μl分を黒色プレートに加えて測定を実施した。
実施例2)-3に記載のLAG-3/MHCクラスII結合試験においては、LAG-3-Fcへの抗LAG-3抗体の結合に伴う立体障害によって、Raji細胞へのLAG-3-Fcの結合を検出するための二次抗体Anti-Human IgG PE conjugateの結合が阻害され、実際には抗体がLAG-3/MHCクラスII結合を直接阻害していないにも関わらず見かけ上、低い蛍光強度を示す可能性を完全には排除できない。そこで検出用の二次抗体を使用しない評価系として、以下のような293T-hLAG-3/Raji細胞接着試験系を構築し、抗体の評価を行った。
A:サンプルウェルの蛍光強度
B:バックグラウンドの蛍光強度。Raji細胞および抗体添加時に培地を添加した。それ以外はサンプルウェルと同様の操作を行った。
C:最大結合の蛍光強度。抗体添加時に培地を添加した。
ラット抗LAG-3抗体rLA204、rLA212、rLA225、rLA869およびrLA1264は、LAG-3の細胞外領域に存在する4つの免疫グロブリン様ドメインのうちN末端から1および2番目(以下、それぞれドメイン1および2と表記)を欠失させた変異体を免疫原として作製した抗体であることから、残るN末端から3および4番目(以下、それぞれドメイン3および4と表記)のいずれのドメインにこれらの抗体が結合するのかを明らかにする目的で、ドメイン3と4、あるいはドメイン4のみを発現させた細胞に対する取得ラット抗LAG-3抗体の結合をフローサイトメトリーにより検討した。
実施例1)-1とは別の免疫方法として、精製LAG-3タンパク質を免疫原としてラット抗ヒトLAG-3抗体の取得を行った。ヒトLAG-3の細胞外領域(1-450)のC末端にHisタグを付加したタンパク質をFreund‘s Complete Adjuvant(和光純薬社製)と混合(体積比で1:2)してエマルジョンにしたものを8週齢のWKY/Izmラットの雌(日本エスエルシー社)の尾根部に1匹あたり200μg投与した。3週間後に抗原タンパク質のみを尾根部に1匹あたり200μg投与し、さらにその2週間後にリンパ節を採取し、実施例1)-2の方法によりハイブリドーマを作製した。実施例1)-3および1)-4などの方法でスクリーニングを行い、得られたモノクローナル抗体のエピトープを実施例2)-5の方法によって解析したところ、評価したクローンの58%がLAG-3細胞外領域に存在する4つの免疫グロブリン様ドメインのうちドメイン1に、26%がドメイン2に結合し、N末端に近い部分に対するモノクローナル抗体が優先的に取得されたことが明らかになった。その中で、フローサイトメトリーでヒト活性化T細胞(PHA blast)に強く結合するクローンの多くは、クローン6D7を含め、LAG-3のドメイン1に結合し、それらはいずれも実施例2)-3に記載のLAG-3/MHCクラスII結合試験で強い阻害活性を示した。この結果は、LAG-3とMHCクラスII分子の結合には、LAG-3の細胞外の4つの免疫グロブリン様ドメインのうち、N末端のドメイン1および2が重要であるというこれまでの知見(非特許文献4)とよく一致するものであり、LAG-3とMHCクラスII分子の結合を阻害しない、すなわちLAG-3のT細胞抑制機能を阻害しない抗体を取得するためには、実施例1)-1のような免疫方法の工夫をしてモノクローナル抗体を作製する必要があることを示している。
3)-1 rLA204の可変領域をコードするcDNAのヌクレオチド配列の決定
3)-1-1 rLA204産生ハイブリドーマからのtotal RNAの調製
rLA204の可変領域を含むcDNAを増幅するため、rLA204産生ハイブリドーマよりTRIzol Reagent(Ambion社)を用いてtotal RNAを調製した。
cDNA(5’-RACE-Ready cDNA)の合成は実施例3)-1-1で調製したtotal RNAの約1μgを用い、SMARTer RACE cDNA Amplification Kit(Clontech社)を用いて実施した。
rLA204の重鎖遺伝子の可変領域のcDNAをPCRで増幅するためのプライマーとして、UPM (Universal Primer A Mix:SMARTer RACE cDNA Amplification Kitに付属)、及び
5’-CTCCAGAGTTCCAGGTCACGGTGACTGGC-3’(RG2AR3;配列番号71)の配列を有するオリゴヌクレオチドを用いた。UPMはSMARTer RACE cDNA Amplification Kit(Clontech社)に付属のものを使用し、RG2AR3はデータベースのラット重鎖の定常領域の配列から設計した。
5’-CTCCAGAGTTCCAGGTCACGGTGACTGGC-3’(RG2AR3;配列番号71)の配列を有するオリゴヌクレオチド、及びNUP (Nested Universal Primer A:SMARTer RACE cDNA Amplification Kitに付属)を用いた。
rLA204の軽鎖遺伝子の可変領域のcDNAをPCRで増幅するためのプライマーとして、UPM (Universal Primer A Mix:SMARTer RACE cDNA Amplification Kitに付属)、及び
5’-TCAGTAACACTGTCCAGGACACCATCTC-3’(RKR5;配列番号72)の配列を有するオリゴヌクレオチドを用いた。UPMはSMARTer RACE cDNA Amplification Kit(Clontech社)に付属のものを使用し、RKR5はデータベースのラット軽鎖の定常領域の配列から設計した。
5’-TCAGTAACACTGTCCAGGACACCATCTC-3’(RKR5;配列番号72)の配列を有するオリゴヌクレオチド、及びNUP (Nested Universal Primer A:SMARTer RACE cDNA Amplification Kitに付属)を用いた。
実施例3)-1と同様の方法で配列を決定した。
実施例3)-1と同様の方法で配列を決定した。
実施例3)-1と同様の方法で配列を決定した。
実施例3)-1と同様の方法で配列を決定した。
4)-1 キメラ及びヒト化抗体軽鎖発現ベクターpCMA-LKの構築
プラスミドpcDNA3.3-TOPO/LacZ(Invitrogen社)を制限酵素XbaI及びPmeIで消化して得られる約5.4kbのフラグメントと、配列番号21に示すヒト軽鎖分泌シグナル及びヒトκ鎖定常領域をコードするDNA配列を含むDNA断片を、In-Fusion Advantage PCRクローニングキット(Clontech社)を用いて結合して、pcDNA3.3/LKを作製した。
プライマーセット
5’-TATACCGTCGACCTCTAGCTAGAGCTTGGC-3’(3.3-F1;配列番号73)
5’-GCTATGGCAGGGCCTGCCGCCCCGACGTTG-3’(3.3-R1;配列番号74)
pCMA-LKをXbaI及びPmeIで消化して軽鎖分泌シグナル及びヒトκ鎖定常領域を取り除いたDNA断片と、配列番号22に示すヒト重鎖シグナル配列及びヒトIgG1定常領域のアミノ酸をコードするDNA配列を含むDNA断片を、In-Fusion Advantage PCRクローニングキット(Clontech社)を用いて結合して、CMVプロモーターの下流にシグナル配列、クローニングサイト、ヒトIgG1重鎖定常領域をもつキメラ及びヒト化抗体IgG1タイプ重鎖発現ベクターpCMA-G1を構築した。
実施例3)-2で得られたrLA212の重鎖の可変領域を含むcDNAをテンプレートとして、KOD-Plus-(TOYOBO社)と下記のプライマーセットで重鎖の可変領域をコードするcDNAを含むDNA断片を増幅し、キメラ及びヒト化IgG1タイプ重鎖発現ベクターpCMA-G1を制限酵素BlpIで切断した箇所にIn-Fusion HD PCRクローニングキット(Clontech社)を用いて挿入することにより、cLA212重鎖発現ベクターを構築した。得られた発現ベクターを「pCMA-G1/cLA212」と命名した。cLA212重鎖のヌクレオチド配列を配列番号23に示し、アミノ酸配列を配列番号24に示した。
cLA212重鎖用プライマーセット
5’-CCAGATGGGTGCTGAGCGAGGTGCAGCTGGTGGAGTCTGGGGGAGG-3’(212H-F;配列番号75)
5’-CTTGGTGGAGGCTGAGCTGACTGTGACCATGACTCCTTGGCCCCAG-3’(212H-R;配列番号76)
実施例3)-2で得られたrLA212の軽鎖の可変領域を含むcDNAをテンプレートとして、KOD-Plus-(TOYOBO社)と下記のプライマーセットで軽鎖の可変領域をコードするcDNAを含むDAN断片を増幅し、キメラ及びヒト化軽鎖発現汎用ベクターpCMA-LKを制限酵素BsiWIで切断した箇所にIn-Fusion HD PCRクローニングキット(Clontech社)を用いて挿入することにより、cLA212の軽鎖発現ベクターを構築した。得られた発現ベクターを「pCMA-LK/cLA212」と命名した。cLA212の軽鎖のヌクレオチド配列を配列番号25に示し、アミノ酸配列を配列番号26に示した。
cLA212軽鎖用プライマーセット
5’-ATCTCCGGCGCGTACGGCAACATTGTGATGACCCAGTCTCCCAAATCC-3’(212L-F;配列番号77)
5’-GGAGGGGGCGGCCACAGCCCGTTTCAGTTCCAGCTCGGTCCCAGC-3’(212L-R;配列番号78)
FreeStyle 293F細胞(Invitrogen社)はマニュアルに従い、継代、培養をおこなった。対数増殖期の1.2×109個のFreeStyle 293F細胞(Invitrogen社)を3L Fernbach Erlenmeyer Flask(CORNING社)に播種し、FreeStyle293 expression medium (Invitrogen社)で希釈して2.0×106細胞/mlに調製したのちに、37℃、8%CO2インキュベーター内で90rpmで1時間振とう培養した。Polyethyleneimine(Polyscience #24765)1.8mgをOpti-Pro SFM培地(Invitrogen社)20mlに溶解し、次にNucleoBond Xtra(TaKaRa社)を用いて調製したH鎖発現ベクター(0.24mg)及びL鎖発現ベクター(0.36mg)を20mlのOpti-Pro SFM培地(Invitrogen社)に添加した。Polyethyleneimine/Opti-Pro SFM混合液20mlに、発現ベクター/Opti-Pro SFM混合液20mlを加え穏やかに攪拌し、さらに5分間放置した後にFreeStyle 293F細胞に添加した。37℃、8%CO2インキュベーターで4時間、90rpmで振とう培養後に600mlのEX-CELL VPRO培地(SAFC Biosciences社)、18mlのGlutaMAX I(GIBCO社)、及び30mlのYeastolate Ultrafiltrate(GIBCO社)を添加し、37℃、8%CO2インキュベーターで7日間、90rpmで振とう培養して得られた培養上清をDisposable Capsule Filter (Advantec #CCS-045-E1H)でろ過した。
実施例4)-5で得られた培養上清から抗体をrProtein Aアフィニティークロマトグラフィー(4-6℃下)で精製した。rProtein Aアフィニティークロマトグラフィー精製後のバッファー置換工程は4-6℃下で実施した。最初に培養上清をPBSで平衡化したMabSelectSuRe(GEヘルスケア社製)が充填されたカラムにアプライした。培養液がカラムに全て入ったのち、カラム容量2倍以上のPBSでカラムを洗浄した。次に2Mアルギニン塩酸塩溶液(pH4.0)で溶出し、抗体の含まれる画分を集めた。その画分を透析(Thermo Scientific社、Slide-A-Lyzer Dialysis Cassette)によりHBSor(25mM ヒスチジン/5% ソルビトール、pH6.0)への液置換を行った。最後にCentrifugal UF Filter Device VIVASPIN20(分画分子量UF10K,Sartorius社,4℃下)にて濃縮し、IgG濃度を2mg/ml以上に調製し精製サンプルとした。最後にMinisart-Plus filter(Sartorius社)でろ過し、精製サンプルとした。
293T-lacZ細胞(実施例1)-5-1に記載)に対し、Lipofectamine 2000(Invitrogen社製)を用いて、ヒトLAG-3の発現プラスミドpcDNA3.1-hLAG-3を導入し、一日間培養した後、フローサイトメトリーに使用した。フローサイトメトリーは、実施例1)-4に記載の方法に準じて行い、ただし二次抗体はFACSバッファーで200倍に希釈したAnti-Human IgG PE conjugate(Jackson ImmunoResearch Laboratories社製)を使用した。図6に示すように、ヒトキメラ化抗LAG-3抗体cLA212は、濃度依存的にヒトLAG-3発現293T-lacZ細胞に結合し、キメラ化によっても結合活性を保持していることが明らかになった。
5-1 ラット抗ヒトLAG-3抗体rLA212のヒト化体デザイン
5)-1-1 rLA212の可変領域の分子モデリング
rLA212の可変領域の分子モデリングは、ホモロジーモデリングとして公知の方法(Methods in Enzymology,203,121-153,(1991))によって実行された。Protein Data Bank(Nuc.Acid Res.35,D301-D303(2007))に登録されているヒト免疫グロブリンの可変領域の1次配列(X線結晶構造から誘導される三次元構造が入手可能である)を、実施例3)-2で決定されたrLA212の可変領域と比較した。結果として2GHWと2ARJがrLA212の重鎖と軽鎖の可変領域に対して最も高い配列同一性を有するとして選択された。フレームワーク領域の三次元構造は、rLA212の重鎖及び軽鎖に対応する2GHWと2ARJの座標を組み合わせて、「フレームワークモデル」を得ることによって作製された。次いで、それぞれのCDRについての代表的なコンホメーションがフレームワークモデルに組み込まれた。最後に、エネルギーの点でrLA212の可変領域の可能性のある分子モデルを得るために、不利な原子間接触を除くためのエネルギー計算を行った。上記手順を、市販のタンパク質立体構造解析プログラムDiscovery Studio(Accelrys社製)を用いて行った。
ヒト化抗ヒトLAG-3抗体hLA212の構築を、CDRグラフティング(Proc.Natl.Acad.Sci.USA 86,10029-10033(1989))として一般的に公知の方法によって行った。アクセプター抗体は、フレームワーク領域内のアミノ酸同一性に基づいて選択された。
5)-2-1 ヒト化hLA212_H2タイプ重鎖
配列番号24に示されるキメラcLA212の重鎖のうち可変領域部分のアミノ酸番号16目のアルギニンをグリシンに、アミノ酸番号19目のリジンをアルギニンに、アミノ酸番号42目のスレオニンをグリシンに、アミノ酸番号43目のアルギニンをリジンに、アミノ酸番号49目のアラニンをグリシンに、アミノ酸番号84目のアスパラギン酸をアスパラギンに、アミノ酸番号88目のセリンをアラニンに、アミノ酸番号93目のスレオニンをバリンに、アミノ酸番号115目のバリンをスレオニンに、アミノ酸番号116目のメチオニンをロイシンに、置き換えることを伴い設計されたヒト化hLA212重鎖を「ヒト化hLA212_H2タイプ重鎖」(「hLA212_H2」と呼ぶこともある)と命名した。
配列番号24に示されるキメラcLA212の重鎖のうち可変領域部分のアミノ酸番号16目のアルギニンをグリシンに、アミノ酸番号19目のリジンをアルギニンに、アミノ酸番号42目のスレオニンをグリシンに、アミノ酸番号43目のアルギニンをリジンに、アミノ酸番号88目のセリンをアラニンに、アミノ酸番号93目のスレオニンをバリンに、アミノ酸番号115目のバリンをスレオニンに、アミノ酸番号116目のメチオニンをロイシンに、置き換えることを伴い設計されたヒト化hLA212重鎖を「ヒト化hLA212_H3タイプ重鎖」(「hLA212_H3」と呼ぶこともある)と命名した。
5)-3-1 ヒト化hLA212_L1タイプ軽鎖
配列番号26に示されるキメラcLA212の軽鎖のうち可変領域部分のアミノ酸番号1目のアスパラギンをアスパラギン酸に、アミノ酸番号3目のバリンをグルタミンに、アミノ酸番号9目のリジンをセリンに、アミノ酸番号11目のメチオニンをロイシンに、アミノ酸番号13目のイソロイシンをアラニンに、アミノ酸番号21目のメチオニンをイソロイシンに、アミノ酸番号22目のアスパラギンをスレオニンに、アミノ酸番号38目のリジンをグルタミンに、アミノ酸番号43目のセリンをアラニンに、アミノ酸番号60目のアスパラギン酸をセリンに、アミノ酸番号63目のスレオニンをセリンに、アミノ酸番号65目のグリシンをセリンに、アミノ酸番号67目のチロシンをセリンに、アミノ酸番号76目のアスパラギンをセリンに、アミノ酸番号78目のバリンをロイシンに、アミノ酸番号80目のアラニンをプロリンに、アミノ酸番号83目のアラニンをフェニルアラニンに、アミノ酸番号85目のフェニルアラニンをスレオニンに、アミノ酸番号100目のアラニンをグルタミンに、アミノ酸番号103目のグルタミン酸をリジンに、アミノ酸番号104目のロイシンをバリンに、アミノ酸番号106目のロイシンをイソロイシンに、アミノ酸番号109目のアラニンをスレオニンに、置き換えることを伴い設計されたヒト化hLA212軽鎖を「ヒト化hLA212_L1タイプ軽鎖」(「hLA212_L1」と呼ぶこともある)と命名した。
配列番号26に示されるキメラcLA212の軽鎖のうち可変領域部分のアミノ酸番号1目のアスパラギンをアスパラギン酸に、アミノ酸番号3目のバリンをグルタミンに、アミノ酸番号9目のリジンをセリンに、アミノ酸番号11目のメチオニンをロイシンに、アミノ酸番号13目のイソロイシンをアラニンに、アミノ酸番号21目のメチオニンをイソロイシンに、アミノ酸番号22目のアスパラギンをスレオニンに、アミノ酸番号38目のリジンをグルタミンに、アミノ酸番号60目のアスパラギン酸をセリンに、アミノ酸番号63目のスレオニンをセリンに、アミノ酸番号65目のグリシンをセリンに、アミノ酸番号76目のアスパラギンをセリンに、アミノ酸番号78目のバリンをロイシンに、アミノ酸番号80目のアラニンをプロリンに、アミノ酸番号83目のアラニンをフェニルアラニンに、アミノ酸番号85目のフェニルアラニンをスレオニンに、アミノ酸番号100目のアラニンをグルタミンに、アミノ酸番号103目のグルタミン酸をリジンに、アミノ酸番号104目のロイシンをバリンに、アミノ酸番号106目のロイシンをイソロイシンに、アミノ酸番号109目のアラニンをスレオニンに、置き換えることを伴い設計されたヒト化hLA212軽鎖を「ヒト化hLA212_L2タイプ軽鎖」(「hLA212_L2」と呼ぶこともある)と命名した。
配列番号26に示されるキメラcLA212の軽鎖のうち可変領域部分のアミノ酸番号3目のバリンをグルタミンに、アミノ酸番号9目のリジンをセリンに、アミノ酸番号11目のメチオニンをロイシンに、アミノ酸番号13目のイソロイシンをアラニンに、アミノ酸番号21目のメチオニンをイソロイシンに、アミノ酸番号22目のアスパラギンをスレオニンに、アミノ酸番号63目のスレオニンをセリンに、アミノ酸番号76目のアスパラギンをセリンに、アミノ酸番号78目のバリンをロイシンに、アミノ酸番号80目のアラニンをプロリンに、アミノ酸番号83目のアラニンをフェニルアラニンに、アミノ酸番号100目のアラニンをグルタミンに、アミノ酸番号103目のグルタミン酸をリジンに、アミノ酸番号104目のロイシンをバリンに、アミノ酸番号106目のロイシンをイソロイシンに、アミノ酸番号109目のアラニンをスレオニンに、置き換えることを伴い設計されたヒト化hLA212軽鎖を「ヒト化hLA212_L3タイプ軽鎖」(「hLA212_L3」と呼ぶこともある)と命名した。
配列番号26に示されるキメラcLA212の軽鎖のうち可変領域部分のアミノ酸番号1目のアスパラギンをアスパラギン酸に、アミノ酸番号3目のバリンをグルタミンに、アミノ酸番号9目のリジンをセリンに、アミノ酸番号22目のアスパラギンをスレオニンに、アミノ酸番号60目のアスパラギン酸をセリンに、アミノ酸番号63目のスレオニンをセリンに、アミノ酸番号65目のグリシンをセリンに、アミノ酸番号67目のチロシンをセリンに、アミノ酸番号76目のアスパラギンをセリンに、アミノ酸番号80目のアラニンをプロリンに、アミノ酸番号83目のアラニンをフェニルアラニンに、アミノ酸番号85目のフェニルアラニンをスレオニンに、アミノ酸番号100目のアラニンをグルタミンに、アミノ酸番号103目のグルタミン酸をリジンに、アミノ酸番号109目のアラニンをスレオニンに、置き換えることを伴い設計されたヒト化hLA212軽鎖を「ヒト化hLA212_L4タイプ軽鎖」(「hLA212_L4」と呼ぶこともある)と命名した。
配列番号26に示されるキメラcLA212の軽鎖のうち可変領域部分のアミノ酸番号3目のバリンをグルタミンに、アミノ酸番号9目のリジンをセリンに、アミノ酸番号22目のアスパラギンをスレオニンに、アミノ酸番号63目のスレオニンをセリンに、アミノ酸番号76目のアスパラギンをセリンに、アミノ酸番号80目のアラニンをプロリンに、アミノ酸番号100目のアラニンをグルタミンに、アミノ酸番号103目のグルタミン酸をリジンに、アミノ酸番号109目のアラニンをスレオニンに、置き換えることを伴い設計されたヒト化hLA212軽鎖を「ヒト化hLA212_L5タイプ軽鎖」(「hLA212_L5」と呼ぶこともある)と命名した。
ヒト化hLA212_H2タイプ重鎖及びヒト化hLA212_L1タイプ軽鎖からなる抗体を設計し「ヒト化hLA212_H2/L1」(「hLA212_H2/L1」と呼ぶこともある)と命名した。ヒト化hLA212_H2タイプ重鎖及びヒト化hLA212_L2タイプ軽鎖からなる抗体を設計し「ヒト化hLA212_H2/L2」(「hLA212_H2/L2」と呼ぶこともある)と命名した。ヒト化hLA212_H2タイプ重鎖及びヒト化hLA212_L3タイプ軽鎖からなる抗体を設計し「ヒト化hLA212_H2/L3」(「hLA212_H2/L3」と呼ぶこともある)と命名した。ヒト化hLA212_H2タイプ重鎖及びヒト化hLA212_L4タイプ軽鎖からなる抗体を設計し「ヒト化hLA212_H2/L4」(「hLA212_H2/L4」と呼ぶこともある)と命名した。ヒト化hLA212_H2タイプ重鎖及びヒト化hLA212_L5タイプ軽鎖からなる抗体を設計し「ヒト化hLA212_H2/L5」(「hLA212_H2/L5」と呼ぶこともある)と命名した。ヒト化hLA212_H3タイプ重鎖及びヒト化hLA212_L1タイプ軽鎖からなる抗体を設計し「ヒト化hLA212_H3/L1」(「hLA212_H3/L1」と呼ぶこともある)と命名した。ヒト化hLA212_H3タイプ重鎖及びヒト化hLA212_L2タイプ軽鎖からなる抗体を設計し「ヒト化hLA212_H3/L2」(「hLA212_H3/L2」と呼ぶこともある)と命名した。ヒト化hLA212_H3タイプ重鎖及びヒト化hLA212_L3タイプ軽鎖からなる抗体を設計し「ヒト化hLA212_H3/L3」(「hLA212_H3/L3」と呼ぶこともある)と命名した。ヒト化hLA212_H3タイプ重鎖及びヒト化hLA212_L4タイプ軽鎖からなる抗体を設計し「ヒト化hLA212_H3/L4」(「hLA212_H3/L4」と呼ぶこともある)と命名した。ヒト化hLA212_H3タイプ重鎖及びヒト化hLA212_L5タイプ軽鎖からなる抗体を設計し「ヒト化hLA212_H3/L5」(「hLA212_H3/L5」と呼ぶこともある)と命名した。以上により設計した抗体は、実施例6に準じて作製し、実施例7及び実施例8に準じて評価することができる。
6)-1 hLA212の重鎖発現ベクターの構築
6)-1-1 hLA212_H2タイプ重鎖発現ベクターの構築
配列番号27に示すhLA212_H2のヌクレオチド配列のヌクレオチド番号36乃至437に示されるhLA212_H2の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 Strings DNA Fragments)。合成したDNA断片を、キメラ及びヒト化抗体IgG1タイプ重鎖発現ベクターpCMA-G1を制限酵素BlpIで切断した箇所にIn-Fusion HD PCRクローニングキット(Clontech社)を用いて挿入することによりhLA212_H2発現ベクターを構築した。得られた発現ベクターを「pCMA/hLA212_H2」と命名した。
配列番号29に示すhLA212_H3のヌクレオチド配列のヌクレオチド番号36乃至437に示されるhLA212_H2の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 Strings DNA Fragments)。実施例6)-1-1と同様の方法でhLA212_H3発現ベクターを構築した。得られた発現ベクターを「pCMA/hLA212_H3」と命名した。
6)-2-1 hLA212_L1タイプ軽鎖発現ベクターの構築
配列番号31に示すhLA212_L1のヌクレオチド配列のヌクレオチド番号37乃至402に示されるhLA212_L1の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 Strings DNA Fragments)。合成したDNA断片を、キメラ及びヒト化抗体軽鎖発現ベクターpCMA-LKを制限酵素BsiWIで切断した箇所にIn-Fusion HD PCRクローニングキット(Clontech社)を用いて挿入することによりhLA212_L1発現ベクターを構築した。得られた発現ベクターを「pCMA/hLA212_L1」と命名した。
配列番号33に示すhLA212_L2のヌクレオチド配列のヌクレオチド番号37乃至402に示されるhLA212_L2の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 Strings DNA Fragments)。実施例6)-2-1と同様の方法でhLA212_L2発現ベクターを構築した。得られた発現ベクターを「pCMA/hLA212_L2」と命名した。
配列番号35に示すhLA212_L3のヌクレオチド配列のヌクレオチド番号37乃至402に示されるhLA212_L3の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 Strings DNA Fragments)。実施例6)-2-1と同様の方法でhLA212_L3発現ベクターを構築した。得られた発現ベクターを「pCMA/hLA212_L3」と命名した。
配列番号37に示すhLA212_L4のヌクレオチド配列のヌクレオチド番号37乃至402に示されるhLA212_L4の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 Strings DNA Fragments)。実施例6)-2-1と同様の方法でhLA212_L4発現ベクターを構築した。得られた発現ベクターを「pCMA/hLA212_L4」と命名した。
配列番号39に示すhLA212_L5のヌクレオチド配列のヌクレオチド番号37乃至402に示されるhLA212_L5の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 Strings DNA Fragments)。実施例6)-2-1と同様の方法でhLA212_L5発現ベクターを構築した。得られた発現ベクターを「pCMA/hLA212_L5」と命名した。
6)-3-1 hLA212抗体の生産
実施例4)-5と同様の方法で生産した。すなわち、pCMA/hLA212_H2とpCMA/hLA212_L1との組合せによって、hLA212_H2/L1を取得した。pCMA/hLA212_H2とpCMA/hLA212_L2との組合せによって、hLA212_H2/L2を取得した。pCMA/hLA212_H2とpCMA/hLA212_L3の組合せによって、hLA212_H2/L3を取得した。pCMA/hLA212_H2とpCMA/hLA212_L4との組合せによって、hLA212_H2/L4を取得した。pCMA/hLA212_H2とpCMA/hLA212_L5との組合せによって、hLA212_H2/L5を取得した。pCMA/hLA212_H3とpCMA/hLA212_L1との組合せによって、hLA212_H3/L1を取得した。pCMA/hLA212_H3とpCMA/hLA212_L2との組合せによって、hLA212_H3/L2を取得した。pCMA/hLA212_H3とpCMA/hLA212_L3の組合せによって、hLA212_H3/L3を取得した。pCMA/hLA212_H3とpCMA/hLA212_L4との組合せによって、hLA212_H3/L4を取得した。pCMA/hLA212_H3とpCMA/hLA212_L5との組合せによって、hLA212_H3/L5を取得した。
6)-3-2 hLA212抗体の精製
6)-3-1で得られた培養上清を、実施例4)-6と同様の方法で精製した。
7)-1 ヒト化抗ヒトLAG-3抗体(hLA212)のBiacoreによる抗原結合活性測定
ヒトLAG-3の細胞外の4つの免疫グロブリン様ドメインのうちN末端から3および4番目(263-450番の領域)の部分のC末端にHisタグを付加したタンパク質LAG-3_D3D4-Hisを、FreeStyle 293F細胞(Invitrogen社)に発現させた。得られた培養上清をバッファー置換(20mM HEPES、300mM NaCl、pH7.5)し、HisTrap HPカラム(GEヘルスケア社)さらにSuperdex75カラム(GEヘルスケア社)を用いて、ヒトLAG-3_D3D4-Hisタンパク質を精製した。最終バッファーはPBSとした。
293T-lacZ細胞(実施例1)-5-1に記載)に対し、Lipofectamine 2000(Invitrogen社製)を用いて、ヒトLAG-3の発現プラスミドpcDNA3.1/hLAG-3を導入し、一日間培養した後、フローサイトメトリーに使用した。フローサイトメトリーは、実施例1)-4に記載の方法に準じて行い、ただし二次抗体はFACSバッファーで200倍に希釈したAnti-Human IgG PE conjugate(Jackson ImmunoResearch Laboratories社製)を使用した。図8に示すように、10クローンのヒト化抗ヒトLAG-3抗体(hLA212_H2/L1、hLA212_H2/L2、hLA212_H2/L3、hLA212_H2/L4、hLA212_H2/L5、hLA212_H3/L1、hLA212_H3/L2、hLA212_H3/L3、hLA212_H3/L4、およびhLA212_H3/L5)はいずれも、ヒトキメラ化抗LAG-3抗体cLA212と同程度に、濃度依存的なヒトLAG-3発現293T-lacZ細胞に対する結合性を示し、ヒト化によっても結合活性を保持していることが明らかになった。
実施例2)-2に記載の方法により、ヒト化抗ヒトLAG-3抗体(hLA212)のADCC活性を検討した。その結果、図9に示すように、10クローンのヒト化抗ヒトLAG-3抗体(hLA212_H2/L1、hLA212_H2/L2、hLA212_H2/L3、hLA212_H2/L4、hLA212_H2/L5、hLA212_H3/L1、hLA212_H3/L2、hLA212_H3/L3、hLA212_H3/L4、およびhLA212_H3/L5)はいずれも、ヒトキメラ化抗LAG-3抗体cLA212とほぼ同程度に、濃度依存的なヒトLAG-3発現293T-lacZ細胞に対するADCC活性を示し、ヒト化によってもADCC活性を保持していることが明らかになった。
LAG-3は、MHCクラスII分子に結合することで、T細胞に何らかの抑制性のシグナルを伝達し、T細胞の機能を負に制御することが知られている(非特許文献1)。LAG-3とMHCクラスII分子の結合には、LAG-3の細胞外の4つの免疫グロブリン様ドメインのうち、N末端のドメイン1および2が重要であると考えられている(非特許文献4)。実施例1の方法で取得した5クローンのラット抗ヒトLAG-3抗体(rLA204、rLA212、rLA225、rLA869およびrLA1264)はいずれもドメイン3を認識し、LAG-3/MHCクラスII結合試験および293T-hLAG-3/Raji細胞接着試験で阻害活性を示さなかったのに対し、先行技術の抗体であるヒトキメラ化抗ヒトLAG-3抗体IMP731はドメイン1を認識し、LAG-3/MHCクラスII結合試験および293T-hLAG-3/Raji細胞接着試験で強力な阻害活性を示したことを実施例2において明らかにした。これらの結果から、実施例1の方法で取得したクローンおよびそれに由来するヒト化抗ヒトLAG-3抗体はLAG-3本来のT細胞抑制機能に影響を与えないのに対し、IMP731はそれを阻害することが想定された。このことを実験的に確かめるために、既報(非特許文献9)に準じて、ヒト化抗ヒトLAG-3抗体hLA212_H3/L2の、LAG-3のT細胞抑制機能に対する影響を検討した。ヒト末梢血からフィコール遠心分離にて分離したPBMCを、2×105 細胞/ウェルで96穴マイクロプレートに播種し、抗体を添加した後、37℃で30分間プレインキュベーションした。そこにSEB(Staphylococcal Enterotoxin B、Sigma社製)を最終濃度1 ng/mLになるように加え、4日間培養したときの培養上清中のIL-2濃度をHuman IL-2 Immunoassay kit(PerkinElmer社製)により定量した。その結果、図10に示すように、作製したヒト化抗ヒトLAG-3抗体hLA212_H3/L2はほとんどIL-2産生に影響を与えなかったのに対し、IMP731はIL-2産生を増加させた。すなわち、当初の予測どおり、作製したヒト化抗ヒトLAG-3抗体hLA212_H3/L2はLAG-3のT細胞抑制機能に影響を与えないのに対し、IMP731はこれを阻害することで、逆に免疫系を活性化してしまうリスクがあることが明らかになった。
配列番号30(図45)で示されるアミノ酸配列のアミノ酸番号20乃至470を含む重鎖、および、配列番号34(図49)で示されるアミノ酸配列のアミノ酸番号21乃至234を含む軽鎖を含んでなるヒト化抗体を、公知の方法に従って、該抗体蛋白質に結合する糖鎖修飾を脱フコース化することにより調節し、得られた抗体をhLA212_H4/L2と命名した。当該修飾体を質量分析に供したところ、フコースを含有するH鎖のピークは検出限界以下であった。本発明においては、hLA212_H4/L2のように糖鎖修飾が調節された抗体も「抗体」または「抗体の修飾体」と呼ぶ。
9)-1 ヒト化抗ヒトLAG-3抗体hLA212_H4/L2のLAG-3発現細胞に対する結合活性
実施例7)-2に記載の方法によりヒトLAG-3を発現させた293T-lacZ細胞に対する、ヒト化抗ヒトLAG-3抗体hLA212_H4/L2の結合をフローサイトメトリーにより検討した。その結果、図11に示すように、hLA212_H4/L2の濃度依存的な結合が観察された。
実施例7)-2に記載の方法により、ヒト化抗ヒトLAG-3抗体hLA212_H4/L2のin vitro ADCC活性を評価した。その結果、図12に示すように、hLA212_H4/L2はヒトLAG-3発現293T-lacZ細胞に対して濃度依存的なADCC活性を示した。これに対し、ヒトLAG-3を発現させていない293T-lacZ細胞に対しては、ADCC活性を示さなかった。
ヒト化抗ヒトLAG-3抗体hLA212_H4/L2は、実施例9に示すようにヒトLAG-3には結合するものの、げっ歯類のLAG-3には交差しないことが明らかになっている。そこでhLA212_H4/L2のin vivoでの評価を可能にするため、ヒトLAG-3をマウスLAG-3の発現調節機構を利用して生理的に発現させたBAC(Bacterial Atrificial Chromosome)トランスジェニックマウスを作製することとした。また、hLA212_H4/L2のような糖鎖修飾の調節によってADCC活性が増強されるためには、ヒトFcγIIIAが必要であり(Junttila,T.T.,et al.,Cancer Res.,vol.70(No.11):pp4481-9(2010))、既報(非特許文献10)に準じてヒトFcγRIIIA遺伝子を含むBACもあわせて導入することとした。
大腸菌内での能動型相同組み換え反応 であるRed/ET Recombination Technology (Zhang Y et al, A new logic for DNA engineering using recombination in E.Coli., Nature 20 (1998) 123-128) を利用して、ヒトLAG-3 RecBACの組換えBACクローンを構築した。
[5’]ATGTGGGAGGCTCAGTTCCTGGGCTTGCTGTTTC[3’](配列番号79)
LAG-3-H2 ヒトLAG-3遺伝子の終止コドン付近の配列
[5’]GCCCGAGCCCGAGCCCGAGCCGGAGCAGCTCTGA[3’](配列番号80)
LAG-3-H3 Rpsl-kan挿入サイト、5’側
[5’]GAGTATGTGTTGACTGGTTGATAACTATCG[3’](配列番号81)
LAG-3-H4 Rpsl-kan挿入サイト、3’側
[5’]GCCATGACAGATTAGCCATGTCTGCAGCAC [3’](配列番号82)
LAG-3-H5 マウスLAG-3遺伝子の5’UTR
[5’]CAGGACCTTTTTCTAACCTCCCTTGGAGGGCTGGGGAGGCCCGGGCCATAGAGGAG[3’](配列番号83)
LAG-3-H6 マウスLAG-3遺伝子の3’UTR
[5’]CCTGGAGCCGAGGCAGCCAGCAGGTCTCAGCAGCTCCGCCCGCCCGCCCGCCCGCC[3’](配列番号84)
ヒトLAG-3 RecBAC遺伝子発現コンストラクトである組換えBACクローンにより形質転換したDH10Bセルを、クロラムフェニコールを含むLBアガー培地上でクローニングし、そのシングルコロニーをピックアップして液体培地で一昼夜震盪培養した。
雌性C57BL/6J マウスにPMSGおよびhCGを投与して過排卵を誘起し、同系統の雄性マウスと交配した後、受精卵を採取した。
ヒトLAG-3 RecBAC/ヒトFcγR BAC発現コンストラクトを注入したC57BL/6J マウス受精卵から自然分娩により得た産子を、離乳まで保育した。ヒトLAG-3 RecBAC/ヒトFcγR BACトランスジェニックマウス、ファウンダー候補個体を3週令で離乳し、個体識別のための耳標をつけた後に、尾部組織を生検して解析に供するまで-80℃に保管した。
ファウンダー個体の後代動物を得てジェノタイピングを行ない、Tgマウスの系統化をおこなった。サザン解析で同定したTgマウス・ファウンダーと野生型C57BL/6Jマウスを体外受精または自然交配し、F1個体を作出した。ジェノタイピングによりF1個体にトランスジーンを伝達し、系統化できたラインを、野生型C57BL/6Jマウスとの体外受精または自然交配による繁殖に供し、ジェノタイピングによりヒトLAG-3およびヒトFcγRIIIAがいずれもヘテロで導入されているマウスを実験に使用した。
取得したヒトLAG-3/ヒトFcγRIIIAダブルトランスジェニックマウスにおける導入した遺伝子の発現をフローサイトメトリー法により検討した。マウスの尾静脈から末梢血をヘパリン処理ヘマトクリット毛細管に採血し、PharmLyse(BD社製)により赤血球を溶血して白血球を得た。その一部をフローサイトメトリー法によるヒトFcγRIIIAの発現解析に使用し、残りについてはLAG-3の発現を誘導するため2μg/mL Concanavalin A(Con A:Sigma社)を含む培地で3日間刺激して活性化T細胞を得た。後者について、PE標識抗マウスLAG-3抗体(BD社製)、ATTO647標識抗ヒトLAG-3抗体(EnzoLifeSciences社製)、FITC標識抗マウスCD3抗体(BD社製)、およびLIVE/DEAD Fixable Dead Cell Stain Kit-near-IR fluorescent reactive dye(Invitrogen社製)を加えて懸濁し、4℃で30分間静置した。なお、ネガティブ集団の位置の同定に使用するために、PE標識抗マウスLAG-3抗体およびATTO647標識抗ヒトLAG-3抗体を含まないコントロールも作製し、同様に処理した。FACSバッファーで洗浄した後、1%パラホルムアルデヒド含有PBSに再懸濁し、フローサイトメーター(CantoII:BD社製)で検出を行った。データ解析はFlowJo(TreeStar社製)で行った。LIVE/DEAD Fixable Dead Cell Stain Kit-near-IR fluorescent reactive dye陽性の死細胞をゲートで除外した後、生細胞を解析対象とした。その結果、図13に示すとおり、コントロールの野生型マウス由来のCon A活性化T細胞には、マウスLAG-3の発現のみが認められヒトLAG-3の発現は認められなかったのに対し、ヒトLAG-3/ヒトFcγRIIIAダブルトランスジェニックマウス由来のCon A活性化T細胞にはマウスLAG-3およびヒトLAG-3の発現がいずれも認めら、しかも個々の細胞を表すドットプロットのドットはほぼ対角線上に分布していた。なお、活性化させていない休止状態のT細胞にはマウスLAG-3およびヒトLAG-3いずれの発現もほとんど認められなかった。これらの結果から、作製したヒトLAG-3/ヒトFcγRIIIAダブルトランスジェニックマウスにおいては、BACトランスジェニックという手法を用いることで当初計画したように、ヒトLAG-3が内因性のマウスLAG-3の発現パターンにしたがって発現することが明らかになった。また、ヒトFcγRIIIAについては、作製したヒトLAG-3/ヒトFcγRIIIAダブルトランスジェニックマウスの末梢血NK細胞(CD3-DX5+)の約47%に発現が認められ、既報(非特許文献10)と同様の結果が確認された。
11-1)ヒト化抗ヒトLAG-3抗体hLA212_H4/L2のLAG-3陽性細胞除去活性
実施例10のヒトLAG-3/ヒトFcγRIIIAダブルトランスジェニックマウスを用いて、取得したヒト化抗ヒトLAG-3抗体hLA212_H4/L2がin vivoにおいてLAG-3陽性細胞を除去する活性を有するかを検討した。ヒトLAG-3/ヒトFcγRIIIAダブルトランスジェニックマウスの腹腔内にヒト化抗ヒトLAG-3抗体hLA212_H4/L2(30mg/kg)あるいは溶媒を投与した直後に、ポリクローナルなT細胞活性化作用を有するCon A(Sigma社製)を15mg/kgの用量で静脈内投与した。その2日後に採血した血液からPharmLyse(BD社製)により赤血球を溶血して白血球を得、フローサイトメトリーに使用した。白血球をFcBlock(BD社製)と反応させた後、PE標識抗マウスLAG-3抗体(BD社製)、ATTO647標識抗ヒトLAG-3抗体(EnzoLifeSciences社製)、FITC標識抗マウスCD3抗体(BD社製)、およびLIVE/DEAD Fixable Dead Cell Stain Kit-near-IR fluorescent reactive dye(Invitrogen社製)を加えて懸濁し、4℃で30分間静置した。なお、ネガティブ集団の位置の同定に使用するために、PE標識抗マウスLAG-3抗体およびATTO647標識抗ヒトLAG-3抗体を含まないコントロールも作製し、同様に処理した。FACSバッファーで洗浄した後、1%パラホルムアルデヒド含有PBSに再懸濁し、フローサイトメーター(CantoII:BD社製)で検出を行った。データ解析はFlowJo(TreeStar社製)で行った。LIVE/DEAD Fixable Dead Cell Stain Kit-near-IR fluorescent reactive dye陽性の死細胞をゲートで除外した後、生細胞を解析対象とした。CD3陽性T細胞におけるヒトLAG-3陽性率を算出したところ、図14に示すとおり、無処置のヒトLAG-3/ヒトFcγRIIIAダブルトランスジェニックマウスの末梢血T細胞においてはヒトLAG-3陽性細胞がほとんど認められなかったのに対し、ポリクローナルなT細胞活性化作用を有するCon A投与により、抗体非投与群では末梢血T細胞のうち平均24%がヒトLAG-3陽性となった。これに対し、hLA212_H4/L2を投与したCon A投与マウスでは、末梢血T細胞におけるヒトLAG-3陽性率が著明に低下していた。同様の傾向は、脾臓におけるT細胞、およびCon Aを投与した翌日の末梢血T細胞でも認められており、またマウスLAG-3および他の活性化マーカーであるCD69の陽性率でみても同様の結果であった。これらの結果から、取得したヒト化抗ヒトLAG-3抗体hLA212_H4/L2がin vivoにおいてLAG-3陽性細胞を除去する活性を有することが明らかになった。
LAG-3陽性細胞をin vivoにおいて除去する活性を有するヒト化抗ヒトLAG-3抗体hLA212_H4/L2が、自己免疫疾患の治療に有用であるかどうかを明らかにする目的で、代表的なT細胞依存性の自己免疫疾患(多発性硬化症)モデルであるEAE(実験的自己免疫性脳脊髄炎)モデル(非特許文献11)に対する薬効を検討した。
ヒト末梢血からフィコール遠心分離にてPBMCを分離し、96穴U底マイクロプレートに4×105細胞/ウェル添加した。ヒトIL-2(Peprotech社、最終濃度100ng/mL)およびDynabeads Human T-Activator CD3/CD28(Life Technologies社、4×105個/ウェル)を加えて4日間培養し、T細胞を活性化した。得られた細胞を回収し、FACSバッファー(PBS、0.1%BSA、0.1%アジ化ナトリウム)に懸濁した後、Human BD Fc Block(BD社)と室温で10分間反応させた。続いてLIVE/DEAD Fixable Dead Cell Stain Kit-near-IR fluorescent reactive dye(Invitrogen社製)を含むFACSバッファーで希釈した蛍光標識抗体と4℃で30分間反応させて細胞表面の染色を行った後、FACSバッファーで洗浄した。蛍光標識抗体としては、FITC標識抗ヒトCD8抗体、PerCP-Cy5.5標識抗ヒトCD3抗体、APC標識抗ヒトCD28抗体、PacificBlue標識抗ヒトCD57抗体(いずれもBD社)、PE標識抗ヒトCD28抗体(Biolegend社)、PE標識キット(Dojindo社)を用いて標識した抗ヒトLAG-3抗体およびアイソタイプコントロール抗体を種々の組み合わせで使用した。一部のサンプルについてはさらに、BD Cytofix/Cytoperm Fixation/Permeabilization Solution Kit(BD社)およびAPC標識抗ヒトパーフォリン抗体(eBiosciences社)を用いて、細胞内のパーフォリンの染色も行った。洗浄後の細胞は、1%パラホルムアルデヒド含有PBSに再懸濁し、フローサイトメーター(BD社製CantoIIあるいはMiltenyi社製MACSQuantX)で検出を行った。データ解析はFlowJo(TreeStar社製)で行った。LIVE/DEAD Fixable Dead Cell Stain Kit-near-IR fluorescent reactive dye陽性の死細胞をゲートで除外した後、生細胞のみについてさらにCD3陽性CD8陽性のCD8T細胞にゲートをかけて解析した。
実施例12の実験系における、ヒト化抗ヒトLAG-3抗体hLA212_H4/L2、カルシニューリン阻害薬であるタクロリムス、コルチコステロイドであるデキサメタゾンの作用を検討した。ヒトPBMCを、hLA212_H4/L2(最終濃度10μg/mL)、コントロールヒトIgG抗体(Jackson ImmunoResearch Laboratories社、最終濃度10μg/mL)、タクロリムス(Focus社、最終濃度10 nM)、およびデキサメタゾン(ENZO Life Sciences社、最終濃度1 μM)と37℃で30分間プレインキュベーションした後、実施例12のようにDynabeads Human T-Activator CD3/CD28で4日間培養し、得られた細胞をフローサイトメトリーに供した。なお、これらの抗体および化合物の濃度は、既報(Henderson,DJ et al.、Immunol.、1991年;第73巻(3号):316-321ページ:Brunetti,M.et al.、Pharmacol.Exp.Ther.、1998年;第285巻(2号):915-919ペーシ゛)等に基づき、最大の薬効を示すと考えられる濃度に設定した。
実施例13のアッセイ系におけるCD28陰性T細胞およびCD57陽性T細胞に対する、ヒト化抗ヒトLAG-3抗体hLA212_H4/L2、カルシニューリン阻害薬であるタクロリムス、コルチコステロイドであるデキサメタゾンの作用を検討した。ヒトPBMCを、hLA212_H4/L2(最終濃度10、1、および0.1μg/mL)、コントロールヒトIgG抗体(Jackson ImmunoResearch Laboratories社、最終濃度10μg/mL)、タクロリムス(Focus社、最終濃度10 nM)、およびデキサメタゾン(ENZO Life Sciences社、最終濃度1 μM)と37℃で30分間プレインキュベーションした後、実施例12のようにDynabeads Human T-Activator CD3/CD28で4日間培養し、得られた細胞をフローサイトメトリーに供した。なお、生細胞のうち、CD3陽性CD8陰性の画分をCD4T細胞、CD3陽性CD8陽性の画分をCD8T細胞とそれぞれして解析した。
配列番号2:rLA204抗体の重鎖可変領域のアミノ酸配列(図17)
配列番号3:rLA204抗体の軽鎖可変領域のアミノ酸配列をコードするヌクレオチド配列(図18)
配列番号4:rLA204抗体の軽鎖可変領域のアミノ酸配列(図19)
配列番号5:rLA212抗体の重鎖可変領域のアミノ酸配列をコードするヌクレオチド配列(図20)
配列番号6:rLA212抗体の重鎖可変領域のアミノ酸配列(図21)
配列番号7:rLA212抗体の軽鎖可変領域のアミノ酸配列をコードするヌクレオチド配列(図22)
配列番号8:rLA212抗体の軽鎖可変領域のアミノ酸配列(図23)
配列番号9:rLA225抗体の重鎖可変領域のアミノ酸配列をコードするヌクレオチド配列(図24)
配列番号10:rLA225抗体の重鎖可変領域のアミノ酸配列(図25)
配列番号11:rLA225抗体の軽鎖可変領域のアミノ酸配列をコードするヌクレオチド配列(図26)
配列番号12:rLA225抗体の軽鎖可変領域のアミノ酸配列(図27)
配列番号13:rLA869抗体の重鎖可変領域のアミノ酸配列をコードするヌクレオチド配列(図28)
配列番号14:rLA869抗体の重鎖可変領域のアミノ酸配列(図29)
配列番号15:rLA869抗体の軽鎖可変領域のアミノ酸配列をコードするヌクレオチド配列(図30)
配列番号16:rLA869抗体の軽鎖可変領域のアミノ酸配列(図31)
配列番号17:rLA1264抗体の重鎖可変領域のアミノ酸配列をコードするcDNAのヌクレオチド配列(図32)
配列番号18:rLA1264抗体の重鎖可変領域のアミノ酸配列(図33)
配列番号19:rLA1264抗体の軽鎖可変領域のアミノ酸配列をコードするヌクレオチド配列(図34)
配列番号20:rLA1264抗体の軽鎖可変領域のアミノ酸配列(図35)
配列番号21:ヒト軽鎖分泌シグナル及びヒトκ鎖定常領域のアミノ酸配列をコードするヌクレオチド配列(図36)
配列番号22:ヒト重鎖分泌シグナル及びヒトIgG1定常領域のアミノ酸配列をコードするヌクレオチド配列(図37)
配列番号23:cLA212抗体の重鎖のアミノ酸配列をコードするヌクレオチド配列(図38)
配列番号24:cLA212抗体の重鎖のアミノ酸配列(図39)
配列番号25:cLA212抗体の軽鎖のアミノ酸配列をコードするヌクレオチド配列(図40)
配列番号26:cLA212抗体の軽鎖のアミノ酸配列(図41)
配列番号27:hLA212抗体の重鎖H2のアミノ酸配列をコードするヌクレオチド配列(図42)
配列番号28:hLA212抗体の重鎖H2のアミノ酸配列(図43)
配列番号29:hLA212抗体の重鎖H3のアミノ酸配列をコードするヌクレオチド配列(図44)
配列番号30:hLA212抗体の重鎖H3のアミノ酸配列(図45)
配列番号31:hLA212抗体の軽鎖L1のアミノ酸配列をコードするヌクレオチド配列(図46)
配列番号32:hLA212抗体の軽鎖L1のアミノ酸配列(図47)
配列番号33:hLA212抗体の軽鎖L2のアミノ酸配列をコードするヌクレオチド配列(図48)
配列番号34:hLA212抗体の軽鎖L2のアミノ酸配列(図49)
配列番号35:hLA212抗体の軽鎖L3のアミノ酸配列をコードするヌクレオチド配列(図50)
配列番号36:hLA212抗体の軽鎖L3のアミノ酸配列(図51)
配列番号37:hLA212抗体の軽鎖L4のアミノ酸配列をコードするヌクレオチド配列(図52)
配列番号38:hLA212抗体の軽鎖L4のアミノ酸配列(図53)
配列番号39:hLA212抗体の軽鎖L5のアミノ酸配列をコードするヌクレオチド配列(図54)
配列番号40:hLA212抗体の軽鎖L5のアミノ酸配列(図55)
配列番号41:rLA204抗体の重鎖CDRH1のアミノ酸配列(図56)
配列番号42:rLA204抗体の重鎖CDRH2のアミノ酸配列(図57)
配列番号43:rLA204抗体の重鎖CDRH3のアミノ酸配列(図58)
配列番号44:rLA204抗体の軽鎖CDRL1のアミノ酸配列(図59)
配列番号45:rLA204抗体の軽鎖CDRL2のアミノ酸配列(図60)
配列番号46:rLA204抗体の軽鎖CDRL3のアミノ酸配列(図61)
配列番号47:rLA212抗体の重鎖CDRH1のアミノ酸配列(図62)
配列番号48:rLA212抗体の重鎖CDRH2のアミノ酸配列(図63)
配列番号49:rLA212抗体の重鎖CDRH3のアミノ酸配列(図64)
配列番号50:rLA212抗体の軽鎖CDRL1のアミノ酸配列(図65)
配列番号51:rLA212抗体の軽鎖CDRL2のアミノ酸配列(図66)
配列番号52:rLA212抗体の軽鎖CDRL3のアミノ酸配列(図67)
配列番号53:rLA225抗体の重鎖CDRH1のアミノ酸配列(図68)
配列番号54:rLA225抗体の重鎖CDRH2のアミノ酸配列(図69)
配列番号55:rLA225抗体の重鎖CDRH3のアミノ酸配列(図70)
配列番号56:rLA225抗体の軽鎖CDRL1のアミノ酸配列(図71)
配列番号57:rLA225抗体の軽鎖CDRL2のアミノ酸配列(図72)
配列番号58:rLA225抗体の軽鎖CDRL3のアミノ酸配列(図73)
配列番号59:rLA869抗体の重鎖CDRH1のアミノ酸配列(図74)
配列番号60:rLA869抗体の重鎖CDRH2のアミノ酸配列(図75)
配列番号61:rLA869抗体の重鎖CDRH3のアミノ酸配列(図76)
配列番号62:rLA869抗体の軽鎖CDRL1のアミノ酸配列(図77)
配列番号63:rLA869抗体の軽鎖CDRL2のアミノ酸配列(図78)
配列番号64:rLA869抗体の軽鎖CDRL3のアミノ酸配列(図79)
配列番号65:rLA1264抗体の重鎖CDRH1のアミノ酸配列(図80)
配列番号66:rLA1264抗体の重鎖CDRH2のアミノ酸配列(図81)
配列番号67:rLA1264抗体の重鎖CDRH3のアミノ酸配列(図82)
配列番号68:rLA1264抗体の軽鎖CDRL1のアミノ酸配列(図83)
配列番号69:rLA1264抗体の軽鎖CDRL2のアミノ酸配列(図84)
配列番号70:rLA1264抗体の軽鎖CDRL3のアミノ酸配列(図85)
配列番号71:プライマーRG2AR3(図86)
配列番号72:プライマーRKR5(図87)
配列番号73:プライマー3.3-F1(図88)
配列番号74:プライマー3.3-R1(図89)
配列番号75:プライマー212H-F(図90)
配列番号76:プライマー212H-R(図91)
配列番号77:プライマー212L-F(図92)
配列番号78:プライマー212L-R(図93)
配列番号79:オリゴヌクレオチドLAG-3-H1(図94)
配列番号80:オリゴヌクレオチドLAG-3-H2(図95)
配列番号81:オリゴヌクレオチドLAG-3-H3(図96)
配列番号82:オリゴヌクレオチドLAG-3-H4(図97)
配列番号83:オリゴヌクレオチドLAG-3-H5(図98)
配列番号84:オリゴヌクレオチドLAG-3-H6(図99)
配列番号85:ヒトLAG-3のアミノ酸配列をコードするヌクレオチド配列(図100)
配列番号86:ヒトLAG-3のアミノ酸配列(図101)
Claims (57)
- 下記(i)乃至(iii)記載の性質を有する抗LAG-3抗体又はその結合断片を含む、細胞傷害性T細胞枯渇用組成物:
(i)イン・ビトロADCC活性を有する;
(ii)低フコース形態で、イン・ビボでLAG-3陽性細胞数を低減させる;及び、
(iii)ヒト活性化T細胞に結合する。 - 細胞傷害性T細胞が、パーフォリン陽性T細胞、グランザイムB陽性T細胞、CD28陰性CD4陽性T細胞、CD28陰性CD8陽性T細胞、CD57陽性CD4陽性T細胞及びCD57陽性CD8陽性T細胞よりなる群から選択される、請求項1記載の組成物。
- 細胞傷害性T細胞がLAG-3陽性である、請求項1又は2に記載の組成物。
- 抗LAG-3抗体又はその結合断片が、ヒトLAG-3のドメイン3に結合し、下記(i)乃至(iii)記載の性質を有する、請求項1乃至3のいずれか一つに記載の組成物:
(i)低フコース形態で、イン・ビボで実験的自己免疫性脳脊髄炎を抑制する;
(ii)該抗体又はその結合断片存在下で、ヒトLAG-3とヒト主要組織適合遺伝子複合体クラスII分子は結合する;及び
(iii)該抗体又はその結合断片存在下で、ヒトLAG-3はヒトT細胞抑制機能を奏する。 - 免疫抑制剤抵抗性の細胞傷害性T細胞関連疾患の治療又は予防に使用される、請求項1乃至4のいずれか一つに記載の組成物。
- 免疫抑制剤がステロイドである、請求項5記載の組成物。
- 免疫抑制剤がカルシニューリン阻害剤である、請求項5又は6記載の組成物。
- 該抗体又はその結合断片が、キメラ抗体、ヒト化抗体若しくはヒト抗体又はその結合断片である、請求項1乃至7のいずれか一つに記載の組成物。
- 該抗体又はその結合断片が、配列番号50又は図65で示されるアミノ酸配列を有するCDRL1、配列番号51又は図66で示されるアミノ酸配列を有するCDRL2及び配列番号52又は図67で示されるアミノ酸配列を有するCDRL3を含む軽鎖、ならびに、配列番号47又は図62で示されるアミノ酸配列を有するCDRH1、配列番号48又は図63で示されるアミノ酸配列を有するCDRH2及び配列番号49又は図64で示されるアミノ酸配列を有するCDRH3を含む重鎖、を含んでなる、請求項4記載の組成物。
- 該抗体又はその結合断片が、ヒト化抗体又はその結合断片である、請求項9記載の組成物。
- 該抗体又はその結合断片が、配列番号28又は図43で示されるアミノ酸配列において、第68番の位置に相当するアミノ酸がGlyであるか又はAlaに置換され、第103番の位置に相当するアミノ酸がAsnであるか又はAspに置換されてなるアミノ酸配列を含む重鎖、並びに、配列番号32又は図47で示されるアミノ酸配列において、第21番の位置に相当するアミノ酸がAspであるか又はAsnに置換され、第31番の位置に相当するアミノ酸がLeuであるか又はMetに置換され、第33番の位置に相当するアミノ酸がAlaであるか又はIleに置換され、第41番の位置に相当するアミノ酸がIleであるか又はMetに置換され、第58番の位置に相当するアミノ酸がGlnであるか又はLysに置換され、第63番の位置に相当するアミノ酸がAlaであるか又はSerに置換され、第80番の位置に相当するアミノ酸がSerであるか又はAspに置換され、第85番の位置に相当するアミノ酸がSerであるか又はGlyに置換され、第87番の位置に相当するアミノ酸がSerであるか又はTyrに置換され、第98番の位置に相当するアミノ酸がLeuであるか又はValに置換され、第103番の位置に相当するアミノ酸がPheであるか又はAlaに置換され、第105番の位置に相当するアミノ酸がThrであるか又はPheに置換され、第124番の位置に相当するアミノ酸がValであるか又はLeuに置換され、126番の位置に相当するアミノ酸がIleであるか又はLeuに置換されてなるアミノ酸配列を含む軽鎖、を含んでなる、請求項10記載の組成物。
- 該抗体又はその結合断片の、軽鎖可変領域のアミノ酸配列が配列番号32、34、36、38及び40からからなる群より選択されるアミノ酸配列の第21番アミノ酸乃至第129番アミノ酸を含み、重鎖可変領域のアミノ酸配列が配列番号28及び30からなる群より選択されるアミノ酸配列の第20番アミノ酸乃至第140番アミノ酸を含む、請求項10又は11記載の組成物。
- 該抗体又はその結合断片の、軽鎖のアミノ酸配列が配列番号32、34、36、38及び40からからなる群より選択されるアミノ酸配列の第21番アミノ酸乃至第234番アミノ酸を含み、重鎖のアミノ酸配列が配列番号28及び30からなる群より選択されるアミノ酸配列の第20番アミノ酸乃至第470番アミノ酸を含む、請求項10乃至12のいずれか一つに記載の組成物。
- 該抗体又はその結合断片が、下記[i]乃至[x]よりなる群から選択される、請求項10乃至13のいずれか一つに記載の組成物:
[i]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号34(図49)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[ii]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号32(図47)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[iii]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号36(図51)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[iv]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号34(図49)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[v]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号36(図51)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[vi]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号38(図53)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[vii]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号40(図55)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[viii]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号32(図47)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[ix]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号38(図53)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;及び、
[x]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号40(図55)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片。 - 該抗体又はその結合断片の有する軽鎖可変領域及び重鎖可変領域のアミノ酸配列と、それぞれ95%以上同一なアミノ酸配列を含む軽鎖可変領域と重鎖可変領域を有する抗体又はその結合断片を含んでなる、請求項14記載の組成物。
- 該抗体又はその結合断片の有する軽鎖可変領域のアミノ酸配列をコードするヌクレオチド配列又はそれに相補的なヌクレオチド配列を有する第1の核酸分子とストリンジェントな条件下でハイブリダイズする第2の核酸分子が含むヌクレオチド配列によりコードされる軽鎖可変領域アミノ酸配列、および、該抗体又はその結合断片の有する重鎖可変領域のアミノ酸配列をコードするヌクレオチド配列又はそれに相補的なヌクレオチド配列を有する第3の核酸分子とストリンジェントな条件下でハイブリダイズする第4の核酸分子が含むヌクレオチド配列によりコードされる重鎖可変領域アミノ酸配列、を含む抗体又はその結合断片を含んでなる、請求項14記載の組成物。
- 下記(i)又は(ii)記載の性質を有する抗体又はその結合断片を含んでなる、請求項14記載の組成物:
(i)該抗体又はその結合断片が認識するヒトLAG-3のドメイン3上の部位に結合する;
(ii)該抗体又はその結合断片と、ヒトLAG-3のドメイン3への結合において競合する。 - 該抗体又はその結合断片が、低フコース形態にある、請求項1乃至17のいずれか一つに記載の組成物。
- 該抗体又はその結合断片が、そのアミノ酸配列をコードするヌクレオチド配列を含む核酸分子若しくは該核酸分子を含むベクターを含む細胞、又は、該抗体又はその結合断片を生産する細胞を培養する工程を含んでなる、該抗体又はその結合断片の製造方法により得られる、請求項1乃至18のいずれか一つに記載の組成物。
- 該抗体又はその結合断片存在下で、ヒトLAG-3はヒトT細胞抑制機能を奏しない、請求項1乃至3のいずれか一つに記載の組成物。
- 該抗体又はその結合断片存在下で、ヒトLAG-3とヒト主要組織適合遺伝子複合体クラスII分子は結合しない、請求項1乃至3及び20のいずれか一つに記載の組成物。
- 該抗体又はその結合断片が、低フコース形態にある、請求項20又は21に記載の組成物。
- 細胞傷害性T細胞枯渇に使用される、下記(i)乃至(iii)記載の性質を有する抗LAG-3抗体又はその結合断片:
(i)イン・ビトロADCC活性を有する;
(ii)低フコース形態で、イン・ビボでLAG-3陽性細胞数を低減させる;及び、
(iii)ヒト活性化T細胞に結合する。 - 細胞傷害性T細胞枯渇のための、下記(i)乃至(iii)記載の性質を有する抗LAG-3抗体又はその結合断片の使用:
(i)イン・ビトロADCC活性を有する;
(ii)低フコース形態で、イン・ビボでLAG-3陽性細胞数を低減させる;及び、
(iii)ヒト活性化T細胞に結合する。 - 下記(i)乃至(iii)記載の性質を有する抗LAG-3抗体又はその結合断片を投与することを含む、細胞傷害性T細胞を枯渇させる方法:
(i)イン・ビトロADCC活性を有する;
(ii)低フコース形態で、イン・ビボでLAG-3陽性細胞数を低減させる;及び、
(iii)ヒト活性化T細胞に結合する。 - 他の医薬と組み合わせて使用される、請求項1乃至22のいずれか一つに記載の組成物。
- 下記(i)乃至(iii)記載の性質を有する抗LAG-3抗体又はその結合断片を含む、 パーフォリン陽性、グランザイムB陽性、CD28陰性CD4陽性、CD28陰性CD8陽性、CD57陽性CD4陽性、及び/又は、CD57陽性CD8陽性の細胞傷害性T細胞関連疾患の治療用又は予防用医薬組成物:
(i)イン・ビトロADCC活性を有する;
(ii)低フコース形態で、イン・ビボでLAG-3陽性細胞数を低減させる;及び、
(iii)ヒト活性化T細胞に結合する。 - パーフォリン陽性、グランザイムB陽性、CD28陰性CD4陽性、CD28陰性CD8陽性、CD57陽性CD4陽性、及び/又は、CD57陽性CD8陽性が、細胞傷害性T細胞又はその細胞膜画分を含む生物学的サンプルについて判定されることを特徴とする、請求項27記載の医薬組成物。
- 該生物学的サンプルが、細胞傷害性T細胞関連疾患に罹患しているか又は罹患を回避することが望ましい個体に由来することを特徴とする、請求項28記載の医薬組成物。
- 細胞傷害性T細胞関連疾患が、特発性肺線維症、慢性閉塞性肺疾患(COPD)、多発性硬化症、バセドウ病、強直性脊椎炎、扁平部炎、喘息、関節リウマチ、多発性筋炎・皮膚筋炎、封入体筋炎、急性冠症候群、全身性エリテマトーデス、ループス腎炎、強皮症、クローン病、潰瘍性大腸炎、再生不良性貧血、骨髄異形成症候群、シェーグレン症候群、ヴェゲナー肉芽腫症、乾癬、2型糖尿病、宿主対移植片反応、慢性B型肝炎、及び/又は、サルコイドーシスである、請求項27乃至29のいずれか一つに記載の医薬組成物。
- 細胞傷害性T細胞関連疾患がLAG-3陽性である、請求項27乃至30のいずれか一つに記載の医薬組成物。
- 抗LAG-3抗体又はその結合断片が、ヒトLAG-3のドメイン3に結合し、下記(i)乃至(iii)記載の性質を有する、請求項27乃至31のいずれか一つに記載の医薬組成物:
(i)低フコース形態で、イン・ビボで実験的自己免疫性脳脊髄炎を抑制する;
(ii)該抗体又はその結合断片存在下で、ヒトLAG-3とヒト主要組織適合遺伝子複合体クラスII分子は結合する;及び
(iii)該抗体又はその結合断片存在下で、ヒトLAG-3はヒトT細胞抑制機能を奏する。 - 細胞傷害性T細胞関連疾患が免疫抑制剤抵抗性である、請求項27乃至32のいずれか一つに記載の医薬組成物。
- 免疫抑制剤がステロイドである、請求項33記載の医薬組成物。
- 免疫抑制剤がカルシニューリン阻害剤である、請求項33又は34記載の医薬組成物。
- 該抗体又はその結合断片が、キメラ抗体、ヒト化抗体若しくはヒト抗体又はその結合断片である、請求項27乃至35のいずれか一つに記載の医薬組成物。
- 該抗体又はその結合断片が、配列番号50で示されるアミノ酸配列を有するCDRL1、配列番号51で示されるアミノ酸配列を有するCDRL2及び配列番号52で示されるアミノ酸配列を有するCDRL3を含む軽鎖、ならびに、配列番号47で示されるアミノ酸配列を有するCDRH1、配列番号48で示されるアミノ酸配列を有するCDRH2及び配列番号49で示されるアミノ酸配列を有するCDRH3を含む重鎖、を含んでなる、請求項27乃至36のいずれか一つに記載の医薬組成物。
- 該抗体又はその結合断片が、ヒト化抗体又はその結合断片である、請求項37記載の医薬組成物。
- 該抗体又はその結合断片が、配列番号28で示されるアミノ酸配列において、第68番の位置に相当するアミノ酸がGlyであるか又はAlaに置換され、第103番の位置に相当するアミノ酸がAsnであるか又はAspに置換されてなるアミノ酸配列を含む重鎖、並びに、配列番号32で示されるアミノ酸配列において、第21番の位置に相当するアミノ酸がAspであるか又はAsnに置換され、第31番の位置に相当するアミノ酸がLeuであるか又はMetに置換され、第33番の位置に相当するアミノ酸がAlaであるか又はIleに置換され、第41番の位置に相当するアミノ酸がIleであるか又はMetに置換され、第58番の位置に相当するアミノ酸がGlnであるか又はLysに置換され、第63番の位置に相当するアミノ酸がAlaであるか又はSerに置換され、第80番の位置に相当するアミノ酸がSerであるか又はAspに置換され、第85番の位置に相当するアミノ酸がSerであるか又はGlyに置換され、第87番の位置に相当するアミノ酸がSerであるか又はTyrに置換され、第98番の位置に相当するアミノ酸がLeuであるか又はValに置換され、第103番の位置に相当するアミノ酸がPheであるか又はAlaに置換され、第105番の位置に相当するアミノ酸がThrであるか又はPheに置換され、第124番の位置に相当するアミノ酸がValであるか又はLeuに置換され、126番の位置に相当するアミノ酸がIleであるか又はLeuに置換されてなるアミノ酸配列を含む軽鎖、を含んでなる、請求項38記載の医薬組成物。
- 該抗体又はその結合断片の、軽鎖可変領域のアミノ酸配列が配列番号32、34、36、38及び40からからなる群より選択されるアミノ酸配列の第21番アミノ酸乃至第129番アミノ酸を含み、重鎖可変領域のアミノ酸配列が配列番号28及び30からなる群より選択されるアミノ酸配列の第20番アミノ酸乃至第140番アミノ酸を含む、請求項38又は39記載の医薬組成物。
- 該抗体又はその結合断片の、軽鎖のアミノ酸配列が配列番号32、34、36、38及び40からからなる群より選択されるアミノ酸配列の第21番アミノ酸乃至第234番アミノ酸を含み、重鎖のアミノ酸配列が配列番号28及び30からなる群より選択されるアミノ酸配列の第20番アミノ酸乃至第470番アミノ酸を含む、請求項38乃至40のいずれか一つに記載の医薬組成物。
- 該抗体又はその結合断片が、下記[i]乃至[x]よりなる群から選択される、請求項38乃至41のいずれか一つに記載の医薬組成物:
[i]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号34(図49)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[ii]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号32(図47)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[iii]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号36(図51)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[iv]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号34(図49)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[v]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号36(図51)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[vi]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号38(図53)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[vii]配列番号28(図43)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号40(図55)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[viii]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号32(図47)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;
[ix]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号38(図53)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片;及び、
[x]配列番号30(図45)のアミノ酸番号20乃至470からなるアミノ酸配列を有する重鎖及び配列番号40(図55)のアミノ酸番号21乃至234からなるアミノ酸配列を有する軽鎖を含む抗体又はその結合断片。 - 該抗体又はその結合断片の有する軽鎖可変領域及び重鎖可変領域のアミノ酸配列と、それぞれ95%以上同一なアミノ酸配列を含む軽鎖可変領域と重鎖可変領域を有する抗体又はその結合断片を含んでなる、請求項42記載の医薬組成物。
- 該抗体又はその結合断片の有する軽鎖可変領域のアミノ酸配列をコードするヌクレオチド配列又はそれに相補的なヌクレオチド配列を有する第1の核酸分子とストリンジェントな条件下でハイブリダイズする第2の核酸分子が含むヌクレオチド配列によりコードされる軽鎖可変領域アミノ酸配列、および、該抗体又はその結合断片の有する重鎖可変領域のアミノ酸配列をコードするヌクレオチド配列又はそれに相補的なヌクレオチド配列を有する第3の核酸分子とストリンジェントな条件下でハイブリダイズする第4の核酸分子が含むヌクレオチド配列によりコードされる重鎖可変領域アミノ酸配列、を含む抗体又はその結合断片を含んでなる、請求項42記載の医薬組成物。
- 下記(i)又は(ii)記載の性質を有する抗体又はその結合断片を含んでなる、請求項42記載の医薬組成物:
(i)該抗体又はその結合断片が認識するヒトLAG-3のドメイン3上の部位に結合する;
(ii)該抗体又はその結合断片と、ヒトLAG-3のドメイン3への結合において競合する。 - 該抗体又はその結合断片が、低フコース形態にある、請求項27乃至45のいずれか一つに記載の医薬組成物。
- 該抗体又はその結合断片が、そのアミノ酸配列をコードするヌクレオチド配列を含む核酸分子若しくは該核酸分子を含むベクターを含む細胞、又は、該抗体又はその結合断片を生産する細胞を培養する工程を含んでなる、該抗体又はその結合断片の製造方法により得られる、請求項27乃至46のいずれか一つに記載の医薬組成物。
- 該抗体又はその結合断片存在下で、ヒトLAG-3はヒトT細胞抑制機能を奏しない、請求項27乃至31のいずれか一つに記載の医薬組成物。
- 該抗体又はその結合断片存在下で、ヒトLAG-3とヒト主要組織適合遺伝子複合体クラスII分子は結合しない、請求項27乃至31及び48のいずれか一つに記載の医薬組成物。
- 該抗体又はその結合断片が、低フコース形態にある、請求項48又は49に記載の医薬組成物。
- 他の医薬と組み合わせて使用される、請求項27乃至50のいずれか一つに記載の医薬組成物。
- パーフォリン陽性、グランザイムB陽性、CD28陰性CD4陽性、CD28陰性CD8陽性、CD57陽性CD4陽性、及び/又は、CD57陽性CD8陽性の細胞傷害性T細胞関連疾患に罹患しているか又は罹患を回避することが望ましい個体に請求項1乃至22のいずれか一つに記載の組成物、又は請求項27乃至51のいずれか一つに記載の医薬組成物を投与する工程を含む、細胞傷害性T細胞関連疾患を治療又は予防する方法。
- 細胞傷害性T細胞関連疾患が、免疫抑制剤抵抗性である、請求項52記載の方法。
- 免疫抑制剤がステロイドである、請求項53記載の方法。
- 免疫抑制剤がカルシニューリン阻害剤である、請求項53又は54記載の方法。
- 細胞傷害性T細胞又はその細胞膜画分を含む生物学的サンプルについて、パーフォリン陽性、グランザイムB陽性、CD28陰性CD4陽性、CD28陰性CD8陽性、CD57陽性CD4陽性、及び/又は、CD57陽性CD8陽性か否かを判定する工程を含む、請求項52乃至55のいずれか一つに記載の方法。
- 該生物学的サンプルが、細胞傷害性T細胞関連疾患に罹患しているか又は罹患を回避することが望ましい個体に由来する、請求項56記載の方法。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019547003A JP7384668B2 (ja) | 2017-10-05 | 2018-10-04 | 細胞傷害性t細胞枯渇用組成物 |
EP18863880.3A EP3693012A4 (en) | 2017-10-05 | 2018-10-04 | COMPOSITION FOR DEPLOYMENT OF T-CYTOTOXIC LYMPHOCYTES |
KR1020207009756A KR20200060407A (ko) | 2017-10-05 | 2018-10-04 | 세포 상해성 t 세포 고갈용 조성물 |
BR112020006860-8A BR112020006860A2 (pt) | 2017-10-05 | 2018-10-04 | composição para depleção de células t citotóxicas |
CN201880078579.XA CN111447952A (zh) | 2017-10-05 | 2018-10-04 | 用于细胞毒性t细胞耗竭的组合物 |
US16/651,531 US20200262917A1 (en) | 2017-10-05 | 2018-10-04 | Composition for cytotoxic t cell depletion |
CA3078436A CA3078436A1 (en) | 2017-10-05 | 2018-10-04 | Composition for cytotoxic t cell depletion |
JP2023191228A JP2024010208A (ja) | 2017-10-05 | 2023-11-09 | 細胞傷害性t細胞枯渇用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017194945 | 2017-10-05 | ||
JP2017-194945 | 2017-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019070013A1 true WO2019070013A1 (ja) | 2019-04-11 |
Family
ID=65994424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/037139 WO2019070013A1 (ja) | 2017-10-05 | 2018-10-04 | 細胞傷害性t細胞枯渇用組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200262917A1 (ja) |
EP (1) | EP3693012A4 (ja) |
JP (2) | JP7384668B2 (ja) |
KR (1) | KR20200060407A (ja) |
CN (1) | CN111447952A (ja) |
BR (1) | BR112020006860A2 (ja) |
CA (1) | CA3078436A1 (ja) |
TW (1) | TW201927336A (ja) |
WO (1) | WO2019070013A1 (ja) |
Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990007861A1 (en) | 1988-12-28 | 1990-07-26 | Protein Design Labs, Inc. | CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1992001047A1 (en) | 1990-07-10 | 1992-01-23 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
WO1995001438A1 (en) | 1993-06-30 | 1995-01-12 | Medical Research Council | Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
WO2000061739A1 (en) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
WO2002031140A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
WO2004061104A2 (en) | 2003-01-07 | 2004-07-22 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
WO2008132601A1 (en) | 2007-04-30 | 2008-11-06 | Immutep | Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
US20110070238A1 (en) | 2007-04-30 | 2011-03-24 | Immutep Parc Club Orsay | Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
JP2012500006A (ja) * | 2008-08-11 | 2012-01-05 | メダレックス インコーポレーティッド | リンパ球活性化遺伝子−3(lag−3)へ結合するヒト抗体およびその使用 |
WO2014140180A1 (en) | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property Development Limited | Anti-lag-3 binding proteins |
JP2015527880A (ja) * | 2012-07-02 | 2015-09-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | リンパ球活性化遺伝子−3(lag−3)へ結合する抗体の最適化およびその使用 |
JP2017516489A (ja) * | 2014-03-14 | 2017-06-22 | ノバルティス アーゲー | Lag−3に対する抗体分子およびその使用 |
WO2018047894A1 (ja) * | 2016-09-08 | 2018-03-15 | 第一三共株式会社 | 自己免疫疾患治療用抗体 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101088178B1 (ko) | 2009-12-18 | 2011-12-02 | 한국과학기술원 | 멀티 라디오 모바일 애드 혹 네트워크 환경에서의 라우팅 방법 |
US10633704B2 (en) * | 2010-07-23 | 2020-04-28 | Raymond M. Johnson | Diagnostic and immunotherapy compositions and methods for disease states mediated by inhibitor-resistant CD8 T-cells |
KR102081232B1 (ko) | 2013-05-28 | 2020-02-25 | 에스케이플래닛 주식회사 | 태그 정보를 이용한 컨텐츠 생성 지원을 위한 장치 |
TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
-
2018
- 2018-10-04 CN CN201880078579.XA patent/CN111447952A/zh active Pending
- 2018-10-04 US US16/651,531 patent/US20200262917A1/en active Pending
- 2018-10-04 CA CA3078436A patent/CA3078436A1/en active Pending
- 2018-10-04 JP JP2019547003A patent/JP7384668B2/ja active Active
- 2018-10-04 EP EP18863880.3A patent/EP3693012A4/en active Pending
- 2018-10-04 TW TW107135110A patent/TW201927336A/zh unknown
- 2018-10-04 KR KR1020207009756A patent/KR20200060407A/ko not_active Application Discontinuation
- 2018-10-04 BR BR112020006860-8A patent/BR112020006860A2/pt unknown
- 2018-10-04 WO PCT/JP2018/037139 patent/WO2019070013A1/ja unknown
-
2023
- 2023-11-09 JP JP2023191228A patent/JP2024010208A/ja active Pending
Patent Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5455030A (en) | 1986-09-02 | 1995-10-03 | Enzon Labs, Inc. | Immunotheraphy using single chain polypeptide binding molecules |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1990007861A1 (en) | 1988-12-28 | 1990-07-26 | Protein Design Labs, Inc. | CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR |
WO1992001047A1 (en) | 1990-07-10 | 1992-01-23 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1995001438A1 (en) | 1993-06-30 | 1995-01-12 | Medical Research Council | Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
WO2000061739A1 (en) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2002031140A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
WO2004061104A2 (en) | 2003-01-07 | 2004-07-22 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
WO2008132601A1 (en) | 2007-04-30 | 2008-11-06 | Immutep | Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
US20110070238A1 (en) | 2007-04-30 | 2011-03-24 | Immutep Parc Club Orsay | Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
JP2012500006A (ja) * | 2008-08-11 | 2012-01-05 | メダレックス インコーポレーティッド | リンパ球活性化遺伝子−3(lag−3)へ結合するヒト抗体およびその使用 |
JP2015527880A (ja) * | 2012-07-02 | 2015-09-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | リンパ球活性化遺伝子−3(lag−3)へ結合する抗体の最適化およびその使用 |
WO2014140180A1 (en) | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property Development Limited | Anti-lag-3 binding proteins |
JP2016516681A (ja) * | 2013-03-15 | 2016-06-09 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 抗lag−3結合タンパク質 |
JP2017516489A (ja) * | 2014-03-14 | 2017-06-22 | ノバルティス アーゲー | Lag−3に対する抗体分子およびその使用 |
WO2018047894A1 (ja) * | 2016-09-08 | 2018-03-15 | 第一三共株式会社 | 自己免疫疾患治療用抗体 |
Non-Patent Citations (78)
Title |
---|
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY |
"Strategies for Protein Purification and Characterization: A Laboratory Course Manual", 1996, COLD SPRING HARBOR LABORATORY PRESS |
ABE KHAZAMA MKATOH HYAMAMURA KSUZUKI M: "Establishment of an efficient BAC transgenesis protocol and its application to functional characterization of the mouse Brachyury locus", EXP ANIM., vol. 53, no. 4, 2004, pages 311 - 20 |
ALTSCHUL, STEPHEN F.THOMAS L. MADDENALEJANDRO A. SCHAFFERJINGHUI ZHANGZHENG ZHANGWEBB MILLERDAVID J. LIPMAN: "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402, XP002905950, DOI: 10.1093/nar/25.17.3389 |
ANALYTICAL BIOCHEMISTRY, vol. 360, 2007, pages 75 - 83 |
ANNU. REV. IMMUNOL, vol. 12, 1994, pages 433 - 455 |
BARNES, P.: "Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease", J. ALLERGY CLIN. IMMUNOL., vol. 131, no. 3, 2013, pages 636 - 645 |
BROUX, B ET AL.: "Pathogenic features of CD4+CD28- T cells in immune disorders", TRENDS. MOL. MED., vol. 18, no. 8, 2012, pages 446 - 453 |
BRUNETTI, M. ET AL., PHARMACOL. EXP. THER., vol. 285, no. 2, 1998, pages 915 - 919 |
CARMEN, S., BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, vol. 1, no. 2, 2002, pages 189 - 203 |
DAI ET AL., CLIN RES HEPATOL GASTROENTEROL., vol. 41, no. 6, 2017, pages 693 - 702 |
FASTH, AE. ET AL., J. IMMUNOL., vol. 183, no. 183, 2009, pages 4792 - 4799 |
GILANI ET AL., PLOS ONE, vol. 5, no. 1, 2010, pages e8959 |
GIUBILATO ET AL., EUR HEART J., vol. 32, no. 10, 2011, pages 1214 - 26 |
GLUZMAN, Y., CELL, vol. 23, 1981, pages 175 - 182 |
HAMERS-CASTERMAN C. ET AL., NATURE, vol. 363, no. 6428, 1993, pages 446 - 8 |
HAMZAOUI, A. ET AL., MEDIATORS. INFLAMM., vol. 3, 2005, pages 160 - 166 |
HAUDEBOURG, T. ET AL.: "Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3 (+))-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates", CLIN. EXP. IMMUNOL., vol. 164, no. 2, May 2011 (2011-05-01), pages 265 - 74, XP055055512, DOI: 10.1111/j.1365-2249.2011.04329.x |
HAUDEBOURG, T. ET AL.: "Depletion of LAG-3 positive cells in cardiac allograft reveals their role in rejection and tolerance.", TRANSPLANTATION, vol. 84, no. 11, December 2007 (2007-12-01), pages 1500 - 06, XP002495209 |
HENDERSON, DJ ET AL., IMMUNOL., vol. 73, no. 3, 1991, pages 316 - 321 |
HODGE, G.HODGE, S.: "Steroid Resistant CD8+CD28null NKT-Like Pro-inflammatory Cytotoxic Cells in Chronic Obstructive Pulmonary Disease", FRONT. IMMUNOL., vol. 7, 2016, pages 617 |
HUARD, B. ET AL.: "Characterization of the major histocompatibility complex class II binding site on LAG-3 protein", PROC. NATL. ACAD. SCI. U.S.A., vol. 94, no. 11, 27 May 1997 (1997-05-27), pages 5744 - 49, XP002037067, DOI: 10.1073/pnas.94.11.5744 |
HUARD, B. ET AL.: "T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding", EUR. J. IMMUNOL., vol. 26, no. 5, May 1996 (1996-05-01), pages 1180 - 06, XP000672293, DOI: 10.1002/eji.1830260533 |
HUSTON, J.S. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879 - 5883 |
JOURNAL OF CHROMATOGRAPHY A, vol. 705, 1995, pages 129 - 134 |
JUNTTILA, T.T. ET AL., CANCER RES., vol. 70, no. 11, 2010, pages 4481 - 9 |
KABAT, E. A.MAYER, M. M.: "Experimental Immunochemistry", 1964, CHARLES C THOMAS PUBLISHER |
KELLER, CW. ET AL., ANN. CLIN. TRANSL. NEUROL., vol. 4, no. 6, 2017, pages 422 - 445 |
KOHLER ET AL., EUR. J. IMMNOL., vol. 6, 1977, pages 511 |
KOHLER ET AL.: "Nature", vol. 256, 1975, pages: 495 |
KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497 |
KOOK ET AL., EXP HEMATOL., vol. 29, no. 11, 2001, pages 1270 - 7 |
KUROIWA, Y., NUC. ACIDS RES., vol. 26, 1998, pages 3447 - 3448 |
LAMPRECHT ET AL., THORAX, vol. 56, no. 10, 2001, pages 751 - 7 |
LEE, H-S ET AL., MOLECULAR IMMUNOLOGY, vol. 36, 1999, pages 61 - 71 |
LI ET AL., J INVEST DERMATOL., vol. 137, no. 5, 2017, pages 1042 - 1050 |
LI, M. ET AL.: "Reconstitution of human Fc gamma RIII cell type specificity in transgenic mice", J. EXP. MED., vol. 183, no. 3, 1 May 1996 (1996-05-01), pages 1259 - 63, XP055552594, DOI: 10.1084/jem.183.3.1259 |
LIMA ET AL., BR J DERMATOL., vol. 173, no. 4, 2015, pages 998 - 1005 |
MACON-LEMAITRE, LTRIEBEL, F: "The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells", IMMUNOLOGY, vol. 115, no. 2, June 2005 (2005-06-01), pages 170 - 08, XP002453818, DOI: 10.1111/j.1365-2567.2005.02145.x |
MALY KSCHIRMER M: "The story of CD4+ CD28- T cells revisited: solved or still ongoing?", J. IMMUNOL. RES., vol. 2015, 2015 |
MATSUJAKI, JUNKO: "Basic Biology and Clinical Application of LAG-3", SAISHIN IGAKU [=LATEST MEDICINE], vol. 70, no. 3, 28 February 2015 (2015-02-28), pages 36 (360) - 41 (365), XP009513842, ISSN: 0370-8241 * |
MENDES ET AL., CLINICS (SAO PAULO, vol. 63, no. 5, 2008, pages 667 - 76 |
METHODS IN ENZYMOLOGY, vol. 203, 1991, pages 121 - 153 |
MILLER, STEPHEN D. ET AL.: "Current Protocols in Immunology", 2010, WILEY, article "Experimental Autoimmune Encephalomyelitis in the Mouse", pages: 15.1.1 - 15.1.20 |
MILLSTEIN ET AL., NATURE, vol. 305, 1983, pages 537 - 539 |
MILSTEIN ET AL., NATURE, vol. 266, 1977, pages 495 |
MUYLDERMANS S. ET AL., PROTEIN ENG., vol. 113, no. 9, 1994, pages 1129 - 315 |
NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1137 - 1146 |
NATURE, vol. 321, 1986, pages 522 - 525 |
NGUYEN, L.T.OHASHI, P.S.: "Clinical blockade of PD1 and LAG3--potential mechanisms of action", NAT. REV. IMMUNOL., vol. 15, no. 1, January 2015 (2015-01-01), pages 45 - 56, XP055216541, DOI: 10.1038/nri3790 |
NUC.ACID RES., vol. 35, 2007, pages D301 - D303 |
OKAZAKI, T. ET AL.: "PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice", J. EXP. MED., vol. 208, no. 2, 7 February 2011 (2011-02-07), pages 395 - 407, XP055676267, DOI: 10.1084/jem.20100466 |
PANDYA ET AL., ARTHRITIS RHEUM., vol. 62, no. 11, 2010, pages 3457 - 66 |
PEDROZA-SERES, M. ET AL., BR. J. OPHTHALMOL., vol. 91, no. 10, 2007, pages 1393 - 1398 |
PEETERS ET AL., FRONT IMMUNOL., vol. 8, 2017, pages 1160 |
QUEEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033 |
ROBERTS ET AL., SARCOIDOSIS VASE DIFFUSE LUNG DIS., vol. 22, no. 1, 2005, pages 13 - 9 |
SCARSI ET AL., J RHEUMATOL., vol. 38, no. 10, 2011, pages 2105 - 11 |
SCARSI, M. ET AL., J. RHEUMATOL., vol. 37, no. 5, 2010, pages 911 - 916 |
SCHIRMER, M. ET AL., ARTHRITIS. RES., vol. 4, no. 1, 2002, pages 71 - 76 |
SCHIRRMANN, T. ET AL., MABS, vol. 2, no. 1, 2010, pages 73 - 76 |
See also references of EP3693012A4 |
SIRIWARDENA, D., OPTHALMOLOGY, vol. 109, no. 3, 2002, pages 427 - 431 |
SMOLENSKA ET AL., CELL IMMUNOL., vol. 278, no. 1-2, 2012, pages 143 - 51 |
STRIOGA, M. ET AL.: "CD8+ CD28-and CD8+ CD57+ T cells and their role in health and disease", IMMUNOLOGY, vol. 134, no. 1, 2011, pages 17 - 32 |
SUN, Z. ET AL., J. CLIN. IMMUNOL., vol. 28, no. 5, 2008, pages 464 - 472 |
TOMIZUKA, K. ET AL., NATURE GENETICS, vol. 16, 1997, pages 133 - 143 |
TOMIZUKA, K., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727 |
TRIEBEL, F.: "LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination.", TRENDS IMMUNOL., vol. 24, no. 12, December 2003 (2003-12-01), pages 619 - 22, XP004476041, DOI: 10.1016/j.it.2003.10.001 |
TURNIS, M.E. ET AL.: "Inhibitory receptors as targets for cancer immunotherapy", EUR. J. IMMUNOL., vol. 45, no. 7, July 2015 (2015-07-01), pages 1892 - 905, XP055577562, DOI: 10.1002/eji.201344413 |
URLAUB, G.CHASIN, L.A., PROC. NATL. ACAD. SCI. U.S.A., vol. 77, 1980, pages 4126 - 4220 |
WANG ET AL., IMMUNOL INVEST. 2009, vol. 38, no. 5, 2009, pages 434 - 46 |
WANG, EC ET AL., ARTHRITIS. RHEUM., vol. 40, no. 2, 1997, pages 237 - 248 |
WEIR, D. M.: "Handbook of Experimental Immunology", vol. I. II. III., 1987, BLACKWELL SCIENTIFIC PUBLICATIONS |
WORMSTONE, I. M., INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 43, no. 7, 2002, pages 2301 - 2308 |
YOSHIDA, H.: "Animal Cell Technology: Basic and Applied Aspects", vol. 10, 1999, KLUWER ACADEMIC PUBLISHERS, pages: 69 - 73 |
ZABINSKA ET AL., J IMMUNOL RES., 2016, pages 1058165 |
ZHANG Y ET AL.: "A new logic for DNA engineering using recombination in E. Coli.", NATURE, vol. 20, 1998, pages 123 - 128, XP002225129, DOI: 10.1038/2417 |
Also Published As
Publication number | Publication date |
---|---|
EP3693012A4 (en) | 2021-07-21 |
JP7384668B2 (ja) | 2023-11-21 |
TW201927336A (zh) | 2019-07-16 |
CA3078436A1 (en) | 2019-04-11 |
CN111447952A (zh) | 2020-07-24 |
US20200262917A1 (en) | 2020-08-20 |
BR112020006860A2 (pt) | 2020-10-20 |
JP2024010208A (ja) | 2024-01-23 |
KR20200060407A (ko) | 2020-05-29 |
JPWO2019070013A1 (ja) | 2020-11-05 |
EP3693012A1 (en) | 2020-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9856321B2 (en) | Anti-DR5 antibodies, polynucleotides and methods | |
JP7478222B2 (ja) | 抗cd3抗体及び該抗体を含む分子 | |
JP7269981B2 (ja) | 自己免疫疾患治療用抗体とその製造 | |
JP6509735B2 (ja) | 抗fgfr2抗体と他剤の組合せ | |
US11459387B2 (en) | Anti-CD147 antibody | |
KR101950898B1 (ko) | 항-robo4 항체 | |
JP7384668B2 (ja) | 細胞傷害性t細胞枯渇用組成物 | |
RU2781148C2 (ru) | Антитело для лечения аутоиммунных заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18863880 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019547003 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3078436 Country of ref document: CA Ref document number: 20207009756 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018863880 Country of ref document: EP Effective date: 20200506 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020006860 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112020006860 Country of ref document: BR Free format text: APRESENTAR, EM ATE 60 (SESSENTA) DIAS, TRADUCAO COMPLETA DO PEDIDO, ADAPTADA A NORMA VIGENTE, CONFORME CONSTA NO DEPOSITO INTERNACIONAL INICIAL PCT/JP2018/037139 DE 04/10/2018, POIS A MESMA NAO FOI APRESENTADA ATE O MOMENTO |
|
ENP | Entry into the national phase |
Ref document number: 112020006860 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200406 |